

Curriculum vitae

Seema Singhal

Current Appointment (December 2000 onwards)
Professor of Medicine
Director, Multiple Myeloma Program
Division of Hematology/Oncology
The Feinberg School of Medicine
The Robert H Lurie Comprehensive Cancer Center
Northwestern University

Contact information 676 N Saint Clair Street, Suite 850
Chicago, IL 60611-2927
Phone: 312-695-6180
FAX: 312-695-6189
s-singhal@northwestern.edu

Previous Appointments Associate Professor of Medicine
Co-Director, Myeloma and Lymphoma Program
Medical Director, Stem Cell Apheresis
Division of Transplantation Medicine
South Carolina Cancer Center and Palmetto Richland Memorial Hospital
University of South Carolina
Columbia, South Carolina
October 1999 to November 2000

Assistant Professor of Medicine
Chief, Section of Investigative Diagnostics
Director, Stem Cell Laboratory
Myeloma and Transplantation Research Center
University of Arkansas for Medical Sciences
Little Rock, Arkansas, USA
July 1996 to June 1999

Senior Registrar and Bone Marrow Transplant Fellow
Leukaemia and Myeloma Units
Royal Marsden Hospital
Surrey, UK
October 1993 to July 1996

Resident Physician
Department of Bone Marrow Transplantation and Cancer Immunobiology
Hadassah University Hospital
Jerusalem, Israel
March 1991 to March 1992

Marital Status Married (Husband: Jayesh Mehta MD; two children)

Citizenship US

Educational
Qualifications

MBBS, Bombay University, 1986
MD (Internal Medicine), Bombay University, 1991

Medical studies

Undergraduate, Seth GS Medical College, Bombay
Internship, KEM Hospital, Bombay
Postgraduate, Seth GS Medical College & KEM Hospital and Bombay Hospital
Institute of Medical Sciences

Residency

House Officer, Internal Medicine, 6 months
House Officer, Internal Medicine/Neurology, 6 months
House Officer, Internal Medicine/Cardiology, 6 months
House Officer and Locum Registrar, Internal Medicine/Hematology, 6 months
Registrar, Internal Medicine, 1 year

Awards and
scholarships

Dinanath S Mankar Gold Medal, 1982, Bombay University
Narayan Mahadeo Parmanand Prize, 1982, Bombay University
College Merit Scholarship (First Rank), 1982, Jai Hind College
Dr Dhayagude Prize in Anatomy, 1983, Seth GS Medical College
Bai Hirabai Pestanji Hormasji Cama Gold Medal in Surgery, 1986,
Bombay University
Bombay Haematology Group Annual Essay Prize, 1990
Best Clinical Poster at the 21st Annual Meeting of the European Group for Blood
and Marrow Transplantation, Davos, Switzerland, March 1995.

Academic
Honors

First in the Bombay University Pre-medical Examinations, 1982
Distinctions in medical examinations of Bombay University:
Anatomy (1983), Pharmacology (1985), Microbiology (1985),
Forensic Medicine (1985), Surgery (1986)

Referee

American Journal of Medicine
Blood
Biology of Blood and Marrow Transplantation
Bone Marrow Transplantation
British Journal of Haematology
Cancer Detection and Prevention
Clinical Cancer Research
Expert Opinion on Investigational Drugs
Expert Opinion on Pharmacotherapy
Lancet Oncology
Leukemia
New England Journal of Medicine

Membership

American Society of Clinical Oncology
American Society of Hematology

Licensure/Boards

ECFMG/USMLE: Certified (Steps I-III)
ABIM (Internal Medicine): Certified (through 2015)
ABIM (Hematology and Oncology): Eligible
Illinois Department of Professional Regulation (Active)
Arkansas State Medical Board (Inactive)
South Carolina Board of Medical Examiners (Inactive)
General Medical Council, London, UK (Inactive)
Israeli Medical Council (Temporary) (Inactive)
Maharashtra Medical Council (Medical Council of India) (Active)

Current Research
Interests

Multiple myeloma with special reference to new treatment approaches including inhibition of angiogenesis, cytogenetic abnormalities, and magnetic resonance imaging

Clinical and experimental autologous and allogeneic hematopoietic stem cell transplantation

Use of hematopoietic stem cells for experimental and clinical tissue repair

Grant Support

PI: Illinois Board of Higher Education, 2002-03.
\$175,000

PI: The Ann Landers Research Fund Award,
Multiple Myeloma Research Foundation, 2003-05.
\$200,000

Invited Lectures

Overview of multiple myeloma

Evanston, Illinois. St Francis Hospital, March 2001

The role of thalidomide in myeloma

Schaumburg, Illinois. International Myeloma Foundation, March 2001.

Recent advances in the therapy of multiple myeloma

Libertyville, Illinois. Lutheran General Hospital, April 2001

Recent advances in the therapy of multiple myeloma

Elk Grove Village, Illinois. Alexian Brothers Hospital, July 2001

Recent advances in the treatment of multiple myeloma

Washington, D.C. Washington Cancer Center/Washington Hospital Center, August 2001

Recent advances in the treatment of multiple myeloma

Davenport, Iowa. Genesis Medical Center, September 2001

The role of thalidomide in myeloma

South Holland, Illinois. Chicago Myeloma Foundation, October 2001.

Waldenstrom's macroglobulinemia

Chicago, Illinois. Sixth Annual Patient Education Forum on Lymphoma, Lymphoma Research Foundation of America, October 2001.

Recent advances in the treatment of multiple myeloma

Evanston, Illinois. Evanston Hospital, November 2001.

The role of thalidomide in the management of myeloma

Chicago, Illinois: Multiple Myeloma Research Foundation, Institutional Insights Symposium for Physicians, November 2001

The role of thalidomide in the management of myeloma

Chicago, Illinois: Multiple Myeloma Research Foundation, Institutional Insights Symposium for Patients, November 2001

Recent advances in the treatment of multiple myeloma

Chicago, Illinois. South Suburban Hospital, January 2002

Frontline therapy of myeloma

Chicago, Illinois: International Myeloma Foundation, August 2002

Recent advances in the treatment of multiple myeloma

Charleston, South Carolina: South Carolina Oncology Society, September 2002

Hematopoietic stem cell transplantation in multiple myeloma

Mumbai, India: 8th Congress of the Asia-Pacific Bone Marrow Transplantation Group, November 2002

Hematopoietic stem cell transplantation in multiple myeloma

Chicago, Illinois: Chicago Myeloma Foundation, September 2003

Novel treatment options in multiple myeloma

Chicago, Illinois: Chicago Myeloma Foundation, September 2003

Recent advances in the treatment of multiple myeloma
Minneapolis, Minnesota: Park Nicollet Hospital, September 2003

Myeloma: Contemporary therapy
Chicago, Illinois: Multiple Myeloma Research Foundation, Institutional Insights Symposium for Physicians, November 2003

Myeloma: Contemporary therapy
Chicago, Illinois: Multiple Myeloma Research Foundation, Institutional Insights Symposium for Patients, November 2003

Recent advances in the treatment of myeloma
Tulsa, Oklahoma: Oklahoma Medical Oncology Society, January 2004

Recent advances in the treatment of myeloma
Chicago, Illinois: Swedish Covenant Hospital, March 2004

Newer agents in the treatment of multiple myeloma
Whistler, British Columbia, Canada: Eighth Annual Winter Oncology Conference – Advances in Hematological Malignancies, March 2004

Multiple myeloma: Diagnosis, work-up, staging and pathophysiology
New York, New York: National Cancer Center Network, Practice Guidelines in Oncology, April 2004

Management of smoldering, indolent, and stage I myeloma, and solitary plasmacytoma
New York, New York: National Cancer Center Network, Practice Guidelines in Oncology, April 2004

Overview of bortezomib in myeloma
Kauai, Hawaii: Therapeutic Advances in the Treatment of Hematologic Malignancies, August 2004

New developments in myeloma
Chicago: Resurrection Hospital, September 2004

Myeloma: Initial therapy
New York, New York: Weill Medical College and the Multiple Myeloma Research Foundation, October 2004

Myeloma Integrated Education Session
Orlando, Florida. Chair, ASCO, May 2005

High-dose therapy in myeloma: A critical appraisal
Santa Monica, California: Therapeutic Advances in the Treatment of Hematologic Malignancies, August 2005

Multiple myeloma: Recent advances
Chicago, Illinois. Weiss Memorial Hospital, October 2005

Multiple myeloma
Chicago, Illinois. University of Illinois at Chicago, November 2005

Frontline therapy of myeloma
Tampa, Florida. Multiple Myeloma Research Foundation, November 2005.

Multiple myeloma: Place of novel agents
Mumbai, India: Bombay Hospital Institute of Medical Sciences, December 2005

Multiple myeloma: An ASH 2005 update

Mumbai, India: Bombay Hospital Institute of Medical Sciences, December 2005

New treatment strategies in multiple myeloma

Lansing, Michigan. Sparrow Regional Cancer Center, February 2006

Making sense of myeloma: ASH 2005 update

Miami, Florida. American Society of Hematology, February 2006

Myeloma: Pitfalls, controversies, and advances

Evanston, Illinois. Kellogg Cancer Center, Evanston Hospital, February 2008.

Patents

Mehta J, Singhal S, Beohar N, Davidson C, Bonow R. G-CSF therapy as an adjunct to reperfusion therapy in the treatment of acute myocardial infarction. US Patent 7,220,407 (Issued 22 May 2007).

Bibliography

Book

1. Mehta J, Singhal S, eds. Myeloma. London, Martin Dunitz, 2002 (ISBN 1-901865-50-9).

Blood and Marrow Transplantation

2. Mehta J, Singhal S, Or R. Cyclophosphamide-induced cardiomyopathy during bone marrow transplantation for severe aplastic anemia. *J Assoc Physicians India* 1994; 42:159-160.
3. Mehta J, Singhal S, Powles R. Approach to the febrile neutropenic patient. II: Antimicrobial therapy and prophylaxis. *Postgrad Doctor Middle East* 1994; 17:392-399.
4. Singhal S, Mehta J, Powles R, Treleaven J, Horton C, Carrington D, Tryhorn Y, Jameson B. Three weeks of ganciclovir for cytomegaloviraemia after allogeneic bone marrow transplantation. *Bone Marrow Transplant* 1995; 15:777-781.
5. Zomas A, Mehta J, Powles R, Treleaven J, Iveson T, Singhal S, Jameson B, Paul B, Brincat S, Catovsky D. Unusual infections following allogeneic bone marrow transplantation for chronic lymphocytic leukemia. *Bone Marrow Transplant* 1994; 14:799-803.
6. Mehta J, Singhal S, Powles R. Approach to the febrile neutropenic patient. I: General principles of management. *Postgrad Doctor Middle East* 1994; 17:327-333.
7. Singhal S, Mehta J, Powles R. Prevention of cytomegalovirus disease by a short course of preemptive ganciclovir or foscarnet. *Blood* 1994; 84:2055.
8. Powles R, Mehta J, Singhal S, Horton C, Tait D, Milan S, Pollard C, Lumley H, Matthey F, Shirley J, Williams H, Samaratunga I, Lakhani A, Millar J, Treleaven J. Autologous bone marrow or peripheral blood stem cell transplantation followed by maintenance chemotherapy for adult acute lymphoblastic leukemia in first remission: 50 cases from a single center. *Bone Marrow Transplant* 1995; 16:241-247.
9. Mehta J, Powles R, Horton C, Milan S, Singhal S, Treleaven J. The relationship between donor-recipient blood group incompatibility and serum bilirubin after allogeneic bone marrow transplantation from HLA-identical siblings. *Bone Marrow Transplant* 1995; 15:853-858.
10. Mehta J, Powles R, Singhal S, Treleaven J. Peripheral blood stem cell transplantation may result in increased relapse of acute myeloid leukaemia due to reinfusion of a higher number of malignant cells. *Bone Marrow Transplant* 1995; 15:652-653.
11. Singhal S, Mehta J, Rattenbury H, Treleaven J, Powles R. Oral pilocarpine hydrochloride for the treatment of refractory xerostomia associated with chronic graft-versus-host disease. *Blood* 1995; 85:1147-1148.
12. Singhal S, Powles R, Milan S, Raje N, Viner C, Treleaven J, Cunningham D, Mehta J. Clearance of paraprotein after autografting for multiple myeloma. *Bone Marrow Transplant* 1995; 16:537-540.

13. Mehta J, Powles R, Singhal S, Horton C, Tait D, Milan S, Meller S, Pinkerton CR, Treleaven J. Autologous bone marrow transplantation for acute myeloid leukemia in first remission: identification of modifiable prognostic factors. *Bone Marrow Transplant* 1995; 16:499-506.
14. Mehta J, Powles R, Cabral S, Shepherd V, Singhal S, Morilla R, Treleaven J. Comparison of Cobe Spectra and Haemonetics MCS-3P cell separators for peripheral blood stem cell harvesting. *Bone Marrow Transplant* 1995; 16:707-709.
15. Mehta J, Powles R, Singhal S, Tait D, Swansbury J, Treleaven J. Cytokine-mediated immunotherapy with or without donor leukocytes for poor-risk acute myeloid leukemia relapsing after allogeneic bone marrow transplantation. *Bone Marrow Transplant* 1995; 16:133-137.
16. Dunlop L, Powles R, Singhal S, Treleaven J, Swansbury GJ, Meller S, Pinkerton CR, Horton C, Mehta J. Bone marrow transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia. *Bone Marrow Transplant* 1996; 17:365-369.
17. Singhal S, Powles R, Treleaven J, Lumley H, Pollard C, Mehta J. Allogeneic bone marrow transplantation for primary myelofibrosis. *Bone Marrow Transplant* 1995; 16:743-746.
18. Chang J, Powles R, Singhal S, Jameson B, Treleaven J, Mehta J. Foscarnet therapy for cytomegalovirus infection after allogeneic bone marrow transplantation. *Clin Infect Dis* 1996; 22:583-584.
19. Mehta J, Mijovic A, Powles R, Pagliuca A, Singhal S, Czepulkowski B, Swansbury GJ, Treleaven J, Mufti GJ. Myelosuppressive chemotherapy to mobilize normal stem cells in chronic myeloid leukemia. *Bone Marrow Transplant* 1996; 17:25-29.
20. Mehta J, Powles R, Singhal S, Iveson T, Treleaven J, Catovsky D. Clinical and hematologic response of chronic lymphocytic and prolymphocytic leukemia persisting after allogeneic bone marrow transplantation with the onset of acute graft-versus-host disease: possible role of graft-versus-leukemia. *Bone Marrow Transplant* 1996; 17:371-375.
21. Mehta J, Powles R, Singhal S, Horton C, Treleaven J. Outcome of autologous rescue after failed engraftment of allogeneic marrow. *Bone Marrow Transplant* 1996; 17:213-217.
22. Singhal S, Vourka-Karussis U, Mehta J, Slavin S, Weiss L. Failure of cyclosporine to induce graft-vs-host disease or graft-vs-leukemia after syngeneic bone marrow transplantation in mice. *Leuk Res* 1996; 20:941-946.
23. Glynne P, Powles R, Steele J, Singhal S, Treleaven J, Tait D, Mehta J. Renal dysfunction following autologous bone marrow transplantation in adult patients with acute leukemia. *Acta Oncol* 1996; 35:709-712.
24. Powles R, Raje N, Cunningham D, Malpas J, Milan S, Horton C, Mehta J, Singhal S, Viner C, Treleaven J. Maintenance therapy for remission in myeloma with Intron A following high-dose melphalan and either an autologous bone marrow transplantation or peripheral blood stem cell rescue. *Stem Cells* 1995; 13 (Suppl 2):114-117.
25. Mehta J, Powles R, Singhal S, Matthey F, Hamblin M, Middleton G, Prendiville J, Glynne P, Zomas A, Treleaven J, Catovsky D. T-cell depleted allogeneic bone marrow transplantation from a partially HLA-mismatched unrelated donor for progressive chronic lymphocytic leukemia and fludarabine-induced bone marrow failure. *Bone Marrow Transplant* 1996; 17:881-883.
26. Powles R, Raje N, Horton C, Mehta J, Singhal S, Hickish T, Viner C, Milan S, Treleaven J, Cunningham D. Comparison of interferon tolerance after autologous bone marrow or peripheral blood

- stem cell transplants for myeloma patients who have responded to induction therapy. *Leuk Lymphoma* 1996; 21:421-427.
27. Mehta J, Powles R, Singhal S, Swansbury GJ, Millar B, Shepherd V, Bell J, Min T, Cabral S, Treleaven J. High-dose hydroxyurea and G-CSF to collect Philadelphia-negative cells in chronic myeloid leukemia. *Leuk Lymphoma* 1996; 23:107-111.
 28. Singhal S, Powles R, Treleaven J, Horton C, Tait D, Meller S, Pinkerton CR, Mehta J. Central nervous system relapse after bone marrow transplantation for acute leukemia in first remission. *Bone Marrow Transplant* 1996; 17:637-641.
 29. Mehta J, Powles R, Singhal S, Horton C, Hamblin M, Zomas A, Saso R, Treleaven J. Transfusion requirements after bone marrow transplantation from HLA-identical siblings: effects of donor-recipient ABO incompatibility. *Bone Marrow Transplant* 1996; 18:151-156.
 30. Mehta J, Powles R, Singhal S, Horton C, Tait D, Treleaven J. Melphalan-total body irradiation and autologous bone marrow transplantation for adult acute leukemia beyond first remission. *Bone Marrow Transplant* 1996; 18:119-123.
 31. Singhal S, Powles R, Treleaven J, Rattenbury H, Mehta J. Pilocarpine hydrochloride for symptomatic relief of xerostomia due to chronic graft-versus-host disease or total-body irradiation after bone-marrow transplantation for hematologic malignancies. *Leuk Lymphoma* 1997; 24:539-543.
 32. Mehta J, Powles R, Treleaven J, Horton C, Shepherd V, Hale G, Waldmann H, Singhal S. Autologous transplantation with CD52 monoclonal antibody-purged marrow for acute lymphoblastic leukemia: long-term follow-up. *Leuk Lymphoma* 1997; 25:479-486.
 33. Millar BC, Millar JL, Bell JBG, Raje N, Milan S, Mehta J, Singhal S, Middleton GW, Shepherd V, Catovsky D, Powles RL. Role of CD34+ cells in engraftment after high-dose melphalan in multiple myeloma patients given peripheral blood stem cell rescue. *Bone Marrow Transplant* 1996; 18:871-878.
 34. Mehta J, Powles R, Horton C, Treleaven J, Singhal S. Factors affecting engraftment and hematopoietic recovery after unpurged autografting in acute leukemia. *Bone Marrow Transplant* 1996; 18:319-324.
 35. Singhal S, Powles R, Treleaven J, Horton C, Mehta J. Long-term safety of GM-CSF (molgramostim) administration after allogeneic bone marrow transplantation for hematologic malignancies: five-year follow-up of a double-blind randomized placebo-controlled study. *Leuk Lymphoma* 1997; 24:301-307.
 36. Mehta J, Powles R, Treleaven J, Horton C, Tait D, Meller S, Pinkerton CR, Middleton G, Eisen T, Singhal S. Long-term follow-up of patients undergoing allogeneic bone marrow transplantation for acute myeloid leukemia in first complete remission after cyclophosphamide-total body irradiation and cyclosporine. *Bone Marrow Transplant* 1996; 18:741-746.
 37. Singhal S, Powles R, Treleaven J, Horton C, Pinkerton CR, Meller S, Mehta J. Cytomegaloviremia after autografting for leukemia: clinical significance and lack of effect on engraftment. *Leukemia* 1997; 11:835-838.
 38. Singhal S, Powles R, Treleaven J, Horton C, Mehta J. Melphalan alone prior to allogeneic bone marrow transplantation from HLA-identical sibling donors for hematologic malignancies: alloengraftment with potential preservation of fertility. *Bone Marrow Transplant* 1996; 18:1049-1055.
 39. Mehta J, Powles R, Singhal S, Horton C, Middleton G, Eisen T, Meller S, Pinkerton CR, Treleaven J. Early identification of patients at risk of death due to infections, hemorrhage, or graft failure after

- allogeneic bone marrow transplantation on the basis of the leukocyte counts. *Bone Marrow Transplant* 1997; 19:349-355.
40. Mehta J, Powles R, Treleaven J, Millar B, Proctor H, Cabral S, Shepherd V, Singhal S. A prospective, concurrent comparison of the Cobe Spectra and Haemonetics MCS-3P cell separators for leukapheresis after high-dose filgrastim in patients with haematologic malignancies. *J Clin Apheresis* 1997; 12:63-67.
 41. Mehta J, Powles R, Treleaven J, Horton C, Meller S, Pinkerton CR, Singhal S. Outcome of acute leukemia relapsing after bone marrow transplantation: utility of second transplants and adoptive immunotherapy. *Bone Marrow Transplant* 1997; 19:709-719.
 42. Singhal S, Powles R, Treleaven J, Mehta J. Sensitivity of secondary acute myeloid leukemia relapsing after allogeneic bone marrow transplantation to immunotherapy with interferon- α 2b. *Bone Marrow Transplant* 1997; 19:1151-1153.
 43. Mehta J, Powles R, Singhal S, Riley U, Treleaven J, Catovsky D. Antimicrobial prophylaxis to prevent opportunistic infections in patients with chronic lymphocytic leukemia after allogeneic blood or marrow transplantation. *Leuk Lymphoma* 1997; 26:83-88.
 44. Raje N, Powles R, Milan S, Middleton G, Singhal S, Mehta J, Millar B, Viner C, Raymond J, Treleaven J, Cunningham D, Gore M. A comparison of vincristine and doxorubicin infusional chemotherapy with methylprednisolone (VAMP) with the addition of weekly cyclophosphamide (C-VAMP) as induction treatment followed by autografting in previously untreated myeloma. *Br J Haematol* 1997; 97:153-160.
 45. Saso R, Zomas A, Hamblin M, Dunlop L, Swansbury GJ, Min T, Singhal S, Powles R, Treleaven J, Mehta J. Sequential development of myelodysplasia and acute myeloid leukemia but with no karyotypic evolution after autografting in a patient with Philadelphia positive acute lymphoblastic leukemia. *Leuk Lymphoma* 1997; 26:625-628.
 46. Mehta J, Kelsey SM, Chu P, Powles R, Hazel D, Reilly U, Evans C, Newland A, Treleaven J, Singhal S. Amphotericin B lipid complex (ABLC) for the treatment of confirmed or presumed fungal infections in immunocompromised patients with hematologic malignancies. *Bone Marrow Transplant* 1997; 20:39-43.
 47. Mehta J, Tricot G, Jagannath S, Desikan KR, Siegel D, Singhal S, Munshi N, Vesole D, Mattox S, Bracy D, Barlogie B. High-dose chemotherapy with carboplatin, cyclophosphamide and etoposide and autologous transplantation for multiple myeloma relapsing after a previous transplant. *Bone Marrow Transplant* 1997; 20:113-116.
 48. Mehta J, Powles R, Treleaven J, Kulkarni S, Singhal S. Induction of graft-versus-host disease as immunotherapy of leukemia relapsing after allogeneic transplantation: single-center experience of 32 adult patients. *Bone Marrow Transplant* 1997; 20:129-135.
 49. Mehta J, Powles R, Horton C, Treleaven J, Singhal S. Leukocyte recovery and early treatment-related mortality after bone marrow transplantation. *Blood* 1997; 89:4237-4238.
 50. Singhal S, Mehta J, Barlogie B. Advances in the treatment of multiple myeloma. *Curr Opin Hematol* 1997; 4:291-297.
 51. Mehta J, Tricot G, Jagannath S, Ayers D, Singhal S, Siegel D, Desikan K, Munshi N, Fassas A, Mattox S, Bracy D, Vesole D, Crowley J, Barlogie B. Salvage autologous or allogeneic transplantation for multiple myeloma refractory to or relapsing after a first-line autograft? *Bone Marrow Transplant* 1998; 21:887-892.

52. Mehta J, Powles R, Treleaven J, Kulkarni S, Horton C, Singhal S. Number of nucleated cells infused during allogeneic and autologous bone marrow transplantation: an important modifiable factor influencing outcome. *Blood* 1997; 90:3808-3810.
53. Raje N, Powles R, Horton C, Millar B, Shepherd V, Middleton G, Kulkarni S, Eisen T, Mehta J, Singhal S, Treleaven J. Comparison of marrow vs blood-derived stem cells for autografting in previously untreated multiple myeloma. *Br J Cancer* 1997; 75:1684-1689.
54. Powles R, Raje N, Milan S, Millar B, Shepherd V, Mehta J, Singhal S, Kulkarni S, Viner C, Gore M, Cunningham D, Treleaven J. Outcome assessment of a population-based group of 195 unselected myeloma patients under 70 years of age offered intensive treatment. *Bone Marrow Transplant* 1997; 20:435-443.
55. Powles R, Singhal S, Treleaven J, Kulkarni S, Horton C, Mehta J. Identification of patients who may benefit from prophylactic immunotherapy after bone marrow transplantation for acute myeloid leukemia on the basis of lymphocyte recovery after transplantation. *Blood* 1998; 91:3481-3486.
56. Zomas A, Saso R, Powles R, Mackay H, Singhal S, Treleaven J, Mehta J. Red cell fragmentation (schistocytosis) after bone marrow transplantation. *Bone Marrow Transplant* 1998; 22:777-780.
57. Singhal S, Powles R, Kulkarni S, Treleaven J, Saso R, Mehta J. Long-term follow-up of relapsed acute leukemia treated with immunotherapy after allogeneic transplantation: the inseparability of graft-versus-host disease and graft-versus-leukemia, and the problem of extramedullary relapse. *Leuk Lymphoma* 1999; 32:505-512.
58. Singhal S, Mehta J. Reimmunization after blood or marrow stem cell transplantation. *Bone Marrow Transplant* 1999; 23:637-646.
59. Mehta J, Singhal S. Graft-versus-myeloma. *Bone Marrow Transplant* 1998; 22:835-843.
60. Singhal S, Powles R, Kulkarni S, Treleaven J, Sirohi B, Millar B, Shepherd V, Saso R, Rowland A, Long S, Cabral S, Horton C, Mehta J. Comparison of marrow and blood cell yields from the same donors in a double-blind, randomized study of allogeneic marrow vs blood stem cell transplantation. *Bone Marrow Transplant* 2000; 25:501-505.
61. Singhal S, Powles R, Treleaven J, Kulkarni S, Horton C, Mehta J. Long-term outcome of adult acute leukemia patients who are alive and well two years after allogeneic bone marrow transplantation from an HLA-identical sibling. *Leuk Lymphoma* 1999; 34:287-294.
62. Singhal S, Powles R, Treleaven J, Kulkarni S, Horton C, Mehta J. Long-term outcome of adult acute leukemia patients who are alive and well 2 years after autologous blood or marrow transplantation. *Bone Marrow Transplant* 1999; 23:875-879.
63. Singhal S, Mehta J, Desikan K, Siegel D, Singh J, Munshi N, Spoon D, Anaissie E, Ayers D, Barlogie B. Collection of peripheral blood stem cells after a preceding autograft: unfavorable effect of prior interferon- α therapy. *Bone Marrow Transplant* 1999; 24:13-17.
64. Desikan KR, Barlogie B, Jagannath S, Vesole DH, Siegel D, Fassas A, Munshi N, Singhal S, Mehta J, Tindle S, Nelson J, Bracy D, Mattox S, Tricot G. Comparable engraftment kinetics following peripheral-blood stem-cell infusion mobilized with granulocyte colony-stimulating factor with or without cyclophosphamide in multiple myeloma. *J Clin Oncol* 1998; 16:1547-1553.
65. Barlogie B, Jagannath S, Desikan KR, Mattox S, Vesole D, Siegel D, Tricot G, Munshi N, Fassas A, Singhal S, Mehta J, Anaissie E, Dhodapkar D, Naucke S, Cromer J, Sawyer J, Epstein J, Spoon D, Ayers D, Cheson B, Crowley J. Total therapy with tandem transplants for newly diagnosed multiple myeloma. *Blood* 1999; 93:55-65.

66. Siegel DS, Desikan KR, Mehta J, Singhal S, Fassas A, Munshi N, Anaissie E, Naucke S, Ayers D, Spoon D, Vesole D, Tricot G, Barlogie B. Age is not a prognostic variable with autotransplants for multiple myeloma. *Blood* 1999; 93:51-54.
67. Sawyer JR, Lukacs JL, Munshi N, Desikan KR, Singhal S, Mehta J, Siegel D, Shaughnessy J, Barlogie B. Identification of new nonrandom translocations in multiple myeloma with multicolor spectral karyotyping. *Blood* 1998; 92:4269-4278.
68. Powles R, Mehta J, Kulkarni S, Treleaven J, Millar B, Marsden J, Shepherd V, Rowland A, Sirohi B, Tait D, Horton C, Long S, Singhal S. Allogeneic blood and bone-marrow stem-cell transplantation in haematological malignant diseases: a randomised trial. *Lancet* 2000; 355:1231-1237.
69. Kulkarni S, Powles RL, Treleaven JG, Singhal S, Saso R, Horton C, Killick S, Tait D, Ramiah V, Mehta J. Impact of previous high-dose therapy on outcome after allografting for multiple myeloma. *Bone Marrow Transplant* 1999; 23:675-680.
70. Kulkarni S, Rodriguez M, Lafuente A, Mateos P, Mehta J, Singhal S, Saso R, Tait D, Treleaven JG, Powles RL. Recombinant tissue plasminogen activator (rtPA) for the treatment of hepatic veno-occlusive disease (VOD). *Bone Marrow Transplant* 1999; 23:803-807.
71. Singhal S, Powles R, Treleaven J, Kulkarni S, Sirohi B, Millar B, Shepherd V, Tait D, Horton C, Saso R, Rowland A, Long S, Mehta J. A low CD34+ cell dose results in higher mortality and poorer survival after blood or marrow stem cell transplantation from HLA-identical siblings: should 2×10^6 CD34+ cells/kg be considered the minimum threshold? *Bone Marrow Transplant* 2000; 26:489-496.
72. Sirohi B, Powles R, Mehta J, Raje N, Kulkarni S, Ramiah V, Saso R, Horton C, Bhagwati N, Singhal S, Treleaven J. Complete remission rate and outcome after intensive treatment of 177 patients under 75 years of age with IgG myeloma defining a circumscribed disease entity with a new staging system. *Br J Haematol* 1999; 107:656-666.
73. Powles R, Sirohi B, Kulkarni S, Bhagwati N, Saso R, Raje N, Horton C, Singhal S, Mehta J, Treleaven J. Acute lymphoblastic leukaemia-type intensive chemotherapy to eliminate minimal residual disease after high-dose melphalan and autologous transplantation in multiple myeloma - a phase I/II feasibility and tolerance study of 17 patients. *Bone Marrow Transplant* 2000; 25:949-956.
74. Sirohi B, Powles R, Treleaven J, Mainwaring P, Kulkarni S, Pandha H, Bhagwati N, Horton C, Singhal S, Mehta J. The role of autologous transplantation in patients with multiple myeloma aged 65 years and over. *Bone Marrow Transplant* 2000; 25:533-539.
75. Kulkarni S, Powles R, Treleaven J, Riley U, Singhal S, Horton C, Sirohi B, Bhagwati N, Meller S, Saso R, Mehta J. Chronic GVHD is associated with long term risk of pneumococcal infections in bone marrow transplant patients. *Blood* 2000; 95:3683-3686.
76. Desikan R, Dhodapkar M, Siegel D, Fassas A, Singh J, Singhal S, Mehta J, Vesole D, Tricot G, Jagannath S, Anaissie E, Barlogie B, Munshi NC. High-dose therapy with autologous haematopoietic stem cell support for Waldenstrom's macroglobulinaemia. *Br J Haematol* 1999; 105:993-996.
77. Aslan T, Fassas ABT, Desikan R, Siegel D, Munshi NC, Mehta J, Singhal S, Barlogie B, Anaissie E. Patients with multiple myeloma may safely undergo autologous transplantation despite ongoing RSV infection and no ribavirin therapy. *Bone Marrow Transplant* 1999; 24:505-509.
78. Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P, Munshi N, Anaissie E, Wilson C, Dhodapkar M, Zeldis J, Barlogie B. Antitumor activity of thalidomide in refractory multiple myeloma. *N Engl J Med* 1999; 341:1565-1571.

79. Kulkarni S, Powles R, Treleaven J, Singhal S, Horton C, Sirohi B, Bhagawati N, Tait D, Saso R, Killick S, Pinkerton R, Atra A, Meller S, Mehta J. Melphalan/TBI is not more carcinogenic than cyclophosphamide/TBI for transplant conditioning: follow-up of 725 patients from a single centre over a period of 26 years. *Bone Marrow Transplant* 2000; 25:365-370.
80. Desikan KR, Tricot G, Dhodapkar M, Fassas A, Siegel D, Vesole DH, Jagannath S, Singhal S, Mehta J, Spoon D, Anaissie E, Barlogie B, Munshi N. Melphalan plus total body irradiation (MEL-TBI) or cyclophosphamide (MEL-CY) as a conditioning regimen with second autotransplant in responding patients with myeloma is inferior compared to historical controls receiving tandem transplants with melphalan alone. *Bone Marrow Transplant* 2000; 25:483-487.
81. Singhal S, Safdar A, Chiang KY, Godder K, van Rhee F, Garner F, Foster B, Dubovsky D, Henslee-Downey PJ, Mehta J. Non-myeloablative allogeneic transplantation ('microallograft') for refractory myeloma after two preceding autografts: feasibility and efficacy in a patient with active aspergillosis. *Bone Marrow Transplant* 2000; 26:1231-1233.
82. Godder KT, Mehta J, Chiang KY, Adams S, van Rhee F, Singhal S, Higgins-Smith K, O'Neal W, DeRienzo S, Henslee-Downey JP. Partially mismatched related donor bone marrow transplantation as salvage for patients with AML who failed autologous stem cell transplant. *Bone Marrow Transplant* 2001; 28:1031-1036.
83. Singhal S, Powles R, Mehta J. Hematopoietic reconstitution by transplantation of stem cells from bone marrow or blood. *N Engl J Med* 2001; 344:1641-1642.
84. Sirohi B, Powles R, Kulkarni S, Rudin C, Saso R, Rigg A, Horton C, Singhal S, Mehta J, Treleaven J. Glomerular filtration rate prior to high dose melphalan 200 mg/m² as a surrogate marker of outcome in patients with myeloma. *Br J Cancer* 2001; 85:325-332.
85. Sirohi B, Powles R, Kulkarni S, Rudin C, Saso R, Lal R, Singhal S, Mehta J, Horton C, Treleaven J. Comparison of new patients with Bence-Jones, IgG and IgA myeloma receiving sequential therapy: the need to regard these immunologic subtypes as separate disease entities with specific prognostic criteria. *Bone Marrow Transplant* 2001; 28:29-37.
86. Safdar A, van Rhee F, Henslee-Downey JP, Singhal S, Mehta J. *Candida glabrata* and *Candida krusei* fungemia after high-risk allogeneic marrow transplantation: no adverse effect of low-dose fluconazole prophylaxis on incidence and outcome. *Bone Marrow Transplant* 2001; 28:873-878.
87. Powles R, Sirohi B, Kulkarni S, Treleaven J, Rudin C, Sankpal S, Goyal S, Horton C, Millar B, Saso R, Singhal S, Mehta J. Collection of peripheral blood stem cells in newly diagnosed myeloma patients without any prior cytoreductive therapy: the first step towards an 'operational cure'? *Bone Marrow Transplant* 2002; 30:479-484.
88. Singhal S, Powles R, Henslee-Downey PJ, Chiang KY, Treleaven J, Godder K, Kulkarni S, van Rhee F, Sirohi B, Pinkerton CR, Meller S, Mehta J. Allogeneic transplantation from HLA-matched sibling or partially HLA-mismatched related donors for primary refractory acute leukemia. *Bone Marrow Transplant* 2002; 29:291-295.
89. Mehta J, Oyama Y, Winter J, Williams S, Tallman M, Singhal S, Villa M, Shook T, Burt R, Traynor A, Soff G, Masarik S, Ramsey G, Gordon L. CD34+ cell collection efficiency does not correlate with the pre-leukapheresis hematocrit. *Bone Marrow Transplant* 2001; 28:597-601.
90. Mehta J, Singhal S. Chronic graft-versus-host disease after allogeneic peripheral-blood stem-cell transplantation: a little methotrexate goes a long way. *J Clin Oncol* 2002; 20:603-604.
91. Sirohi B, Powles R, Mehta J, Treleaven J, Raje N, Kulkarni S, Rudin C, Bhagwati N, Horton C, Saso R, Singhal S, Parikh P. The implication of compromised renal function at presentation in myeloma -

- Similar outcome in Patients who receive high-dose therapy: A single-center study of 251 previously untreated patients. *Med Oncol* 2001; 18:39-50.
92. Mehta J, Powles R, Sirohi B, Treleaven J, Kulkarni S, Saso R, Tait D, Singhal S. Does donor-recipient ABO-incompatibility protect against relapse after allogeneic bone marrow transplantation in first remission acute myeloid leukemia? *Bone Marrow Transplant* 2002; 29:853-859.
 93. Mehta J, Singhal S, Gordon L, Tallman M, Williams S, Luyun R, Ali MY, Oyama Y, Villa M, Shook T, Winter J. Cobe Spectra is superior to Fenwal CS 3000 Plus for collection of hematopoietic stem cells. *Bone Marrow Transplant* 2002; 29:563-567.
 94. Singhal S, Powles R, Sirohi B, Treleaven J, Kulkarni S, Mehta J. Response to induction chemotherapy is not essential to obtain survival benefit from high-dose melphalan and autotransplantation in myeloma. *Bone Marrow Transplant* 2002; 30:673-679.
 95. Ali MY, Oyama Y, Monreal J, Winter J, Tallman M, Gordon LI, Williams S, Singhal S, Mehta J. Reassessing the definition of myeloid engraftment after autotransplantation: it is not necessary to see $0.5 \times 10^9/L$ neutrophils on 3 consecutive days to define myeloid recovery. *Bone Marrow Transplant* 2002; 30:749-752.
 96. Tomblyn M, Gordon L, Singhal S, Tallman M, Williams S, Winter J, Mehta J. Rarity of toxigenic *Clostridium difficile* infections after hematopoietic stem cell transplantation: implications for symptomatic management of diarrhea. *Bone Marrow Transplant* 2002; 30:517-519.
 97. Kulkarni S, Powles R, Sirohi B, Treleaven J, Horton C, Atra A, Rudin C, Goyal S, Sankpal S, Meller S, Pinkerton CR, Mehta J, Singhal S. Thalidomide after allogeneic hematopoietic stem cell transplantation: activity in chronic but not in acute graft-versus-host disease. *Bone Marrow Transplant* 2003; 32:165-170.
 98. Powles R, Sirohi B, Treleaven J, Kulkarni S, Tait D, Singhal S, Mehta J. The role of post-transplant maintenance chemotherapy in improving the outcome of autotransplantation in adult acute lymphoblastic leukemia. *Blood* 2002; 100:1641-1647.
 99. Mehta J, Powles R, Sirohi B, Treleaven J, Swansbury GJ, Kulkarni S, Saso R, Singhal S. Impact of cytogenetics on the outcome of autotransplantation for acute myeloid leukemia in first remission: is the benefit of intensive pre-transplant therapy limited to patients with good karyotypes? *Bone Marrow Transplant* 2003; 32:157-164.
 100. Singhal S, Henslee-Downey PJ, Powles R, Chiang KY, Godder K, Treleaven J, Kulkarni S, van Rhee F, Sirohi B, Pinkerton CR, Meller S, Jovanovic B, Mehta J. Haploidentical vs autologous hematopoietic stem cell transplantation in patients with acute leukemia beyond first remission. *Bone Marrow Transplant* 2003; 31:889-895.
 101. Ali MY, Oyama Y, Monreal J, Winter JN, Tallman MS, Williams SF, Singhal S, Gordon LI, Mehta J. Ideal or actual body weight to calculate CD34+ cell doses for autologous hematopoietic stem cell transplantation? *Bone Marrow Transplant* 2003; 31:861-864.
 102. Durie BGM, Kyle RA, Belch A, Bensinger W, Blade J, Boccadoro M, Child JA, Comenzo R, Djulbegovic B, Fantl D, Gahrton G, Harousseau JL, Hungria V, Joshua D, Ludwig H, Mehta J, Morales AR, Morgan G, Nouel A, Oken M, Powles R, Roodman D, San Miguel J, Shimizu K, Singhal S, Sirohi B, Sonneveld P, Tricot G, Van Ness B. Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation. *Hematol J* 2003; 4:379-398.
 103. Singhal S, Mehta J. Treatment of relapsed and refractory multiple myeloma. *Curr Treatment Options Oncol* 2003; 4:229-237.

104. Pichardo D, Singhal S, Mehta J, Rosen S. Recent developments and future directions in the treatment of multiple myeloma. *Cancer Biother Radiopharm* 2003; 18:497-511.
105. Verma A, Pedicano J, Trifilio S, Singhal S, Tallman M, Winter J, Williams S, Gordon L, Monreal J, Mehta J. How long after neutrophil recovery should myeloid growth factors be continued in autologous hematopoietic stem cell transplant recipients? *Bone Marrow Transplant* 2004; 33:715-719.
106. Mehta J, Singhal S, Gee AP, Chiang KY, Godder K, van Rhee F, DeRienzo S, O'Neal W, Lamb L, Henslee-Downey PJ. Bone marrow transplantation from partially HLA-mismatched family donors for acute leukemia: single-center experience of 201 patients. *Bone Marrow Transplant* 2004; 33:389-396.
107. Cilley J, Rihn C, Monreal J, Gordon LI, Singhal S, Tallman MS, Williams S, Winter JN, Mehta J. Ideal or actual body weight to calculate CD34+ cell doses for allogeneic hematopoietic stem cell transplantation? *Bone Marrow Transplant* 2004; 33:161-164.
108. Sirohi B, Powles R, Kulkarni S, Rudin C, Frassoni F, Bacigalupo A, Singhal S, Vaidya S, Labopin M, Michallet M, Blaise D, Reiffers J, Meloni G, Rio B, Treleaven J, Horton C, Mehta J. Reassessing autotransplantation for acute myeloid leukaemia in first remission - a matched pair analysis of autologous marrow versus peripheral blood stem cells. *Bone Marrow Transplant* 2004; 33:1209-1214.
109. Mehta J, Powles R, Sirohi B, Treleaven J, Kulkarni S, Singhal S. High-dose melphalan and autotransplantation followed by post-transplant maintenance chemotherapy for acute lymphoblastic leukemia in first remission. *Bone Marrow Transplant* 2004; 33:1107-1114.
110. Safdar A, Singhal S, Mehta J. Clinical significance of non-Candida fungal blood isolation in patients undergoing high-risk allogeneic hematopoietic stem cell transplantation (1993-2001). *Cancer* 2004; 100:2456-2461.
111. Sirohi B, Powles R, Mehta J, Rudin C, Kulkarni S, Horton C, Saso R, Singhal S, Treleaven J. An elective single autograft with high-dose melphalan: single-center study of 451 patients. *Bone Marrow Transplant* 2005; 36:19-24.
112. Sirohi B, Powles R, Rudin C, Singhal S, Kulkarni S, Saso R, Horton C, Mehta J, Treleaven J. Re-use of the original infusional induction chemotherapy as salvage therapy in myeloma patients relapsing after one autograft. *Hematology* 2005; 10:361-364.
113. Tomblyn M, Gordon LI, Singhal S, Tallman MS, Williams S, Winter JN, Evens A, Mehta J. Use of total leukocyte and platelet counts to guide stem cell apheresis in healthy allogeneic donors treated with G-CSF. *Bone Marrow Transplant* 2005; 36:663-666.
114. Gidron A, Verma A, Doyle M, Boggio L, Evens A, Gordon L, Singhal S, Tallman M, Williams S, Winter J, Mehta J. Can the stem cell mobilization technique influence CD34+ cell collection efficiency of leukapheresis procedures in patients with hematologic malignancies? *Bone Marrow Transplant* 2005; 35:243-246.
115. Singhal S, Gordon LI, Tallman MS, Winter JN, Evens AO, Frankfurt O, Williams SF, Grinblatt D, Kaminer L, Meagher R, Mehta J. Ideal rather than actual body weight should be used to calculate cell dose in allogeneic hematopoietic stem cell transplantation. *Bone Marrow Transplant* 2006; 37:553-557.
116. Trifilio S, Gordon L, Singhal S, Tallman M, Evens A, Rashid K, Fishman M, Masino K, Pi J, Mehta J. Reduced-dose rasburicase (recombinant xanthine oxidase) in adult cancer patients with hyperuricemia. *Bone Marrow Transplant* 2006; 37:997-1001.

117. Mehta J, Gordon LI, Tallman MS, Winter JN, Evens AO, Frankfurt O, Williams SF, Grinblatt D, Kaminer L, Meagher R, Singhal S. Does younger donor age affect the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies beneficially? *Bone Marrow Transplant* 2006; 38:95-100.
118. Barlogie B, Tricot GJ, van Rhee F, Anghuaco E, Walker R, Epstein J, Shaughnessy JD, Jagannath S, Bolejack V, Gurlley J, Hoering A, Vesole D, Desikan R, Siegel D, Mehta J, Singhal S, Munshi NC, Dhodapkar M, Jenkins B, Attal M, Harousseau JL, Crowley J. Long-term outcome results of the first tandem autotransplant trial for multiple myeloma. *Br J Haematol* 2006; 135:158-164.
119. Singhal S, Mehta J. Multiple myeloma. *Clin J Am Soc Nephrol* 2006; 1:1322-1330.
120. Sirohi B, Powles R, Treleaven J, Kulkarni S, Saso R, Potter M, Ethell M, Morgan G, Singhal S, Mehta J. The role of maintenance chemotherapy after autotransplantation for acute lymphoblastic leukemia in first remission: single-center experience of 100 patients. *Bone Marrow Transplant* 2008; 42:105-112.
121. Trifilio S, Pennick G, Pi J, Zook J, Golf M, Kaniecki K, Singhal S, Williams S, Winter J, Tallman M, Gordon L, Frankfurt O, Evens A, Mehta J. Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients. *Cancer* 2007; 109:1532-1535.
122. Evens AM, Altman JK, Mittal BB, Hou N, Rademaker A, Patton D, Kaminer L, Williams S, Duffey S, Variakojis D, Singhal S, Tallman MS, Mehta J, Winter JN, Gordon LI. Phase I/II trial of total lymphoid irradiation and high-dose chemotherapy with autologous stem-cell transplantation for relapsed and refractory Hodgkin's lymphoma. *Ann Oncol* 2007; 18:679-688.
123. Trifilio S, Singhal S, Williams S, Frankfurt O, Gordon L, Evens A, Winter J, Tallman M, Pi J, Mehta J. Breakthrough fungal infections after allogeneic hematopoietic stem cell transplantation in patients on prophylactic voriconazole. *Bone Marrow Transplant* 2007; 40:451-456.
124. Mehta J, Singhal S. High-dose chemotherapy and autologous hematopoietic stem cell transplantation in myeloma patients under the age of 65 years. *Bone Marrow Transplant* 2007; 40:1101-1114.
125. Evens AM, Winter JN, Hou N, Nelson BP, Rademaker A, Patton D, Singhal S, Frankfurt O, Tallman MS, Rosen ST, Mehta J, Gordon LI. A phase II clinical trial of intensive chemotherapy followed by consolidative stem cell transplant: long-term follow-up in newly diagnosed mantle cell lymphoma. *Br J Haematol* 2008; 140:385-393.
126. Mehta J, Singhal S. Current status of autologous hematopoietic stem cell transplantation in myeloma. *Bone Marrow Transplant* 2008; 42:S28-S34.
127. Sirohi B, Powles R, Singhal S, Smith K, Jones RL, Saso R, Kulkarni S, Treleaven J, Swansbury GJ, Potter M, Morgan G, Mehta J. Outcome of high-dose cytarabine-based induction therapy followed by hematopoietic stem cell transplantation in acute myeloid leukemia: influence of karyotype. *Leuk Lymphoma* 2008; 49:2284-2290.
128. Singh V, Krishnamurthy J, Duffey S, Meagher R, Villa M, Monreal J, Evens A, Frankfurt O, Altman J, Gordon L, Tallman M, Williams S, Winter J, Singhal S, Mehta J. Actual or ideal body weight to calculate CD34+ cell dose in patients undergoing autologous hematopoietic stem cell transplantation for myeloma? *Bone Marrow Transplant* 2009; 43:301-305.
129. Mehta J, Frankfurt O, Altman J, Evens A, Tallman M, Gordon L, Williams S, Winter J, Krishnamurthy J, Duffey S, Singh V, Meagher R, Grinblatt D, Kaminer L, Singhal. Optimizing the CD34+ cell dose for reduced-intensity allogeneic hematopoietic stem cell transplantation. *Leuk Lymphoma* (Accepted for publication).

Non-transplant

130. Mehta JB, Singhal S. Evans' syndrome - response to immunoglobulin therapy: A case report. *Indian J Hematol* 1989; 7:83-84.
131. Mehta JB, Singhal S. Plasma cell leukemia - an unusual case. *Indian J Hematol* 1989; 7:135-137.
132. Mehta BC, Gandhi SH, Singhal SB, Rao PS. Naked eye single tube red cell osmotic fragility test for beta thalassemia trait: Experience in antenatal clinic. *J Obs Gyn India* 1989; 39:450-453.
133. Mehta JB, Singhal SB, Mehta BC. Ascorbic-acid-induced haemolysis in G-6-PD deficiency. *Lancet* 1990; 336:944.
134. Mehta JB, Singhal SB. Acquired haemophilia. *J Assoc Physicians India* 1990; 38:895-896.
135. Mehta JB, Singhal SB, Mehta BC. Preoperative hemostatic assessment: A scoring system. *Indian J Hematol Blood Transf* 1990; 8:93-94.
136. Mehta JB, Singhal SB, Mehta BC. Bone marrow biopsy in staging malignant lymphomas. *J Assoc Physicians India* 1990; 38:818.
137. Mehta JB, Singhal SB, Mehta BC. Aplastic crisis and leg ulceration: Two rare complications of hereditary sideroblastic anemia. *J Assoc Physicians India* 1992; 40:466-467.
138. Mehta JB, Singhal SB, Mehta BC. Disseminated intravascular coagulation. *J Assoc Physicians India* 1990; 38:877-878.
139. Mehta JB, Singhal SB, Mehta BC. Spontaneous complete remission in chronic lymphatic leukaemia - a case report. *J Assoc Physicians India* 1991; 39:714.
140. Mehta J, Singhal S, Mehta BC. Excellent response to low-dose long-term danazol in a case of haemophilia A. *Indian J Hematol Blood Transf* 1991; 9:41-42.
141. Mehta JB, Singhal SB, Mehta BC. Intravenous immunoglobulin therapy of immune thrombocytopenia. *J Assoc Physicians India* 1992; 40:340-342.
142. Mehta J, Singhal S, Mehta BC. Factor VII inhibitor - a case report. *J Assoc Physicians India* 1992; 40:44.
143. Mehta J, Singhal S, Revankar R, Walvankar A, Chablani A, Mehta BC. Fatal systemic lupus erythematosus in patient taking oral iron chelator L1. *Lancet* 1991; 337:298.
144. Mehta J, Singhal S, Mehta BC, Patel JC. Erythrocyte sedimentation rate in multiple myeloma: Relation with the skull roentgenogram. *J Assoc Physicians India* 1992; 40:353-354.
145. Mehta J, Harjai K, Vasani J, Banghar P, Sanklecha M, Singhal S, Pathare A, Tilve GH, Mehta BC, Patel JC. Hereditary spherocytosis: Experience of 145 cases. *Indian J Med Sci* 1992; 46:103-114.
146. Mehta J, Singhal S, Mehta BC. Prognosis and therapy in chronic myeloid leukaemia. *J Assoc Physicians India* 1992; 40:130-131.
147. Mehta J, Singhal S, Chablani A, Revankar R, Walvankar A. L1-induced lupus erythematosus. *Indian J Hematol Blood Transf* 1991; 9:33-37.

148. Mehta J, Singhal S, Mehta G, Mehta BC. Megaloblastosis: A cause of false negative NESTROFT. *J Assoc Physicians India* 1991; 39:364-365.
149. Mehta J, Singhal S, Mehta BC. Low-dose cyclosporin for severe aplastic anemia. *Am J Hematol* 1992; 40:73.
150. Mehta J, Mehta BC, Singhal S, Kamath MV. A randomized placebo-controlled double-blind study of danazol in hemophilia A. *Acta Haematol* 1992; 88:14-16.
151. Mehta J, Singhal S, Mehta BC. A tale of two boys and a soft drink: ascorbic acid-induced hemolysis in glucose-6-phosphate dehydrogenase deficient subjects. *Indian J Hematol Blood Transf* 1991; 9:85-86.
152. Mehta J, Chablani A, Reporter R, Singhal S, Mehta BC. Autoantibodies in thalassaemia major: relationship with oral iron chelator L1. *J Assoc Physicians India* 1993; 41:339-341.
153. Mehta J, Singhal S, Mehta BC. Approach to tuberculosis of the bone marrow. *J Assoc Physicians India* 1992; 40:639-640.
154. Mehta J, Singhal S, Huilgol N, Merchant R, Mehta BC. Treatment of severe aplastic anaemia with total lymphoid irradiation and methylprednisolone. *Br J Haematol* 1992; 81:127-128.
155. Mehta J, Singhal S, Sampat NG, Mehta BC. Enlargement of paraspinal extramedullary haematopoietic mass with cord compression after splenectomy in thalassaemia intermedia and response to irradiation. *J Assoc Physicians India* 1995; 43:563-564.
156. Mehta J, Singhal S, Mehta BC. Oral iron chelator L1 and autoimmunity. *Blood* 1993; 81:1970-1971.
157. Mehta J, Singhal S, Mehta BC. Future of oral iron chelator deferiprone (L1). *Lancet* 1993; 341:1479-1480.
158. Mehta J, Singhal S, Mehta BC. Deaths in patients receiving oral iron chelator L1. *Br J Haematol* 1993; 85:430-431.
159. Mehta J, Singhal S, Mehta BC. Oral iron chelator L1 - efficacy v/s toxicity. *Indian J Hematol Blood Transf* 1993; 11:113-119.
160. Mehta J, Singhal S, Powles R. Approach to the febrile neutropenic patient. II: Antimicrobial therapy and prophylaxis. *Postgrad Doctor Caribbean* 1995; 11:170-177.
161. Philpott N, Mehta J, Treleaven J, Powles R. Idarubicin, high-dose cytarabine and etoposide for remission induction in therapy-related acute myeloid leukemia. *Leuk Lymphoma* 1994; 15:127-130.
162. Mehta J, Singhal S, Powles R. Approach to the febrile neutropenic patient. I: General principles of management. *Postgrad Doctor Caribbean* 1995; 11:100-107.
163. Singhal S, Mehta J. Management of acute emesis. *J Assoc Physicians India* 1995; 43:560-562.
164. Mehta J, Singhal S, Mehta BC. Deferiprone in iron overload. *N Engl J Med* 1995; 333:597-599.
165. Mehta J, Powles R, Singhal S, Horton C, Hamblin M, Zomas A, Saso R, Prendiville J, Glynne P, Allford S, Mackay H, Treleaven J. Idarubicin, high-dose cytarabine and etoposide for induction of remission in acute leukemia. *Semin Hematol* 1996; 33 (Suppl 3):18-23.

166. Mehta J, Powles R, Treleaven J, Swansbury GJ, Kulkarni S, Saso R, Min T, Singhal S. The impact of karyotype on remission rates in adult patients with *de novo* acute myeloid leukemia receiving high-dose cytarabine-based induction chemotherapy. *Leuk Lymphoma* 1999; 34:553-560.
167. Singhal S, Mehta J. Thalidomide in cancer - Potential uses and limitations. *BioDrugs* 2001; 15:163-172.
168. Singhal S, Mehta J. Thalidomide in cancer. *Biomed Pharmacother* 2002; 56:4-12.
169. Mehta J, Singhal S. Authorship limits. *N Engl J Med* 2002; 347:1118.
170. Singhal S, Mehta J. Novel therapies in myeloma. *Int J Hematol* 2003; 77:226-231.
171. Mehta J, Singhal S. Hyperviscosity syndrome in plasma cell dyscrasias. *Semin Hemost Thromb* 2003; 29:467-471.
172. Desikan R, Barlogie B, Sethi R, Toor A, Spoon D, Angtuaco E, Vanhemert R, Vijayagopal A, Singhal S, Mehta J, Jagannath S, Munshi N, Zangari M, Fassas A, Tricot G, Anaissie E. Infection - an underappreciated cause of bone pain in multiple myeloma. *Br J Haematol* 2003; 120:1047-1050.
173. Singhal S, Mehta J. Easy to see but hard to find. *N Engl J Med* 2003; 348:1931-1932.
174. Singhal S. Treatment of multiple myeloma. *BMJ* 2003; 327:575-576.
175. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, Rajkumar SV, Srkalovic G, Alsina M, Alexanian R, Siegel D, Orlovski RZ, Kuter D, Limentani SA, Lee S, Hideshima T, Esseltine DL, Kauffman M, Adams J, Schenkein DP, Anderson KC. A phase 2 study of bortezomib in relapsed, refractory myeloma. *N Engl J Med* 2003; 348:2609-2617.
176. Singhal S, Kut V, Mehta J. Bortezomib: safety aspects. *Am J Oncol Rev* 2004; 3 (Suppl 3):16-19.
177. Horn KB, Horn MA, Swan J, Singhal S, Guitart J. A complete and durable clinical response to high-dose dexamethasone in a patient with scleromyxedema. *J Am Acad Dermatol* 2004; 51(2 Suppl S):S120-S123.
178. Jagannath S, Barlogie B, Berenson JR, Singhal S, Alexanian R, Srkalovic G, Orlovski RZ, Richardson PG, Anderson J, Nix D, Esseltine DL, Anderson KC. Bortezomib in recurrent and/or refractory multiple myeloma. Initial clinical experience in patients with impaired renal function. *Cancer* 2005; 103:1195-1200.
179. Berenson JR, Jagannath S, Barlogie B, Siegel DT, Alexanian R, Richardson PG, Irwin D, Alsina M, Rajkumar SV, Srkalovic G, Singhal S, Limentani S, Niesvizky R, Esseltine DL, Trehu E, Schenkein DP, Anderson K. Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma. *Cancer* 2005; 104:2141-2148.
180. Lonial S, Waller EK, Richardson PG, Jagannath S, Orlovski RZ, Giver CR, Jaye DL, Francis D, Giusti S, Torre C, Barlogie B, Berenson JR, Singhal S, Schenkein DP, Esseltine DL, Anderson J, Xiao H, Heffner LT, Anderson KC. Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma. *Blood* 2005; 106:3777-3784.
181. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, Rajkumar SV, Hideshima T, Xiao H, Esseltine D, Schenkein D, Anderson KC. Clinical factors predictive of outcome with bortezomib in patients with relapsed, refractory multiple myeloma. *Blood* 2005; 106:2977-2981.

182. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin DH, Rajkumar SV, Srkalovic G, Alsina M, Anderson KC. Extended follow-up of a phase II trial in relapsed, refractory multiple myeloma: Final time-to-event results from the SUMMIT trial. *Cancer* 2006; 106:1316-1319.
183. Jagannath S, Richardson PG, Barlogie B, Berenson JR, Singhal S, Irwin D, Srkalovic G, Schenkein DP, Esseltine DL, Anderson KC. Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to bortezomib alone. *Haematologica* 2006; 91:929-934.
184. Richardson PG, Briemberg H, Jagannath S, Wen PY, Barlogie B, Berenson J, Singhal S, Siegel DS, Irwin D, Schuster M, Srkalovic G, Alexanian R, Rajkumar SV, Limentani S, Alsina M, Orlowski RZ, Najarian K, Esseltine D, Anderson KC, Amato AA. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. *J Clin Oncol*. 2006; 24:3113-3120.
185. Chanan-Khan AA, Kaufman JL, Mehta J, Richardson PG, Miller KC, Lonial S, Munshi NC, Schlossman R, Tariman J, Singhal S. Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study. *Blood* 2007; 109:2604-2606.
186. Berenson JR, Jagannath S, Barlogie B, Siegel DT, Alexanian R, Richardson PG, Irwin D, Alsina M, Rajkumar SV, Srkalovic G, Singhal S, Limentani S, Niesvizky R, Esseltine DL, Trehu E, Schenkein DP, Anderson K. Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma. *Cancer* 2005; 104:2141-2148.
187. Singhal S, Stein R, Vickrey E, Mehta J. The serum free light chain assay cannot replace 24-hour urine protein estimation in patients with plasma cell dyscrasias. *Blood* 2007; 109:3611-3612.
188. Singhal S, Mehta J. Lenalidomide in myeloma. *Curr Treatment Options Oncol* 2007; 8:154-163.
189. Beohar N, Flaherty JD, Davidson CJ, Vidovich M, Singhal S, Rapp JA, Erdogan A, Lee DC, Rammohan C, Brodsky A, Wu E, Chundra S, Klaus H, Davidson L, Pieper K, Virmani R, Bonow RO, Mehta J. Granulocyte-colony stimulating factor administration after myocardial infarction in a porcine ischemia-reperfusion model: functional and pathological effects of dose timing. *Catheter Cardiovasc Interv* 2007; 69:257-265.
190. Zhao LR, Singhal S, Duan WM, Mehta J, Kessler JA. Brain repair by hematopoietic growth factors in a rat model of stroke. *Stroke* 2007; 38:2584-2591.
191. Zhao LR, Navalitloha Y, Singhal S, Mehta J, Piao CS, Guo WP, Kessler JA, Groothuis DR. Hematopoietic growth factors pass through the blood-brain barrier in intact rats. *Exp Neurol* 2007; 204:569-573.
192. Zhao LR, Berra HH, Duan WM, Singhal S, Mehta J, Apkarian AV, Kessler JA. Beneficial effects of hematopoietic growth factor therapy in chronic ischemic stroke in rats. *Stroke* 2007; 38:2804-2811.
193. Sezer O, Vesole DH, Singhal S, Richardson P, Stadtmauer E, Jakob C, Boral AL, Esseltine DL, Mehta J. Bortezomib-induced tumor lysis syndrome in multiple myeloma. *Clin Lymphoma Myeloma* 2006; 7:233-235.
194. Anderson KC, Alsina M, Bensinger W, Biermann JS, Chanan-Khan A, Comenzo RL, De Castro CM, Djulbegovic B, Farag S, Huff CA, Meredith R, Schriber J, Shrieve D, Singhal S, Smith MR, Stockerl-Goldstein K, Vose JM, Weber D, Yahalom J, Yunus F. Multiple myeloma. Clinical practice guidelines in oncology. *J Natl Compr Canc Netw* 2007; 5:118-147.
195. Stadtmauer EA, Lonial S, Vesole DH, Abonour R, Alsina M, Badros A, Comenzo R, Durie B, Giral S, Hussein M, Jakubowiak A, Mehta J, Niesvizky R, Orlowski R, Siegel D, Singhal S, Vescio R, Wang M,

- Zangari M, Munshi NC. A practical guide to achieving and maintaining the best response to lenalidomide in multiple myeloma: roundtable proceedings. *Clin Adv Hematol Oncol* 2007; 5 (10 Suppl 15):7-19.
196. Paiva CM, Kurtis B, Mekki M, Newman MA, Singhal S, Lacouture ME. Neutrophilic dermatitis associated with bortezomib in a patient with multiple myeloma. *Ann Oncol* 2007; 18:1744-1745.
 197. Van Rhee F, Dhodapkar M, Shaughnessy JD Jr, Anaissie E, Siegel D, Hoering A, Zeldis J, Jenkins B, Singhal S, Mehta J, Crowley J, Jagannath S, Barlogie B. First thalidomide clinical trial in multiple myeloma: a decade later. *Blood* 2008; 112:1035-1038.
 198. Vickrey E, Allen S, Mehta J, Singhal S. Acyclovir to prevent reactivation of varicella zoster virus (herpes zoster) in multiple myeloma patients receiving bortezomib therapy. *Cancer* 2009; 115:229-232.
 199. Edwards BJ, Gounder M, McKoy JM, Boyd I, Farrugia M, Migliorati C, Marx R, Ruggiero S, Dimopoulos M, Raisch DW, Singhal S, Carson K, Obadina E, Trifilio S, West D, Mehta J, Bennett CL. Pharmacovigilance and reporting oversight in US FDA fast-track process: bisphosphonates and osteonecrosis of the jaw. *Lancet Oncol* 2008; 9:1166-1172.
 200. Cao W, Goolsby CL, Nelson BP, Singhal S, Mehta J, Peterson LC. Instability of immunophenotype in plasma cell myeloma. *Am J Clin Pathol* 2008; 129:926-933.
 201. Singhal S, Vickrey E, Krishnamurthy J, Singh V, Allen S, Mehta J. The relationship between the serum free light chain assay and serum immunofixation electrophoresis, and the definition of concordant and discordant free light chain ratios. *Blood* 2009 [Epub ahead of print].

Conference Abstracts (Journals)

202. Mehta BC, Kamath MV, Mehta JB, Singhal SB. Double blind crossover trial of danazol in hemophilia A. *Blood* 1990; 76 (Suppl 1):429a.
203. Mehta J, Chablani A, Reporter R, Singhal S, Mehta BC. Occurrence of autoantibodies in thalassemia major and their possible relationship with oral iron chelator L1. *Br J Haematol* 1993; 84 (Suppl 1):64.
204. Mehta J, Powles R, Treleaven J, Iveson T, Singhal S, Zomas A, De Lord C, Elebute M, Philpott N, Tait D, Catovsky D. Melphalan-total body irradiation (M-TBI) and allogeneic bone marrow transplantation (BMT) for chronic lymphocytic leukemia (CLL) and prolymphocytic leukemia (PLL). *Br J Haematol* 1994; 86 (Suppl 1):81.
205. Mehta J, Powles R, Singhal S, Horton C, Milan S, Treleaven J. Autologous bone marrow or peripheral blood stem cell transplantation with maintenance chemotherapy for acute lymphoblastic leukemia. *Ann Oncol* 1994; 5 (Suppl 8):127.
206. Singhal S, Powles R, Mehta J, Treleaven J, Horton C, Carrington D, Tryhorn Y, Milan S, Jameson B. A short course of preemptive ganciclovir for cytomegaloviremia after allogeneic bone marrow transplantation. *Blood* 1994; 84 (Suppl 1):489a.
207. Mehta J, Powles R, Singhal S, Chang J, Smith J, Treleaven J. Cytokine-mediated immunotherapy with or without donor cells for acute leukemia relapsing after allogeneic bone marrow transplantation. *Blood* 1994; 84 (Suppl 1):714a.
208. Singhal S, Powles R, Mehta J, Milan S, Horton C, Treleaven J, Raje N, Barton C, Viner C, Cunningham D. Second autografts for relapsed multiple myeloma. *Blood* 1994; 84 (Suppl 1):721a.
209. Mehta J, Powles R, Treleaven J, Singhal S, Horton C, Milan S, Catovsky D. High-dose ARA-C and VP-16 with or without idarubicin for induction of remission in untreated primary acute myeloid leukemia. *Blood* 1994; 84 (Suppl 1):145a.
210. Powles R, Mehta J, Singhal S, Treleaven J, Horton C, Tait D, Milan S, Meller S, Pinkerton CR, Catovsky D. Autografting for acute myeloid leukemia in first remission: Evaluation of a conditioning regimen containing melphalan and identification of modifiable treatment-related prognostic factors. *Blood* 1994; 84 (Suppl 1):718a.
211. Powles R, Mehta J, Singhal S, Williams H, Matthey F, Lumley H, Pollard C, Samaratunga I, Lakhani A, Treleaven J. Sequential high-dose therapy of adult acute lymphoblastic leukemia with blood stem cell autografting and maintenance chemotherapy in first remission reserving allografting for second remission. *Blood* 1994; 84 (Suppl 1):213a.
212. Mehta J, Powles R, Treleaven J, Singhal S, Horton C, Tait D, Milan S, Meller S, Pinkerton CR, Chang J, Hamblin M, O'Driscoll A, Zomas A, Catovsky D. Melphalan versus cyclophosphamide with total body irradiation as conditioning for allogeneic bone marrow transplantation in first remission acute myeloid leukemia. *Blood* 1994; 84 (Suppl 1):714a.
213. Raje N, Powles R, Mehta J, Singhal S, Milan S, Horton C, Viner C, Treleaven J. Peripheral blood stem cell transplantation in multiple myeloma. *Blood* 1994; 84 (Suppl 1):719a.
214. Powles R, Cunningham D, Malpas JS, Raje N, Milan S, Singhal S, Mehta J, Viner C, Treleaven J, Raymond J. A randomised trial of maintenance therapy with Intron-A following high-dose melphalan and ABMT in myeloma. *Blood* 1994; 84 (Suppl 1):535a.

215. Mehta J, Powles R, Singhal S, Treleaven J. Idarubicin, high-dose cytarabine and etoposide for induction of remission in acute myeloid leukemia. *Br J Haematol* 1995; 89 (Suppl 1):66.
216. Mehta J, Powles R, Singhal S, Shepherd V, Cabral S, Treleaven J. Peripheral blood stem cell autografts for acute lymphoblastic leukemia: Effect of G-CSF dose and harvest schedule on cell yields. *Br J Haematol* 1995; 89 (Suppl 1):19.
217. Mehta J, Powles R, Singhal S, Willis A, Chang J, Horton C, Tait D, Milan S, Treleaven J. Melphalan-total body irradiation and allogeneic bone marrow transplantation for acute myeloid leukemia in first remission. *Br J Haematol* 1995; 89 (Suppl 1):16.
218. Powles R, Singhal S, Mehta J, Tait D, Catovsky D, Treleaven J. Total therapy of acute myeloid leukemia: Outcome evaluation of a package of treatment options. *Br J Haematol* 1995; 89 (Suppl 1):66.
219. Singhal S, Powles R, Mehta J, Pollard C, Lumley H, Treleaven J. Allogeneic bone marrow transplantation for primary myelofibrosis. *Br J Haematol* 1995; 89 (Suppl 1):17.
220. Singhal S, Powles R, Mehta J, Horton C, Meller S, Pinkerton CR, Milan S, Treleaven J. Effect of cell dose on transplant-related mortality after autografting for acute myeloid leukemia. *Br J Haematol* 1995; 89 (Suppl 1):19.
221. Powles R, Mufti GJ, Mehta J, Pagliuca A, Mijovic A, Swansbury J, Czepulkowski B, Singhal S, Treleaven J. Harvesting peripheral blood stem cells after myelosuppressive chemotherapy in chronic myeloid leukaemia. *Br J Haematol* 1995; 89 (Suppl 1):38.
222. Powles R, Singhal S, Mehta J, Tait D, Milan S, Treleaven J. Total therapy of acute lymphoblastic leukemia. *Br J Haematol* 1995; 89 (Suppl 1):66.
223. Powles RL, Raje NS, Milan S, Mehta J, Singhal S, Viner C, Treleaven J, Cunningham D. VAMP/C-VAMP infusional chemotherapy as induction treatment for previously untreated multiple myeloma. *Br J Haematol* 1995; 89 (Suppl 1):83.
224. Raje NS, Powles RL, Horton CAP, Mehta J, Singhal S, Viner C, Treleaven J. Peripheral blood stem cell transplantation in multiple myeloma. *Br J Haematol* 1995; 89 (Suppl 1):84.
225. Powles RL, Raje N, Milan S, Mehta J, Singhal S, Viner C, Treleaven J, Cunningham D. Single centre results of total therapy including autografts in previously untreated myeloma. *Br J Haematol* 1995; 89 (Suppl 1):53.
226. Dunlop LC, Mehta J, Treleaven J, Powles R. Results of bone marrow transplantation in Philadelphia chromosome positive acute lymphoblastic leukaemia. *Br J Haematol* 1995; 89 (Suppl 1):18.
227. Mehta J, Powles R, Treleaven J, Singhal S, Tait D, Millar J. Autografting for adult acute lymphoblastic leukemia: The role of post-transplant maintenance chemotherapy. *Bone Marrow Transplant* 1995; 15 (Suppl 2):S53.
228. Singhal S, Powles R, Mehta J, Rattenbury H, Treleaven J. Oral pilocarpine for refractory xerostomia associated with chronic graft-versus-host disease. *Bone Marrow Transplant* 1995; 15 (Suppl 2):S142.
229. Mehta J, Powles R, Singhal S, Chang J, Willis A, Treleaven J. Interferon-mediated immunotherapy for acute leukemia relapsing after allogeneic BMT. *Bone Marrow Transplant* 1995; 15 (Suppl 2):S68.
230. Singhal S, Powles R, Mehta J, Milan S, Horton C, Treleaven J, Raje N, Viner C, Cunningham D. Second autografts for relapsed multiple myeloma. *Bone Marrow Transplant* 1995; 15 (Suppl 2):S113.

231. Powles R, Mehta J, Treleaven J, Singhal S, Chang J, Willis A, Horton C, Milan S, Tait D. Melphalan or cyclophosphamide and total body irradiation prior to allogeneic bone marrow transplantation for acute myeloid leukemia in first remission. *Bone Marrow Transplant* 1995; 15 (Suppl 2):S149.
232. Mehta J, Powles R, Singhal S, Horton C, Tait D, Milan S, Treleaven J. Melphalan-total body irradiation and unpurged autografting for acute myeloid leukemia: Impact of consolidation therapy on outcome. *Bone Marrow Transplant* 1995; 15 (Suppl 2):S68.
233. Singhal S, Powles R, Mehta J, Milan S, Horton C, Raje N, Viner C, Treleaven J, Cunningham D. Kinetics of paraprotein disappearance after autografting for myeloma. *Bone Marrow Transplant* 1995; 15 (Suppl 2):S113.
234. Powles R, Singhal S, Mehta J, Tait D, Milan S, Horton C, Treleaven J. A package of treatment options for total therapy of acute myeloid leukaemia. *Bone Marrow Transplant* 1995; 15 (Suppl 2):S62.
235. Raje N, Powles R, Mehta J, Singhal S, Milan S, Horton C, Viner C, Treleaven J. Peripheral blood stem cell transplantation in multiple myeloma. *Bone Marrow Transplant* 1995; 15 (Suppl 2):S30.
236. Mehta J, Powles R, Singhal S, Treleaven J. Idarubicin, high-dose cytarabine and VP-16 for remission induction in acute myeloid leukemia. *Can J Infect Dis* 1995; 6 (Suppl C):305C.
237. Mehta J, Powles R, Singhal S, Jameson B, Treleaven J. Amphotericin B Lipid Complex (ABLC) for fungal sepsis in high-risk immunocompromised patients. *Can J Infect Dis* 1995; 6 (Suppl C):365C.
238. Singhal S, Powles R, Mehta J, Cabral S, Treleaven J. Mobilization of peripheral blood stem cells in healthy donors using G-CSF. *Can J Infect Dis* 1995; 6 (Suppl C):370C.
239. Singhal S, Powles R, Mehta J, Treleaven J. Allogeneic bone marrow transplantation for primary myelofibrosis. *Can J Infect Dis* 1995; 6 (Suppl C):370C.
240. Singhal S, Mehta J, Powles R, Treleaven J. Effect of G-CSF dose and harvest schedule on peripheral blood stem cell yields. *Can J Infect Dis* 1995; 6 (Suppl C):370C.
241. Raje N, Powles R, Milan S, Mehta J, Singhal S, Viner C, Treleaven J, Cunningham D. VAMP/C-VAMP infusional chemotherapy as induction treatment for previously untreated multiple myeloma. *Can J Infect Dis* 1995; 6 (Suppl C):307C.
242. Raje N, Powles R, Horton C, Mehta J, Singhal S, Viner C, Treleaven J. Peripheral blood stem cell transplantation in multiple myeloma. *Can J Infect Dis* 1995; 6 (Suppl C):371C.
243. Singhal S, Powles R, Mehta J, Treleaven J. Immunotherapy of relapsed leukemia after allogeneic bone marrow transplantation. *Can J Infect Dis* 1995; 6 (Suppl C):370C.
244. Raje N, Powles R, Milan S, Mehta J, Singhal S, Viner C, Treleaven J, Cunningham D. Prognostic factors in multiple myeloma. *Can J Infect Dis* 1995; 6 (Suppl C):307C.
245. Powles R, Raje N, Milan S, Mehta J, Singhal S, Viner C, Treleaven J, Cunningham D. Single centre results of total therapy including autografts in previously untreated myeloma. *Can J Infect Dis* 1995; 6 (Suppl C):289C.
246. Powles R, Cunningham D, Malpas JS, Raje N, Milan S, Singhal S, Mehta J, Viner C, Treleaven J. A randomised trial of maintenance therapy with Intron-A following high-dose melphalan in myeloma - an update. *Can J Infect Dis* 1995; 6 (Suppl C):307C.
247. Mehta J, Powles R, Singhal S, Jameson B, Treleaven J. Amphotericin B Lipid Complex (ABLC) for fungal sepsis in high-risk immunocompromised patients. *Eur J Cancer* 1995; 31A (Suppl 5):S255.

248. Singhal S, Powles R, Cabral S, Treleaven J, Mehta J. G-CSF (Filgrastim) for mobilization of stem cells in healthy donors. *Eur J Cancer* 1995; 31A (Suppl 5):S123.
249. Mehta J, Singhal S, Treleaven J, Horton C, Tait D, Powles R. Long-term follow-up of allogeneic marrow transplantation for acute myeloid leukemia after cyclophosphamide-total body irradiation and cyclosporine. *Eur J Cancer* 1995; 31A (Suppl 5):S236.
250. Powles R, Singhal S, Horton C, Treleaven J, Mehta J. Total therapy of acute myeloid leukemia. *Eur J Cancer* 1995; 31A (Suppl 5):S162.
251. Singhal S, Powles R, Cunningham D, Hickish T, Middleton G, Raje N, Viner C, Mehta J. Second autografts for relapsed myeloma. *Eur J Cancer* 1995; 31A (Suppl 5):S168.
252. Mehta J, Powles R, Singhal S, Tait D, Hjiyiannakis P, Prendiville J, Glynne P, Horton C, Treleaven J. Allogeneic bone marrow transplantation for acute myeloid leukemia after melphalan and total body irradiation. *Eur J Cancer* 1995; 31A (Suppl 5):S236-S237.
253. Mehta J, Singhal S, Treleaven J, Horton C, Powles R. Sequential high-dose therapy of adult acute lymphoblastic leukemia. *Eur J Cancer* 1995; 31A (Suppl 5):S170.
254. Singhal S, Powles R, Treleaven J, Prendiville J, Glynne P, Mehta J. Immunotherapy for acute leukemia relapsing after allogeneic bone marrow transplantation. *Eur J Cancer* 1995; 31A (Suppl 5):S237.
255. Raje N, Powles R, Hickish T, Gore M, Milan S, Mehta J, Singhal S, Viner C, Treleaven J, Cunningham D. VAMP/C-VAMP infusional chemotherapy as induction treatment for previously untreated multiple myeloma. *Eur J Cancer* 1995; 31A (Suppl 5):S167.
256. Raje N, Powles R, Horton C, Middleton G, Hickish T, Mehta J, Singhal S, Morton C, Porter H, Viner C, Treleaven J. Peripheral blood transplants followed by maintenance interferon in myeloma. *Eur J Cancer* 1995; 31A (Suppl 5):S170-S171.
257. Powles R, Raje N, Hickish T, Middleton G, Milan S, Mehta J, Singhal S, Viner C, Treleaven J, Cunningham D. Single centre results of therapy including autografts in previously untreated myeloma. *Eur J Cancer* 1995; 31A (Suppl 5):S167.
258. Raje N, Powles R, Milan S, Mehta J, Singhal S, Viner C, Treleaven J, Cunningham D. Prognostic factors in multiple myeloma. *Eur J Cancer* 1995; 31A (Suppl 5):S167.
259. Mehta J, Powles R, Singhal S, Horton C, Tait D, Treleaven J. Allogeneic bone marrow transplantation for acute myeloid leukemia in first remission after cyclophosphamide-total body irradiation and cyclosporine: long-term follow-up. *Blood* 1995; 86 (Suppl 1):93a.
260. Mehta J, Singhal S, Powles R, Horton C, Milan S, Treleaven J. Transfusion requirements after bone marrow transplantation from HLA-identical siblings: the effect of donor-recipient ABO incompatibility. *Blood* 1995; 86 (Suppl 1):959a.
261. Mehta J, Powles R, Singhal S, Horton C, Treleaven J. Autologous hematopoietic rescue after primary failure of alloengraftment. *Blood* 1995; 86 (Suppl 1):392a.
262. Singhal S, Vourka-Karussis U, Weiss L, Mehta J, Slavin S. Failure of cyclosporine to induce graft-versus-host disease or graft-versus-leukemia after syngeneic murine bone marrow transplantation. *Blood* 1995; 86 (Suppl 1):977a.

263. Glynne P, Powles R, Steele J, Singhal S, Prendiville J, Horton C, Treleaven J, Mehta J. Long-term renal dysfunction after autologous bone marrow transplantation. *Blood* 1995; 86 (Suppl 1):947a.
264. Powles R, Singhal S, Treleaven J, Hayward T, Ellis C, Mehta J. The first patients to have received cyclosporine for graft-versus-host disease prophylaxis after bone marrow transplantation: 15-year follow-up. *Blood* 1995; 86 (Suppl 1):394a.
265. Mehta J, Powles R, Singhal S, Horton C, Prendiville J, Glynne P, Zomas A, Hamblin M, Saso R, Mackay H, Treleaven J. Idarubicin, high-dose cytarabine and etoposide for remission induction in patients with relapsed acute leukemia. *Blood* 1995; 86 (Suppl 1):513a.
266. Mehta J, Powles R, Singhal S, Prendiville J, Glynne P, Zomas A, Hamblin M, Saso R, Mackay H, Swansbury GJ, Treleaven J, Catovsky D. Allogeneic bone marrow transplantation for chronic lymphocytic leukemia. *Blood* 1995; 86 (Suppl 1):958a.
267. Mehta J, Powles R, Singhal S, Horton C, Treleaven J. Consolidation therapy of adult acute lymphoblastic leukemia: Role of sequential auto and allografting. *Blood* 1995; 86 (Suppl 1):384a.
268. Treleaven J, Powles R, Singhal S, Saso R, Zomas A, Hamblin M, Mackay H, Mehta J. Addition of CCNU to daunorubicin-cytarabine (3+7) for remission induction in acute myeloid leukemia patients over 50 years. *Blood* 1995; 86 (Suppl 1):784a.
269. Singhal S, Powles R, Treleaven J, Horton C, Jameson B, Mehta J. Cytomegaloviremia after autografting. *Blood* 1995; 86 (Suppl 1):966a.
270. Treleaven J, Powles R, Singhal S, Horton C, Tait D, Meller S, Pinkerton CR, Mehta J. Melphalan and total-body irradiation as a conditioning regimen for autologous bone marrow transplantation in acute myeloid leukemia. *Blood* 1995; 86 (Suppl 1):968a.
271. Powles R, Singhal S, Horton C, Treleaven J, Mehta J. Total therapy of adult acute myeloid leukemia: evaluation of bone marrow transplantation. *Blood* 1995; 86 (Suppl 1):518a.
272. Mehta J, Powles R, Singhal S, Horton C, Pinkerton CR, Meller S, Treleaven J. Factors affecting engraftment after unpurged autografting in acute leukemia. *Blood* 1995; 86 (Suppl 1):958a.
273. Mehta J, Powles R, Singhal S, Milan S, Treleaven J. GM-CSF after allogeneic bone marrow transplantation for hematologic malignancies: 5-year follow-up. *Blood* 1995; 86 (Suppl 1):385a.
274. Singhal S, Powles R, Treleaven J, Horton C, Hamblin M, Zomas A, Prendiville J, Saso R, Mackay H, Milan S, Mehta J. Idarubicin, high-dose cytarabine and etoposide for induction of remission in acute myeloid leukemia. *Blood* 1995; 86 (Suppl 1):513a.
275. Mehta J, Powles R, Hamblin M, Zomas A, Singhal S, Glynne P, Prendiville J, Swansbury GJ, Min T, Saso R, Mackay H, Treleaven J. Bleeding diathesis 4 weeks into the course of tretinoin therapy in promyelocytic leukemia. *Blood* 1995; 86 (Suppl 1):770a.
276. Treleaven J, Powles R, Singhal S, Swansbury GJ, Millar B, Shepherd V, Bell J, Min T, Cabral S, Mehta J. High-dose hydroxyurea and G-CSF to collect philadelphia-negative cells in chronic myeloid leukemia. *Blood* 1995; 86 (Suppl 1):405a.
277. Singhal S, Powles R, Treleaven J, Horton C, Meller S, Pinkerton CR, Mehta J. Central nervous system relapse after bone marrow transplantation for acute leukemia in first remission. *Blood* 1995; 86 (Suppl 1):98a.

278. Mehta J, Kelsey SM, Chu P, Powles R, Singhal S, Hazel D, Newland AC, Treleaven J. Amphotericin B lipid complex (ABLC) for fungal sepsis in immunocompromised patients. *Blood* 1995; 86 (Suppl 1):513a.
279. Singhal S, Powles R, Treleaven J, Mehta J. Immunotherapy of acute leukemia relapsing after allogeneic bone marrow transplantation. *Blood* 1995; 86 (Suppl 1):98a.
280. Singhal S, Powles R, Treleaven J, Horton C, Jameson B, Mehta J. Temporal pattern of cytomegalovirus infection after allogeneic bone marrow transplantation. *Blood* 1995; 86 (Suppl 1):966a.
281. Singhal S, Powles R, Cunningham D, Horton C, Treleaven J, Raje N, Viner C, Mehta J. Repeat autografts for relapsed myeloma. *Blood* 1995; 86 (Suppl 1):207a.
282. Singhal S, Powles R, Treleaven J, Rattenbury H, Mehta J. Pilocarpine for xerostomia after bone marrow transplantation. *Blood* 1995; 86 (Suppl 1):400a.
283. Raje N, Powles R, Hickish T, Milan S, Horton C, Mehta J, Singhal S, Treleaven J, Cunningham D. Beta 2 microglobulin levels in patients of myeloma following high dose treatment and interferon maintenance. *Blood* 1995; 86 (Suppl 1):841a.
284. Raje N, Powles R, Milan S, Hickish T, Mehta J, Singhal S, Viner C, Treleaven J, Cunningham D. Induction treatment with VAMP/C-VAMP infusional chemotherapy in previously untreated myeloma. *Blood* 1995; 86 (Suppl 1):186a.
285. Powles R, Raje N, Milan S, Hickish T, Mehta J, Singhal S, Viner C, Treleaven J, Cunningham D. Prognostic factors in multiple myeloma. *Blood* 1995; 86 (Suppl 1):186a.
286. Raje N, Powles R, Hickish T, Horton CAP, Milan S, Mehta J, Singhal S, Viner C, Treleaven J, Cunningham D. Outcome of relapsed/resistant multiple myeloma: The Royal Marsden experience. *Blood* 1995; 86 (Suppl 1):841a.
287. Powles R, Raje N, Milan S, Mehta J, Singhal S, Hickish T, Viner C, Treleaven J, Cunningham D. Impact of induction chemotherapy followed by high dose treatment in previously untreated myeloma: A single centre experience. *Blood* 1995; 86 (Suppl 1):186a.
288. Hamblin M, Powles R, Singhal S, Saso R, Wilson K, Thornton P, Treleaven J, Mehta J. Addition of lomustine (CCNU) to standard daunorubicin-cytarabine (3+7) for induction of remission in acute myeloid leukaemia patients over 50 years. *Br J Haematol* 1996; 93 (Suppl 1):66.
289. Middleton G, Mehta J, Powles R, Singhal S, Swansbury GJ, Treleaven J, Catovsky D. Allogeneic bone marrow transplantation for chronic lymphocytic leukemia and prolymphocytic leukemia. *Br J Haematol* 1996; 93 (Suppl 1):44.
290. Middleton G, Powles R, Singhal S, Eisen T, Treleaven J, Mehta J. Factors affecting engraftment after unpurged autografting in acute leukemia. *Br J Haematol* 1996; 93 (Suppl 1):44.
291. Eisen T, Powles R, Singhal S, Middleton G, Treleaven J, Mehta J. Idarubicin, high-dose cytarabine and etoposide for remission induction in patients with relapsed acute leukemia. *Br J Haematol* 1996; 93 (Suppl 1):66.
292. Eisen T, Powles R, Singhal S, Middleton G, Treleaven J, Mehta J. Long-term follow-up of allogeneic bone marrow transplantation for acute myeloid leukemia in first remission after cyclophosphamide-total body irradiation and cyclosporine. *Br J Haematol* 1996; 93 (Suppl 1):67.

293. Singhal S, Powles R, Horton C, Treleaven J, Mehta J. Melphalan-total body irradiation and autologous transplantation for acute leukemia beyond first remission in adult patients. *Br J Haematol* 1996; 93 (Suppl 1):45.
294. Singhal S, Powles R, Horton C, Shepherd V, Meller S, Pinkerton CR, Hale G, Waldmann H, Treleaven J, Mehta J. Autologous transplantation with CD52 monoclonal antibody-purged marrow for acute lymphoblastic leukemia. *Br J Haematol* 1996; 93 (Suppl 1):37.
295. Singhal S, Vourka-Karussis U, Weiss L, Mehta J, Slavin S. Cyclosporine does not induce graft-versus-host disease or graft-versus-leukemia after syngeneic marrow transplantation in mice. *Br J Haematol* 1996; 93 (Suppl 1):39.
296. Singhal S, Powles R, Treleaven J, Horton C, Jameson B, Pinkerton CR, Meller S, Mehta J. Cytomegalovirus infection after autografting for hematologic malignancies: clinical significance and lack of effect on engraftment. *Br J Haematol* 1996; 93 (Suppl 1):37.
297. Singhal S, Powles R, Treleaven J, Long S, Rowland A, Mehta J. Comparison of cell yields in a double-blind randomized study of allogeneic marrow versus blood stem cell transplantation. *Br J Haematol* 1996; 93 (Suppl 1):37.
298. Raje N, Powles R, Milan S, Middleton G, Eisen T, Mehta J, Singhal S, Treleaven J. Autografting in myeloma patients with renal impairment. *Br J Haematol* 1996; 93 (Suppl 1):79.
299. Raje N, Powles R, Eisen T, Middleton G, Field M, Mehta J, Singhal S, Treleaven J, Milan S. A randomised trial of short course consolidation chemotherapy following high dose chemotherapy in multiple myeloma. *Br J Haematol* 1996; 93 (Suppl 1):79.
300. Glynne P, Powles R, Steele J, Singhal S, Tait D, Horton C, Prendiville J, Treleaven J, Mehta J. Renal dysfunction beyond one year in survivors of autologous bone marrow transplantation. *Bone Marrow Transplant* 1996; 17 (Suppl 1):S38.
301. Mehta J, Powles R, Singhal S, Zomas A, Saso R, Hamblin M, Mackay H, Horton C, Treleaven J. Transfusion requirements after allogeneic bone marrow transplantation: The effect of donor-recipient ABO incompatibility. *Bone Marrow Transplant* 1996; 17 (Suppl 1):S42.
302. Singhal S, Vourka-Karussis U, Weiss L, Mehta J, Slavin S. Cyclosporine does not induce graft-versus-host disease or graft-versus-leukemia after syngeneic marrow transplantation in mice. *Bone Marrow Transplant* 1996; 17 (Suppl 1):S86.
303. Mehta J, Powles R, Singhal S, Hayward T, Ellis C, Treleaven J. 15-year follow-up of the first group of patients to have received cyclosporine for graft-versus-host disease prophylaxis. *Bone Marrow Transplant* 1996; 17 (Suppl 1):S123.
304. Mehta J, Powles R, Singhal S, Treleaven J, Prendiville J, Allford S, Matthey F, Tait D, Saso R, Hamblin M, Zomas A, Mackay H, Catovsky D. Allogeneic bone marrow transplantation for chronic lymphocytic leukemia. *Bone Marrow Transplant* 1996; 17 (Suppl 1):S67.
305. Treleaven J, Powles R, Singhal S, Horton C, Tait D, Prendiville J, Hamblin M, Saso R, Zomas A, Mackay H, Allford S, Meller S, Pinkerton CR, Mehta J. Allografting for acute myeloid leukemia in first remission after cyclophosphamide-total body irradiation and cyclosporine: Long-term follow-up. *Bone Marrow Transplant* 1996; 17 (Suppl 1):S24.
306. Mehta J, Powles R, Singhal S, Zomas A, Saso R, Hamblin M, Mackay H, Treleaven J. High-dose hydroxyurea and G-CSF to collect Philadelphia-negative cells in chronic myeloid leukemia. *Bone Marrow Transplant* 1996; 17 (Suppl 1):S67.

307. Singhal S, Powles R, Treleaven J, Horton C, Jameson B, Mehta J. Cytomegaloviremia after autografting. *Bone Marrow Transplant* 1996; 17 (Suppl 1):S95.
308. Singhal S, Powles R, Treleaven J, Milan S, Prendiville J, Allford S, Hamblin M, Saso R, Zomas A, Mackay H, Mehta J. Long-term follow-up of patients receiving GM-CSF after allogeneic marrow transplantation for hematologic malignancies. *Bone Marrow Transplant* 1996; 17 (Suppl 1):S42.
309. Mehta J, Powles R, Singhal S, Horton C, Atra A, Pinkerton CR, Meller S, Tait D, Treleaven J. Central nervous system relapse after bone marrow transplantation for acute leukemia. *Bone Marrow Transplant* 1996; 17 (Suppl 1):S38.
310. Singhal S, Powles R, Treleaven J, Saso R, Long S, Rowland A, Shepherd V, Millar B, Bell J, Field M, Morton C, Cabral S, Newman A, Mehta J. Comparison of cell yields in a double-blind randomized study of allogeneic marrow versus blood stem cell transplantation. *Bone Marrow Transplant* 1996; 17 (Suppl 1):S116.
311. Singhal S, Powles R, Horton C, Treleaven J, Hamblin M, Zomas A, Saso R, Prendiville J, Mackay H, Mehta J. Melphalan-total body irradiation and unpurged autografting for acute leukemia beyond first remission. *Bone Marrow Transplant* 1996; 17 (Suppl 1):S79.
312. Mehta J, Powles R, Singhal S, Prendiville J, Allford S, Zomas A, Saso R, Hamblin M, Mackay H, Treleaven J. Adoptive immunotherapy of acute leukemia relapsing after allogeneic bone marrow transplantation. *Bone Marrow Transplant* 1996; 17 (Suppl 1):S10.
313. Mehta J, Powles R, Singhal S, Horton C, Atra A, Pinkerton CR, Meller S, Treleaven J. Factors affecting engraftment after autografting for acute leukemia. *Bone Marrow Transplant* 1996; 17 (Suppl 1):S136.
314. Singhal S, Powles R, Treleaven J, Horton C, Jameson B, Mehta J. Temporal pattern of CMV infections after allogeneic bone marrow transplantation. *Bone Marrow Transplant* 1996; 17 (Suppl 1):S95.
315. Singhal S, Powles R, Cunningham D, Horton C, Treleaven J, Eisen T, Raje N, Viner C, Mehta J. Repeat autografts for relapsed myeloma. *Bone Marrow Transplant* 1996; 17 (Suppl 1):S71.
316. Singhal S, Powles R, Treleaven J, Rattenbury H, Tait D, Mehta J. Pilocarpine for xerostomia after bone marrow transplantation. *Bone Marrow Transplant* 1996; 17 (Suppl 1):S39.
317. Mehta J, Powles R, Singhal S, Horton C, Tait D, Treleaven J. Melphalan-total body irradiation and allogeneic bone marrow transplantation for acute myeloid leukemia in first remission. *Bone Marrow Transplant* 1996; 17 (Suppl 1):S22.
318. Treleaven J, Powles R, Singhal S, Horton C, Tait D, Prendiville J, Allford S, Mehta J. Sequential high-dose therapy of adult acute lymphoblastic leukemia. *Bone Marrow Transplant* 1996; 17 (Suppl 1):S24.
319. Mehta J, Chu P, Powles R, Singhal S, Jameson B, Treleaven J. Amphotericin B lipid complex (ABLC) for fungal sepsis in immunocompromised patients. *Bone Marrow Transplant* 1996; 17 (Suppl 1):S64.
320. Powles R, Singhal S, Treleaven J, Horton C, Tait D, Mehta J. Total therapy of acute myeloid leukaemia: Evaluation of bone marrow transplantation. *Bone Marrow Transplant* 1996; 17 (Suppl 1):S24.
321. Mehta J, Powles R, Singhal S, Horton C, Treleaven J. Outcome of acute leukemia relapsing after bone marrow transplantation: Utility of second transplants. *Bone Marrow Transplant* 1996; 17 (Suppl 1):S22.

322. Mehta J, Powles R, Singhal S, Horton C, Treleaven J. Early identification of patients at risk of death due to infection, hemorrhage or graft failure after allogeneic bone marrow transplantation. *Bone Marrow Transplant* 1996; 17 (Suppl 1):S36.
323. Powles R, Milan S, Horton C, Singhal S, Treleaven J, Mehta J. A prospective haemato-oncology patient database: Structure and description. *Bone Marrow Transplant* 1996; 17 (Suppl 1):S140.
324. Powles R, Milan S, Horton C, Singhal S, Treleaven J, Mehta J. A prospective haemato-oncology patient database for use in routine care and clinical research. *Bone Marrow Transplant* 1996; 17 (Suppl 1):S55.
325. Raje N, Powles R, Eisen T, Milan S, Horton C, Mehta J, Singhal S, Treleaven J, Cunningham D. Beta 2 microglobulin ($\beta 2M$) levels in patients of myeloma following high dose treatment and interferon maintenance. *Bone Marrow Transplant* 1996; 17 (Suppl 1):S71.
326. Raje N, Powles R, Eisen T, Horton CAP, Milan S, Mehta J, Singhal S, Viner C, Treleaven J, Cunningham D. Outcome of relapsed/resistant multiple myeloma: The Royal Marsden experience. *Bone Marrow Transplant* 1996; 17 (Suppl 1):S71.
327. Raje N, Millar BC, Bell JA, Mehta J, Singhal S, Milan S, Shepherd V, Treleaven J, Powles R. Favourable predictors of rapid engraftment in myeloma following peripheral blood stem cell transplant (PBSCT). *Bone Marrow Transplant* 1996; 17 (Suppl 1):S138.
328. Singhal S, Powles R, Treleaven J, Horton C, Swansbury GJ, Mehta J. Melphalan alone prior to allogeneic marrow transplantation for hematologic malignancies: alloengraftment with potential preservation of female fertility. *Br J Haematol* 1996; 93 (Suppl 2):259.
329. Mehta J, Kelsey SM, Chu P, Powles R, Singhal S, Hazel D, Newland AC, Treleaven J. Amphotericin B lipid complex (ABLC) for fungal infections in immunocompromised patients with hematologic malignancies. *Br J Haematol* 1996; 93 (Suppl 2):265.
330. Singhal S, Powles R, Treleaven J, Long S, Rowland A, Mehta J. Bone marrow and peripheral blood stem cell yields from healthy donors in a double-blind randomized study of allogeneic marrow versus blood stem cell transplantation. *Br J Haematol* 1996; 93 (Suppl 2):248.
331. Singhal S, Powles R, Treleaven J, Long S, Rowland A, Mehta J. Harvesting both marrow and G-CSF-mobilized blood stem cells within a week in healthy donors: clinical and hematologic consequences. *Br J Haematol* 1996; 93 (Suppl 2):258-259.
332. Zomas A, Powles R, Saso R, Mackay H, Singhal S, Hamblin M, Treleaven J, Mehta J. Incidence and clinical significance of red cell fragmentation after allogeneic or autologous bone marrow transplantation. *Br J Haematol* 1996; 93 (Suppl 2):260.
333. Raje N, Powles R, Milan S, Horton C, Mehta J, Singhal S, Treleaven J, Cunningham D. Significance of serial beta 2 microglobulin levels in patients of myeloma following high dose treatment and interferon maintenance. *Br J Haematol* 1996; 93 (Suppl 2):127.
334. Raje N, Powles R, Milan S, Middleton G, Eisen T, Mehta J, Singhal S, Treleaven J. Autografting in myeloma patients with renal impairment. *Br J Haematol* 1996; 93 (Suppl 2):87.
335. Powles R, Raje N, Horton C, Mehta J, Singhal S, Kulkarni S, Treleaven J. Complete remission patients with myeloma - factors influencing subsequent outcome. *Ann Oncol* 1996; 7 (Suppl 5):86-87.
336. Kulkarni S, Powles R, Field M, Dowding A, Mehta J, Singhal S, Treleaven J, Milan S, Raje N. Toxicity and feasibility of short course consolidation chemotherapy following autografting in multiple myeloma. *Ann Oncol* 1996; 7 (Suppl 5):86.

337. Raje N, Powles R, Horton CAP, Mehta J, Singhal S, Kulkarni S, Middleton G, Treleaven J, Milan S. Comparison of marrow versus blood derived stem cells for autografting in previously treated multiple myeloma. *Ann Oncol* 1996; 7 (Suppl 5):87.
338. Singhal S, Powles R, Treleaven J, Cabral S, Prendiville J, Glynne P, Zomas A, Saso R, Hamblin M, Mehta J. Collection of G-CSF-mobilized stem cells from the marrow donor for treatment of primary graft failure or adoptive immunotherapy. *Bone Marrow Transplant* 1996; 17 (Suppl 2):S72.
339. Treleaven J, Powles R, Singhal S, Horton C, Kulkarni S, Hale G, Waldmann H, Mehta J. Autografting with CD52 monoclonal antibody-purged marrow for acute lymphoblastic leukemia. *Blood* 1996; 88 (Suppl 1):255a.
340. Singhal S, Powles R, Treleaven J, Horton C, Swansbury GJ, Kulkarni S, Mehta J. Single-agent melphalan conditioning for allografting in leukemia: engraftment with potential preservation of fertility in women. *Blood* 1996; 88 (Suppl 1):611a.
341. Mehta J, Powles R, Singhal S, Millar B, Shepherd V, Treleaven J. Cobe Spectra or Haemonetics MCS-3P for leukapheresis in patients with hematologic malignancies? *Blood* 1996; 88 (Suppl 1):109a.
342. Mehta J, Powles R, Singhal S, Middleton G, Eisen T, Saso R, Kulkarni S, Wilson K, Benjamin A, Dent J, Alton P, Killick S, Gravett P, Treleaven J. Induction of graft-versus-host disease as immunotherapy of leukemia relapsing after allografting: single-center experience of 28 adults. *Blood* 1996; 88 (Suppl 1):260a.
343. Mehta J, Powles R, Treleaven J, Horton C, Meller S, Pinkerton CR, Singhal S. Acute leukemia relapsing after bone marrow transplantation: the place of second grafts. *Blood* 1996; 88 (Suppl 1):260a.
344. Singhal S, Powles R, Treleaven J, Kulkarni S, Horton C, Tait D, Mehta J. Sequential high-dose therapy of adult acute lymphoblastic leukemia: blood cell autografts with maintenance therapy in first remission and allografting in second remission for relapsing patients. *Blood* 1996; 88 (Suppl 1):125a.
345. Mehta J, Powles R, Singhal S, Riley U, Saso R, Wilson K, Eisen T, Middleton G, Treleaven J, Catovsky D. Allogeneic bone marrow transplantation for chronic lymphocytic leukemia: importance of infection prophylaxis. *Blood* 1996; 88 (Suppl 1):263b.
346. Mehta J, Powles R, Singhal S, Horton C, Meller S, Pinkerton CR, Treleaven J. Early identification of patients at risk of death due to infection, hemorrhage, or graft failure after allografting on the basis of the leukocyte counts. *Blood* 1996; 88 (Suppl 1):417a.
347. Mehta J, Kelsey SM, Chu P, Powles R, Singhal S, Hazel D, Newland AC, Treleaven J. Amphotericin B lipid complex (ABLC) for fungal sepsis in immunocompromised adults. *Blood* 1996; 88 (Suppl 1):264b.
348. Zomas A, Saso R, Powles R, Mackay H, Singhal S, Hamblin M, Treleaven J, Mehta J. Red cell fragmentation (schistocytosis) after bone marrow transplantation: incidence and clinical significance. *Blood* 1996; 88 (Suppl 1):260b.
349. Singhal S, Powles R, Treleaven J, Saso R, Kulkarni S, Long S, Rowland A, Mehta J. Hematologic and biochemical consequences of donating both marrow and blood cells within a week in normal donors. *Blood* 1996; 88 (Suppl 1):242b.
350. Wilson K, Powles R, Treleaven J, Singhal S, Horton C, Tait D, Kulkarni S, Saso R, Alton P, Killick S, Mehta J. Allografting after melphalan-total body irradiation for first remission acute myeloid leukemia. *Blood* 1996; 88 (Suppl 1):613a.

351. Singhal S, Powles R, Treleaven J, Saso R, Kulkarni S, Long S, Rowland A, Millar B, Shepherd V, Cabral S, Morton C, Field M, Mehta J. Cell yields in a double-blind randomized study of allogeneic marrow versus blood stem cell transplantation. *Blood* 1996; 88 (Suppl 1):403a.
352. Powles R, Milan S, Singhal S, Horton C, Treleaven J, Mehta J. An institution-based database of consecutive hemato-oncology patients: uses and potential integration with international transplant registries. *Blood* 1996; 88 (Suppl 1):270b.
353. Saso R, Zomas A, Hamblin M, Swansbury GJ, Min T, Singhal S, Powles R, Treleaven J, Mehta J. Sequential transformation of Philadelphia-positive acute lymphoblastic leukemia after autografting into myelodysplasia and acute myeloid leukemia with no evolution of the original complex karyotype. *Blood* 1996; 88 (Suppl 1):160b.
354. Powles R, Singhal S, Treleaven J, Swansbury GJ, Min T, Horton C, Middleton G, Eisen T, Catovsky D, Mehta J. Effect of karyotype abnormalities (including failure to obtain metaphases) on response to induction chemotherapy and survival in acute myeloid leukemia. *Blood* 1996; 88 (Suppl 1):159b.
355. Singhal S, Powles R, Millar B, Shepherd V, Horton C, Treleaven J, Mehta J, Catovsky D. Variability in CFU-GM measurements and correlation with CD34-positive cell yields from the blood and marrow of normal donors. *Blood* 1996; 88 (Suppl 1):242b.
356. Hamblin M, Powles R, Treleaven J, Saso R, Singhal S, Middleton G, Kulkarni S, Cabral S, Mehta J. Defibrotide for refractory thrombotic thrombocytopenic purpura (TTP) after bone marrow transplantation. *Blood* 1996; 88 (Suppl 1):60b.
357. Kulkarni S, Powles R, Eisen T, Treleaven J, Singhal S, Middleton G, Horton C, Mehta J. High-dose cytarabine and VP-16 with or without idarubicin for relapsed acute leukemia. *Blood* 1996; 88 (Suppl 1):174b.
358. Middleton G, Powles R, Singhal S, Horton C, Kulkarni S, Eisen T, Dent J, Treleaven J, Mehta J. Bone marrow transplantation from HLA-mismatched family donors for acute myeloid leukemia: 10-year follow-up. *Blood* 1996; 88 (Suppl 1):269a.
359. Powles R, Treleaven J, Singhal S, Kulkarni S, Horton C, Middleton G, Eisen T, Mehta J. Early lymphocyte recovery after allografting for acute myeloid leukemia and risk of relapse: identification of patients who may benefit from prophylactic immunotherapy. *Blood* 1996; 88 (Suppl 1):681a.
360. Saso R, Kulkarni S, Powles R, Hiorns L, Swansbury GJ, Treleaven J, Singhal S, Catovsky D, Mehta J. Treatment of acute promyelocytic leukemia: single-center experience of 54 cytogenetically confirmed cases. *Blood* 1996; 88 (Suppl 1):177b.
361. Powles R, Treleaven J, Singhal S, Kulkarni S, Horton C, Middleton G, Eisen T, Mehta J. Hematopoiesis in acute myeloid leukemia patients in long-term remission and at relapse: influence of previous therapy. *Blood* 1996; 88 (Suppl 1):270b.
362. Kulkarni S, Powles R, Mehta J, Horton C, Treleaven J, Middleton G, Eisen T, Singhal S. Thalidomide for acute or chronic graft-versus-host disease. *Blood* 1996; 88 (Suppl 1):609a.
363. Powles R, Raje N, Kulkarni S, Eisen T, Middleton G, Field M, Mehta J, Singhal S, Treleaven J, Milan S. The feasibility of short course consolidation chemotherapy following high dose chemotherapy in multiple myeloma. *Blood* 1996; 88 (Suppl 1):286b.
364. Singhal S, Siegel D, Mattox S, Jagannath S, Tricot G, Mehta J, Desikan KR, Munshi N, Zent C, Barlogie B. Central nervous system involvement in multiple myeloma. *Blood* 1996; 88 (Suppl 1):218b.

365. Singhal S, Tricot G, Jagannath S, Mehta J, Siegel D, Desikan KR, Munshi N, Vesole D, Bracy D, Barlogie B. Outcome of relapse after transplantation in myeloma. *Blood* 1996; 88 (Suppl 1):611a.
366. Singhal S, Barlogie B, Jagannath S, Bracy D, Mehta J, Desikan KR, Siegel D, Munshi N, Tricot G. Feasibility and efficacy of third transplant procedures in myeloma. *Blood* 1996; 88 (Suppl 1):611a.
367. Mehta J, Tricot G, Jagannath S, Ayers D, Singhal S, Bracy D, Siegel D, Desikan KR, Munshi N, Vesole D, Barlogie B. A single-center, matched-pair comparison of auto- and allografting in multiple myeloma. *Blood* 1996; 88 (Suppl 1):618a.
368. Powles R, Kulkarni S, Raje N, Horton C, Milan S, Middleton G, Eisen T, Sumpter K, Hill M, Singhal S, Mehta J, Treleaven J. Relapse following complete response in myeloma: outcome predictors. *Bone Marrow Transplant* 1997; 19 (Suppl 1):S158.
369. Powles R, Singhal S, Treleaven J, Swansbury GJ, Min T, Horton C, Middleton G, Eisen T, Catovsky D, Mehta J. Effect of karyotype abnormalities (including failure to obtain metaphases) on response to induction chemotherapy and survival in acute myeloid leukemia. *Bone Marrow Transplant* 1997; 19 (Suppl 1):S97.
370. Singhal S, Powles R, Millar B, Shepherd V, Horton C, Treleaven J, Mehta J, Catovsky D. Variability in CFU-GM measurements and correlation with CD34-positive cell yields from the blood and marrow of normal donors. *Bone Marrow Transplant* 1997; 19 (Suppl 1):S117.
371. Powles R, Treleaven J, Singhal S, Kulkarni S, Horton C, Middleton G, Eisen T, Mehta J. Early lymphocyte recovery after allografting for acute myeloid leukemia and risk of relapse: identification of patients who may benefit from prophylactic immunotherapy. *Bone Marrow Transplant* 1997; 19 (Suppl 1):S97.
372. Powles R, Treleaven J, Singhal S, Kulkarni S, Horton C, Middleton G, Eisen T, Mehta J. Hematopoiesis in acute myeloid leukemia patients in long-term remission and at relapse: influence of previous therapy. *Bone Marrow Transplant* 1997; 19 (Suppl 1):S98.
373. Hill M, Powles R, Kulkarni S, Horton C, Mehta J, Singhal S, Treleaven J. Effect of body weight at transplant on outcome in adult acute myeloid leukaemia. *Bone Marrow Transplant* 1997; 19 (Suppl 1):S96.
374. Mehta J, Powles R, Singhal S, Riley U, Saso R, Wilson K, Eisen T, Middleton G, Treleaven J, Catovsky D. Allogeneic bone marrow transplantation for chronic lymphocytic leukemia: importance of infection prophylaxis. *Bone Marrow Transplant* 1997; 19 (Suppl 1):S24.
375. Mehta J, Powles R, Singhal S, Middleton G, Eisen T, Saso R, Kulkarni S, Wilson K, Benjamin A, Dent J, Alton P, Killick S, Gravett P, Treleaven J. Induction of graft-versus-host disease as immunotherapy of leukaemia relapsing after allografting: single-centre experience of 28 adults. *Bone Marrow Transplant* 1997; 19 (Suppl 1):S182.
376. Singhal S, Powles R, Treleaven J, Saso R, Kulkarni S, Long S, Rowland A, Millar B, Shepherd V, Cabral S, Morton C, Field M, Mehta J. Cell yields in a double-blind randomized study of allogeneic marrow versus blood stem cell transplantation. *Bone Marrow Transplant* 1997; 19 (Suppl 1):S117.
377. Zomas A, Saso R, Powles R, Mackay H, Singhal S, Hamblin M, Treleaven J, Mehta J. Red cell fragmentation (schistocytosis) after bone marrow transplantation: incidence and clinical significance. *Bone Marrow Transplant* 1997; 19 (Suppl 1):S17.
378. Wilson K, Powles R, Treleaven J, Singhal S, Horton C, Tait D, Kulkarni S, Saso R, Alton P, Killick S, Mehta J. Allografting after melphalan-total body irradiation for first remission acute myeloid leukemia. *Bone Marrow Transplant* 1997; 19 (Suppl 1):S97.

379. Saso R, Zomas A, Hamblin M, Swansbury GJ, Min T, Singhal S, Powles R, Treleaven J, Mehta J. Sequential transformation of Philadelphia-positive acute lymphoblastic leukemia after autografting into myelodysplasia and acute myeloid leukemia with no evolution of the original complex karyotype. *Bone Marrow Transplant* 1997; 19 (Suppl 1):S102.
380. Hamblin M, Powles R, Treleaven J, Saso R, Singhal S, Middleton G, Kulkarni S, Cabral S, Mehta J. Defibrotide for refractory thrombotic thrombocytopenic purpura (TTP) after bone marrow transplantation. *Bone Marrow Transplant* 1997; 19 (Suppl 1):S126.
381. Middleton G, Powles R, Singhal S, Horton C, Kulkarni S, Eisen T, Dent J, Treleaven J, Mehta J. Bone marrow transplantation from HLA-mismatched family donors for acute myeloid leukemia: 10-year follow-up. *Bone Marrow Transplant* 1997; 19 (Suppl 1):S97.
382. Saso R, Kulkarni S, Powles R, Hiorns L, Swansbury GJ, Treleaven J, Singhal S, Catovsky D, Mehta J. Treatment of acute promyelocytic leukaemia: single-centre experience of 54 cytogenetically confirmed cases. *Bone Marrow Transplant* 1997; 19 (Suppl 1):S98.
383. Kulkarni S, Powles R, Mehta J, Horton C, Treleaven J, Middleton G, Eisen T, Singhal S. Thalidomide for acute or chronic graft-versus-host disease. *Bone Marrow Transplant* 1997; 19 (Suppl 1):S181.
384. Kulkarni S, Powles R, Mehta J, Raje N, Singhal S, Treleaven J. Allogeneic bone marrow transplantation for multiple myeloma. *Bone Marrow Transplant* 1997; 19 (Suppl 1):S201.
385. Mehta J, Powles R, Treleaven J, Horton C, Meller S, Pinkerton CR, Singhal S. Acute leukaemia relapsing after bone marrow transplantation: the place of second grafts. *Bone Marrow Transplant* 1997; 19 (Suppl 1):S98.
386. Mehta J, Ayers D, Mattox S, Singhal S, Siegel D, Fassas A, Hilton J, Anaissie E, Desikan K, Munshi N, Jagannath S, Tricot G, Barlogie B. Allogeneic bone marrow transplantation in multiple myeloma: single-center experience of 97 patients. *Blood* 1997; 90 (Suppl 1):225a.
387. Singhal S, Mehta J, Hood S, Mattox S, Siegel D, Fassas A, Desikan K, Anaissie E, Tricot G, Jagannath S, Barlogie B. Third transplants for myeloma relapsing after two prior autografts. *Blood* 1997; 90 (Suppl 1):547a.
388. Desikan KR, Nelson J, Tindle S, Siegel D, Singhal S, Fassas A, Tricot G, Jagannath S, Barlogie B, Mehta J. Stem cell collection in myeloma patients: repeated attempts may be needed to obtain an adequate harvest in patients failing to collect well initially. *Blood* 1997; 90 (Suppl 1):324b.
389. Singhal S, Hood S, Mehta J, Mattox S, Siegel D, Fassas A, Desikan K, Nelson J, Tindle S, Jagannath S, Tricot G, Barlogie B. Collection of peripheral blood stem cells after a preceding autotransplant. *Blood* 1997; 90 (Suppl 1):547a.
390. Mehta J, Singhal S, Fassas A, Hilton J, Siegel D, Desikan K, Jagannath S, Anaissie E, Barlogie B, Tricot G. Autologous marrow infusion without further conditioning for life-threatening GVHD: resolution of GVHD with persistent donor-type chimerism. *Blood* 1997; 90 (Suppl 1):372b.
391. Mehta J, Ayers D, Mattox S, Singh J, Singhal S, Siegel D, Fassas A, Desikan K, Vesole D, Munshi N, Anaissie E, Tricot G, Barlogie B, Jagannath S. High-dose melphalan and autotransplantation in myeloma with renal impairment: a matched-pair comparison with patients without renal failure. *Blood* 1997; 90 (Suppl 1):419a.
392. Treleaven J, Powles R, Singhal S, Kulkarni S, Tait D, Horton C, Mehta J. Long-term outcome of patients who are alive and well two years after autografting for acute leukemia. *Blood* 1997; 90 (Suppl 1):380a.

393. Mehta J, Powles R, Treleaven J, Kulkarni S, Singhal S. Peripheral blood stem cell autografts in acute myeloid leukemia: is relapse the only eventual outcome? *Blood* 1997; 90 (Suppl 1):405b.
394. Powles R, Treleaven J, Singhal S, Kulkarni S, Horton C, Tait D, Mehta J. Total therapy of acute myeloid leukemia: 7-year follow-up. *Blood* 1997; 90 (Suppl 1):227a.
395. Singhal S, Powles R, Treleaven J, Kulkarni S, Horton C, Tait D, Mehta J. Sequential high-dose therapy of acute lymphoblastic leukemia in adult patients: long-term follow-up. *Blood* 1997; 90 (Suppl 1):235a.
396. Mehta J, Powles R, Treleaven J, Kulkarni S, Horton C, Tait D, Singhal S. Long-term outcome of patients who are alive and well two years after allografting for acute leukemia. *Blood* 1997; 90 (Suppl 1):380a.
397. Kulkarni S, Powles R, Treleaven J, Singhal S, Sastry P, Raje N, Tait D, Mehta J. Allogeneic bone marrow transplantation for multiple myeloma. *Blood* 1997; 90 (Suppl 1):389b.
398. Singhal S, Powles R, Kulkarni S, Treleaven J, Mehta J. Immunotherapy of acute leukemia relapsing after allogeneic transplantation: the inseparability of GVHD and graft-vs-leukemia, and the problem of extramedullary relapse. *Blood* 1997; 90 (Suppl 1):547a.
399. Mehta J, Powles R, Cabral S, Proctor H, Millar B, Shepherd V, Kulkarni S, Treleaven J, Singhal S, De Reys S. A new automated apheresis system for the Cobe Spectra cell separator utilizing the platelet channel. *Blood* 1997; 90 (Suppl 1):331b.
400. Kulkarni S, Powles R, Singhal S, Treleaven J, Horton C, Meller S, Pinkerton CR, Atra A, Tait D, Mehta J. Second cancers after non-autologous bone marrow transplantation for hematologic malignancies: single-center experience of 883 patients. *Blood* 1997; 90 (Suppl 1):376a.
401. Kulkarni S, Powles R, Mehta J, Horton C, Treleaven J, Meller S, Atra A, Pinkerton CR, Singhal S. Thalidomide is very effective for chronic GVHD but has no activity in acute GVHD. *Blood* 1997; 90 (Suppl 1):376a.
402. Mehta J, Powles R, Treleaven J, Kulkarni S, Singhal S, Saso R, Hamblin M, Rege K, Cunningham D, Killick S, Tait D, Catovsky D. Bone marrow transplantation for chronic lymphocytic leukemia. *Blood* 1997; 90 (Suppl 1):390b.
403. Powles R, Kulkarni S, Mehta J, Treleaven J, Millar B, Shepherd V, Tait D, Antrum J, Neville F, Long S, Rowland A, Singhal S. A double-blind randomized study comparing the efficacy of allogeneic marrow versus blood stem cell transplantation. *Blood* 1997; 90 (Suppl 1):254a.
404. Kulkarni S, Powles R, Mehta J, Treleaven J, Saso R, Long S, Rowland A, Singhal S. Feasibility of donating both marrow and blood cells within a week in normal donors. *Blood* 1997; 90 (Suppl 1):328b.
405. Singhal S, Powles R, Kulkarni S, Treleaven J, Saso R, Long S, Rowland A, Millar B, Shepherd V, Cabral S, Mehta J. Comparison of cell yields in a single-center, double-blind, randomized study of allogeneic marrow versus blood stem cell transplantation. *Blood* 1997; 90 (Suppl 1):592a.
406. Powles R, Cunningham D, Gore M, Kulkarni S, Singhal S, Horton C, Milan S, Sastry P, Raje N, Treleaven J, Ramiah V, Mehta J. Long-term follow-up of myeloma patients treated with 140 mg/m² melphalan without autologous transplantation. *Blood* 1997; 90 (Suppl 1):356a.
407. Kulkarni S, Powles R, Treleaven J, Singhal S, Raje N, Ramiah V, Gregory K, Dark G, Millar B, Shepherd V, Neville F, Antrum J, Horton C, Milan S, Mehta J. Comparison of equal doses of

- lenograstim and filgrastim for mobilization of peripheral blood stem cells in patients with hematologic malignancies. *Blood* 1997; 90 (Suppl 1):328b.
408. Mehta J, Powles R, Treleaven J, Kulkarni S, Swansbury GJ, Hamblin M, Saso R, Killick S, Rege K, Singhal S. High-dose cytarabine and etoposide for induction of remission in acute myeloid leukemia: the effect of additional idarubicin. *Blood* 1997; 90 (Suppl 1):507a.
 409. Saso R, Kulkarni S, Treleaven J, Killick S, Rege K, Mehta J, Singhal S, Morilla R, Atra A, Swansbury GJ, Powles R, Catovsky D. Immunophenotypic and cytogenetic features of 10 patients with minimally differentiated acute myeloid leukemia (FAB M0). *Blood* 1997; 90 (Suppl 1):221b.
 410. Waldron J, Jazieh R, Jagannath S, Desikan KR, Siegel D, Fassas A, Singhal S, Mehta J, Tricot G, Vesole D, Wilson C, Hough A, Naucke S, Spoon D, Barlogie B. Bone marrow morphology (BMM) adds critical prognostic information to other standard parameters (SP) including cytogenetics among newly diagnosed multiple myeloma (MM) patients (pts) receiving total therapy (TT). *Blood* 1997; 90 (Suppl 1):90a.
 411. Desikan KR, Mehta J, Fassas A, Siegel D, Munshi N, Singhal S, Jagannath S, Tricot G, Barlogie B. Peripheral blood stem cell (PBSC) collection with G-CSF alone in multiple myeloma (MM): factors associated with post transplant (Tx) recovery. *Blood* 1997; 90 (Suppl 1):231a.
 412. Desikan KR, Fassas A, Siegel D, Jagannath S, Mehta J, Singhal S, Bracy D, Tricot G, Barlogie B. Superior outcome with melphalan 200 mg/m² (Mel 200) for scheduled second autotransplant compared with Mel+TBI or CTX for myeloma (MM) in pre-Tx2 PR. *Blood* 1997; 90 (Suppl 1):231a.
 413. Siegel D, Jagannath S, Desikan KR, Tricot G, Vesole D, Fassas A, Singhal S, Mehta J, Hood S, Barlogie B. Similar prognosis after tandem autotransplants (TAT) for myeloma <65 yr and ≥65 yr. *Blood* 1997; 90 (Suppl 1):419a.
 414. Siegel D, Mehta J, Anaissie E, Desikan KR, Fassas A, Jagannath S, Singhal S, Tricot G, Munshi N, Barnhart S, Hood S, Spoon D, Mattox S, Barlogie B. Prolonged immunosuppression after CD34+ or CD34+/Thy-1+/Lin- selected autologous peripheral blood stem cell (PBSC) transplants (Tx) for multiple myeloma. *Blood* 1997; 90 (Suppl 1):112a.
 415. Fassas A, Desikan KR, Golper T, Siegel D, Singhal S, Mehta J, Mattox S, Jagannath S, Tricot G, Barlogie B. Tumor lysis syndrome (TLS) following intermediate and high dose therapy in patients (pts) with multiple myeloma (MM) - association with high tumor mass, immature morphology, high labeling index (LI) and abnormal cytogenetics (CG). *Blood* 1997; 90 (Suppl 1):527a.
 416. Jagannath S, Vesole D, Siegel D, Desikan KR, Munshi N, Fassas A, Singhal S, Mehta, Spoon D, Tricot G, Evans T, Naucke S, Tindle S, Nelson J, Copeland N, Barlogie B. Final analysis of total therapy (TT) with tandem transplants (Tx) for 231 newly diagnosed patients (pts) with multiple myeloma (MM). *Blood* 1997; 90 (Suppl 1):418a-419a.
 417. Koneru B, Hough A, Fassas A, Tricot G, Desikan KR, Siegel D, Jagannath S, Singhal S, Mehta J, Barlogie B, Anaissie E. Autopsy review in multiple myeloma (MM) reveals aspergillosis (ASP) as a significant cause of death after high dose therapy (HDT) especially with allotransplants (allo-tx). *Blood* 1997; 90 (Suppl 1):353a.
 418. Koneru B, Anaissie E, Tricot G, Jagannath S, Mehta J, Desikan R, Siegel D, Singhal S, Fassas A, Barlogie B. High incidence of and mortality from *Toxoplasma gondii* infections in T-cell depleted allogeneic bone marrow transplant recipients. *Blood* 1997; 90 (Suppl 1):224a.
 419. Munshi NC, Tricot G, Jagannath S, Mehta J, Desikan K, Siegle S, Singhal S, Fassas A, Fink L, Schichman S, Chiang Y, Reynolds C, Barlogie B. Clinical results of thymidine kinase (TK) gene

- transduced donor lymphocyte infusion following allogeneic transplantation in myeloma. *Blood* 1997; 90 (Suppl 1):111a.
420. Munshi NC, Jagannath S, Desikan K, Mehta J, Singhal S, Siegle S, Fassas A, Ayers D, Mattox S, Anaissie A, Tricot G, Barlogie B. Significance of recovery of uninvolved immunoglobulins (UIg) following total therapy (TT) with tandem autotransplants in newly diagnosed multiple myeloma (MM). *Blood* 1997; 90 (Suppl 1):353a.
 421. Ramiah V, Powles R, Sumpter K, Raje N, Kulkarni S, Hill M, Gregory K, Dark G, Horton C, Milan S, Mehta J, Singhal S, Field M, Neville F, Antrum J, Treleaven J. A randomised trial of short course consolidation chemotherapy (MRC UKALL X) following high dose chemotherapy in multiple myeloma. *Blood* 1997; 90 (Suppl 1):407b.
 422. Hill ME, Powles RL, Kulkarni S, Horton C, Sumpter K, Mehta J, Singhal S, Treleaven J. Influence of nutritional status on outcome following transplantation for AML. *Blood* 1997; 90 (Suppl 1):221a.
 423. Sumpter K, Powles R, Raje N, Kulkarni S, Ramiah V, Hill M, Horton C, Milan S, Mehta J, Singhal S, Rodriguez M, Mateos P, Laufente A, Treleaven J. A single institution review of cases of AL amyloidosis. *Blood* 1997; 90 (Suppl 1):408b.
 424. Sumpter K, Powles R, Raje N, Kulkarni S, Ramiah V, Hill M, Horton C, Milan S, Mehta J, Singhal S, Rodriguez M, Mateos P, Laufente A, Treleaven J. Oral idarubicin as single agent therapy for patients with relapsed multiple myeloma. *Blood* 1997; 90 (Suppl 1):310b.
 425. Mateos P, Lafuente A, Rodriguez M, Kulkarni S, Mehta J, Singhal S, Saso R, Gregory K, Dark G, Tait D, Treleaven J, Powles R. Hepatic veno-occlusive disease (VOD) treated with recombinant tissue plasminogen activator (rt-PA). *Blood* 1997; 90 (Suppl 1):219a.
 426. Raje N, Powles R, Kulkarni S, Ramiah V, Sumpter K, Horton C, Mehta J, Singhal S, Treleaven J. Plasma cell leukaemia: outcome following infusional chemotherapy and autografts. *Blood* 1997; 90 (suppl 1):407b.
 427. Powles R, Kulkarni S, Mehta J, Treleaven J, Millar B, Shepherd V, Tait D, Antrum J, Neville F, Long S, Rowland A, Shaw K, Singhal S. A double-blind randomised study comparing the efficacy of allogeneic marrow versus blood stem cell transplantation. *Bone Marrow Transplant* 1998; 21 (Suppl 1):S35.
 428. Sumpter K, Powles R, Raje N, Kulkarni S, Ramiah V, Hill M, Horton C, Milan S, Mehta J, Singhal S, Treleaven J. A single institution review of cases of AL amyloidosis. *Bone Marrow Transplant* 1998; 21 (Suppl 1):S210.
 429. Mehta J, Powles R, Kulkarni S, Treleaven J, Singhal S, Cunningham D, Tait D, Catovsky D. Bone marrow transplantation for chronic lymphocytic leukemia. *Bone Marrow Transplant* 1998; 21 (Suppl 1):S78.
 430. Singhal S, Powles R, Kulkarni S, Treleaven J, Saso R, Long S, Rowland A, Shaw K, Millar B, Shepherd V, Cabral S, Mehta J. Comparison of cell yields in a single-centre, double blind, randomised study of allogeneic marrow vs blood stem cell transplantation. *Bone Marrow Transplant* 1998; 21 (Suppl 1):S41.
 431. Kulkarni S, Powles R, Treleaven J, Singhal S, Raje N, Ramiah V, Gregory K, Dark G, Millar B, Shepherd V, Neville F, Antrum J, Horton C, Milan S, Mehta J. Comparison of equal doses of lenograstim and filgrastim for mobilization of peripheral blood stem cells in patients with haematologic malignancies. *Bone Marrow Transplant* 1998; 21 (Suppl 1):S196.

432. Kulkarni S, Powles R, Singhal S, Treleaven J, Horton C, Meller S, Pinkerton CR, Atra A, Tait D, Mehta J. Second cancers after non-autologous bone marrow transplantation for haematological malignancies: Single centre experience of 883 patients. *Bone Marrow Transplant* 1998; 21 (Suppl 1):S162.
433. Lafuente A, Mateos P, Rodriguez M, Kulkarni S, Mehta J, Singhal S, Saso R, Gregory K, Dark G, Treleaven J, Powles R. Hepatic veno-occlusive (VOD) treated with recombinant tissue plasminogen activator (rt-PA). *Bone Marrow Transplant* 1998; 21 (Suppl 1):S240.
434. Kulkarni S, Powles R, Treleaven J, Singhal S, Mehta J, Saso R, Horton C. Factors affecting blood component requirement after autograft for haematological malignancies. *Bone Marrow Transplant* 1998; 21 (Suppl 1):S9.
435. Kulkarni S, Powles R, Singhal S, Mehta J, Treleaven J, Shaw K, Long S, Rowland A. Feasibility of donating both marrow and blood cells within a week in normal donors. *Bone Marrow Transplant* 1998; 21 (Suppl 1):S41.
436. Singhal S, Powles R, Kulkarni S, Treleaven J, Mehta J. Immunotherapy of acute leukemia relapsing after allogeneic transplantation: the inseparability of GVHD and graft-vs-leukemia, and the problem of extramedullary relapse. *Bone Marrow Transplant* 1998; 21 (Suppl 1):S69.
437. Mehta J, Powles R, Treleaven J, Kulkarni S, Horton C, Tait D, Singhal S. Long-term outcome of patients who are alive and well two years after allografting for acute leukaemia. *Bone Marrow Transplant* 1998; 21 (Suppl 1):S7.
438. Treleaven J, Powles R, Singhal S, Kulkarni S, Tait D, Horton C, Mehta J. Long-term outcome of patients who are alive and well two years after autografting for acute leukaemia. *Bone Marrow Transplant* 1998; 21 (Suppl 1):S8.
439. Kulkarni S, Powles R, Singhal S, Reiley U, Horton C, Treleaven J, Mehta J. Outcome of bone marrow transplantation in patients with evidence of viral hepatitis. *Bone Marrow Transplant* 1998; 21 (Suppl 1):S154.
440. Mehta J, Powles R, Treleaven J, Kulkarni S, Singhal S. Peripheral blood stem cell autografts in acute myeloid leukemia: is relapse the only eventual outcome? *Bone Marrow Transplant* 1998; 21 (Suppl 1):S8.
441. Kulkarni S, Powles R, Mehta J, Singhal S, Horton C, Treleaven J. Transplants for haematological malignancies in patients above the age of 50 years. *Bone Marrow Transplant* 1998; 21 (Suppl 1):S78.
442. Singhal S, Powles R, Treleaven J, Kulkarni S, Horton C, Tait D, Mehta J. Melphalan-TBI for allogeneic transplantation in acute myeloid leukemia: lack of veno-occlusive disease and hemorrhagic cystitis. *Blood* 1998; 92 (Suppl 1):658a.
443. Kulkarni S, Powles R, Singhal S, Treleaven J, Horton C, Ramiah V, Saso R, Sirohi B, Sastry P, Mehta J. Second autografts for relapsed multiple myeloma: Is tandem autotransplantation better? *Blood* 1998; 92 (suppl 1):344b.
444. Kulkarni S, Powles R, Singhal S, Treleaven J, Horton C, Mehta J. Late pneumococcal infections in bone marrow transplant recipients: is penicillin prophylaxis inadequate? *Blood* 1998; 92 (Suppl 1):320a.
445. Mehta J, Powles R, Kulkarni S, Treleaven J, Singhal S, Saso R, Tait D, Mehta J. Melphalan-TBI and T-cell-non depleted allografts for chronic lymphocytic leukemia: Long-term follow-up shows excellent anti-leukemic activity. *Blood* 1998; 92 (Suppl 1):288a.

446. Powles R, Kulkarni S, Mehta J, Treleaven J, Millar B, Shepherd V, Tait D, Rowland A, Long S, Singhal S. Pattern of immune reconstitution after allograft: results of double blind randomised trial of allogeneic bone marrow or peripheral blood stem cells transplantation. *Blood* 1998; 92 (Suppl 1):141a.
447. Powles R, Kulkarni S, Mehta J, Treleaven J, Horton C, Shepherd V, Millar B, Rowland A, Marsden J, Long S, Singhal S. Incidence and outcome of GVHD and its correlation with immune reconstitution in a double blind randomised single centre trial of PBSC versus bone marrow for allogeneic HLA identical sibling BMT. *Blood* 1998; 92 (Suppl 1):354b.
448. Powles R, Kulkarni S, Treleaven J, Mehta J, Singhal S, Horton C. Assessment of patients who are alive in first complete remission (CR) for more than 10 years following autograft for haematological malignancies. *Blood* 1998; 92 (Suppl 1):455a.
449. Kulkarni S, Powles R, Treleaven J, Singhal S, Mehta J, Saso R, Horton C. Factors affecting blood component requirement after autograft for haematological malignancies. *Blood* 1998; 92 (Suppl 1):280a.
450. Kulkarni S, Powles R, Singhal S, Reiley U, Horton C, Treleaven J, Mehta J. Outcome of bone marrow transplantation in patients with evidence of viral hepatitis. *Blood* 1998; 92 (Suppl 1):333b.
451. Kulkarni S, Powles R, Mehta J, Horton C, Treleaven J, Meller S, Atra A, Pinkerton CR, Singhal S. Thalidomide in GVHD - is anti-GVHD effect separable from the antiangiogenesis? *Blood* 1998; 92 (Suppl 1):344b.
452. Treleaven J, Kulkarni S, Powles R, Singhal S, Horton C, Mehta J. Transplantation for haematological malignancies in patients above the age of 50 years. *Blood* 1998; 92 (Suppl 1):328b.
453. Kulkarni S, Powles R, Mehta J, Raje N, Singhal S, Horton C, Tait D, Treleaven J. Allogeneic bone marrow transplantation for multiple myeloma. *Blood* 1998; 92 (Suppl 1):352b.
454. Kulkarni S, Singhal S, Powles R, Neville F, Shaw K, Antrum J, Rowland A, Long S, Field M, Treleaven J, Mehta J. Donor preference assessment regarding bone marrow (BM) versus lenograstim mobilized peripheral stem cells (PBSC) for allograft. *Blood* 1998; 92 (Suppl 1):141a.
455. Kulkarni S, Powles R, Treleaven J, Singhal S, Mehta J, Saso R, Horton C. Predictors of transfusion requirement beyond three months for AML autografts in first remission. *Blood* 1998; 92 (Suppl 1):367b.
456. Powles R, Cunningham D, Jameson B, Tiley C, Mehta J, Milan S, Hewitson M. Randomized placebo-controlled evaluation of prophylactic fluconazole after bone marrow transplantation. *Blood* 1998; 92 (Suppl 1):337b.
457. Singhal S, Mehta J, Eddlemon P, Gray P, Cromer J, Desikan R, Ayers D, Siegel D, Munshi N, Anaissie E, Kantarjian H, Zeldsi J, Barlogie B. Marked anti-tumor effect from anti-angiogenesis (AA) therapy with thalidomide (T) in high risk refractory multiple myeloma (MM). *Blood* 1998; 92 (Suppl 1):318a.
458. Munshi N, Wilson C, Penn J, Sanderson R, Hough A, Desikan R, Siegel D, Singhal S, Mehta J, Barlogie B. Angiogenesis in newly diagnosed multiple myeloma (MM): poor prognosis with increased microvessel density (MVD) in one marrow biopsies (BMBX). *Blood* 1998; 92 (Suppl 1):98a.
459. Butch A, Ayers D, Sawyer J, Drach J, Desikan R, Munshi N, Siegel D, Mehta J, Singhal S, Anaissie E, Barlogie B. Cytogenetics (CG) and cytokinetics (CK) in multiple myeloma (MM). *Blood* 1998; 92 (Suppl 1):258a-259a.

460. Drach J, Ayers D, Govindarajan R, Sawyer J, Shaughnessy J, Siegel D, Desikan R, Singhal S, Mehta J, Munshi N, Anaissie E, Barlogie B. MDS-associated cytogenetic abnormalities (CGA) in both hematopoietic and neoplastic cells after autotransplants (AT) in 868 patients with multiple myeloma (MM). *Blood* 1998; 92 (Suppl 1):97a.
461. Barlogie B, Sawyer J, Ayers D, Desikan R, Siegel D, Singhal S, Mehta J, Munshi N, Anaissie E, Drach J, Shaughnessy J. Chromosome 13 myeloma (- 13 MM) is a distinct entity with poor prognosis despite tandem autotransplants. *Blood* 1998; 92 (Suppl 1):258a.
462. Sawyer J, Drach J, Ayers D, Desikan R, Munshi , Siegel D, Mehta J, Singhal S, Anaissie E, Barlogie B. Adverse prognosis in multiple myeloma (MM) in the presence of MDS-associated cytogenetic (CG) abnormalities within a MM typical karyotype. *Blood* 1998; 92 (Suppl 1):98a.
463. Desikan R, Siegel D, Anaissie E, Singhal S, Mehta J, Munshi N, Spoon D, Ayers D, Barlogie B. Peripheral blood stem cell (PBSC) mobilization with DCEP, an effective regimen for high risk multiple myeloma (MM) and prompt engraftment after melphalan (MEL 200 mg/m²)-based high dose therapy. *Blood* 1998; 92 (Suppl 1):273a.
464. Desikan R, Dhodapkar M, Siegel D, Fassas A, Singh J, Singhal S, Mehta J, Vesole D, Tricot G, Jagannath S, Kamble R, Anaissie E, Munshi N, Barlogie B. High dose therapy with autologous peripheral blood stem cell (PBSC) support for Waldenstrom's macroglobulinemia: a pilot study. *Blood* 1998; 92 (Suppl 1):660a.
465. Barlogie B, Desikan R, Munshi N, Siegel D, Mehta J, Singhal S, Anaissie E. Single course D.T. PACE anti-angiochemotherapy effects CR in plasma cell leukemia and fulminant multiple myeloma (MM). *Blood* 1998; 92 (Suppl 1):273b.
466. Desikan R, Siegel D, Fassas A, Mehta J, Singhal S, Munshi N, Anaissie E, Ayers D, Cromer J, Spoon D, Barlogie B. DCEP consolidation after tandem autotransplants in (AT) in high risk multiple myeloma (MM) - improved prognosis compared to matched historical controls. *Blood* 1998; 92 (Suppl 1):660a.
467. Drach J, Angtuaco E, Shah H, Sawyer J, Siegel D, Munshi N, Singhal S, Mehta J, Anaissie E, Barlogie B. Fine needle aspiration (FNA) of MRI-detected focal medullary lesions is a novel tool to improve cytogenetics (CG) yield in multiple myeloma (MM). *Blood* 1998; 92 (Suppl 1):262b.
468. Munshi N, Mitani Y, Schichman SA, Butch A, Rosen N, Fink LM, Vesole D, Singhal S, Desikan R, Siegel D, Mehta J, Barlogie B, Lue C. restricted T-cell receptor (TCR) α chain repertoire following T-cell depleted allogeneic transplantation and partial reconstitution following donor lymphocyte infusion as studied by the CDR3 length analysis. *Blood* 1998; 92 (Suppl 1):358b.
469. Mehta J, Sawyer J, Ayers D, Desikan R, Munshi N, Singhal S, Siegel D, Anaissie E, Epstein J, Shaughnessy J, Drach J, Barlogie B. Different prognostic implications post-transplant of certain cytogenetic abnormalities (Δ CG) in multiple myeloma (MM) in relation to the duration of prior standard therapy. *Blood* 1998; 92 (Suppl 1):267b.
470. Angtuaco E, Jazieh A, Ferris E, Stringer W, Van Hemert R, Siegel D, Desikan R, Mehta J, Singhal S, Anaissie E, Barlogie B. Complete remission by MRI (MR-CR) after tandem autotransplants associated with superior survival. *Blood* 1998; 92 (Suppl 1):259b.
471. Powles R, Sirohi B, Treleaven J, Kulkarni S, Bhagwati N, Saso R, Horton C, Singhal S, Mehta J. Post-transplant consolidation chemotherapy to eliminate minimal residual disease in myeloma patients after high-dose melphalan and autotransplantation: feasibility and tolerance. *Blood* 1999; 94 (Suppl 1):314b.
472. Sirohi B, Powles R, Sumpter K, Kulkarni S, Singhal S, Bhagwati N, Horton C, Saso R, Mehta J, Treleaven J. A comparison of kinetics of paraprotein clearance after infusional chemotherapy versus

- high-dose melphalan in previously untreated patients with IgG multiple myeloma. *Blood* 1999; 94 (Suppl 1):314b.
473. Munshi NC, Badros A, Mehta J, Desikan RK, Zangari M, Singhal S, Cromer JL, Anaissie EJ, Barlogie B. Melphalan based non-myeloablative chemotherapy achieves durable chimerism in patients (pts) with multiple myeloma. *Blood* 1999; 94 (Suppl 1):323b.
474. Powles R, Kulkarni S, Sirohi B, Bhagwati N, Mehta J, Singhal S, Treleaven J, Neville F, Hobbs K, Indri Annesley N, Gourlay ML, Barouki F. Phase I/II evaluation of intravenous tresperimus (LF 08-0299) and methyprednisone as first line therapy for acute graft versus host disease (GVHD). *Blood* 1999; 94 (Suppl 1):331b.
475. Singhal S, Powles R, Treleaven J, Kulkarni S, Sirohi B, Tait D, Horton C, Rowland A, Long S, Millar B, Shepherd V, Mehta J. A low CD34+ cell dose results in higher mortality and lower survival after blood or marrow stem cell transplantation from HLA-identical siblings: Should 2×10^6 CD34+ cells/kg be considered the threshold? *Blood* 1999; 94 (Suppl 1):388b.
476. Sirohi B, Powles R, Singhal S, Treleaven J, Kulkarni S, Bhagwati N, Mehta J. Sequential high-dose therapy of adult acute lymphoblastic leukemia (ALL) with autotransplantation in first remission and salvage allogeneic transplantation in second remission: Long-term follow-up. *Blood* 1999; 94 (Suppl 1):388b.
477. Powles R, Mehta J, Kulkarni S, Treleaven J, Sirohi B, Tait D, Horton C, Rowland A, Long S, Millar B, Shepherd V, Singhal S. More powerful graft-versus-tumor effects with blood-derived stem cells? Significantly lower relapse after blood stem cell allografts in a randomized study comparing allogeneic blood versus marrow transplantation. *Blood* 1999; 94 (Suppl 1):164a.
478. Powles R, Kulkarni S, Treleaven J, Hobbs K, Sirohi B, Bhagwati N, Mehta J, Singhal S, Williams T. Phase III randomized trial of Nyotran (liposomal nystatin) or amphotericin B for the empiric antifungal therapy in febrile neutropenic patients. *Blood* 1999; 94 (Suppl 1): 342a.
479. Sirohi B, Powles R, Treleaven J, Singhal S, Kulkarni S, Parikh P, Bhagwati N, Horton C, Mehta J. The implication of compromised renal function at the time of presentation in myeloma: A single-centre study of 251 patients. *Blood* 1999; 94 (Suppl 1):575a.
480. Sirohi B, Powles R, Treleaven J, Singhal S, Parikh P, Bhagwati N, Horton C, Kulkarni S, Mehta J. Light chain disease (LCD): A different form of myeloma compared with IgG and IgA disease? *Blood* 1999; 94 (Suppl 1):576a.
481. Sirohi B, Powles R, Treleaven J, Mainwaring P, Kulkarni S, Bhagwati N, Horton C, Singhal S, Mehta J. High-dose chemotherapy and autologous transplantation in myeloma patients aged 65 years and over: A case-control comparison with younger patients. *Blood* 1999; 94 (Suppl 1): 578a.
482. Bhagwati NS, Powles RL, Sirohi B, Treleaven JG, Horton CA, Tait D, Mehta J, Singhal S, Kulkarni SS. Single center evaluation of long term follow-up of ABMT/PBSCT for first remission adult ALL: Potential for cure without excessive toxicity. *Blood* 1999; (Suppl 1):580a.
483. Desikan R, Munshi N, Zeldis J, Eddlemon P, Badros A, Zangari M, Singhal S, Mehta J, Ayers D, Lim S, Wilson C, Anaissie E, Crowley J, Barlogie B. Activity of thalidomide (THAL) in multiple myeloma (MM) confirmed in 180 patients with advanced disease. *Blood* 1999; (Suppl 1):603a.
484. Powles R, Cunningham D, Kulkarni S, Sirohi B, Gregory RK, Mehta J, Singhal S, Bhagwati N, Treleaven J, Fletcher L, Fisher T, O'Dea S, Millar B, Sheperd V, Sampson M, Watson D, Penny J. Combination of ancestim (r-metHu stem cell factor, SCF) and filgrastim (r-metHu G-CSF, G-CSF) for peripheral blood stem cell (PBSC) collection in patients who have previously failed to mobilize with G-CSF alone. *Blood* 1999; (Suppl 1):606a.

485. Bhagwati N, Powles R, Sirohi B, Treleaven J, Horton C, Tait D, Mehta J, Singhal S, Kulkarni S. Single centre evaluation of long term follow-up of ABMT/PBSCT for first remission adult ALL: potential for cure without excessive toxicity. *Bone Marrow Transplant* 2000; 25 (Suppl 1):S5.
486. Sirohi B, Powles R, Kulkarni S, Bhagwati N, Horton C, Saso R, Singhal S, Mehta J, Treleaven J. Central nervous system relapse after stem cell transplantation (SCT) for acute leukemia beyond first remission. *Bone Marrow Transplant* 2000; 25 (Suppl 1):S6.
487. Powles R, Kulkarni S, Mehta J, Treleaven J, Millar B, Shepherd V, Rowland A, Sirohi B, Tait, D, Horton C, Long S, Singhal S. Pattern of immune reconstitution after allograft: results of double blind randomised trial of allogeneic bone marrow or peripheral blood stem cells transplantation. *Bone Marrow Transplant* 2000; 25 (Suppl 1):S30.
488. Powles R, Kulkarni S, Bhagwati N, Mehta J, Singhal S, Sirohi B, Treleaven J, Neville F, Inriannesley N, Gourlay ML, Barouki F. Phase I/II evaluation of intravenous tresperimus (LF 08-0299) and methylprednisone as first line therapy for acute graft-versus-host disease. *Bone Marrow Transplant* 2000; 25 (Suppl 1):S39.
489. Kulkarni S, Powles R, Treleaven J, Singhal S, Mehta J, Sirohi B, Barlow C, Chau I, Horton C. Predictors of transfusion requirement beyond three months for AML autografts in first remission. *Bone Marrow Transplant* 2000; 25 (Suppl 1):S83.
490. Powles R, Kulkarni S, Treleaven J, Singhal S, Sirohi B, Bhagwati N, Horton C, Tait D, Mehta J. Delivery of intensive acute myeloid leukaemia curative care in real world environments: A single center experience of 92 population based patients with potential implications to future multi-center trials. *Bone Marrow Transplant* 2000; 25 (Suppl 1):S85.
491. Kulkarni S, Powles R, Mehta J, Singhal S, Treleaven J, Saso R, Matutes E, Dearden C, Cunningham D, Catovsky D. Allogeneic and autologous haematopoietic stem cell transplantation for chronic lymphocytic leukaemia. *Bone Marrow Transplant* 2000; 25 (Suppl 1):S95.
492. Barlow C, Powles R, Chau I, Horton C, Treleaven J, Mehta J, Singhal S, Kulkarni S. Allograft beyond the age of 50 years: Matched pair analysis with cases transplanted at younger age. *Bone Marrow Transplant* 2000; 25 (Suppl 1):S138.
493. Kulkarni S, Powles R, Mehta J, Treleaven J, Saso R, Horton C, Sirohi B, Singhal S. Thalidomide in GVHD - is anti-GVHD effect separable for the antiangiogenesis. *Bone Marrow Transplant* 2000; 25 (Suppl 1):S153.
494. Powles, R, Kulkarni S, Treleaven J, Hobbs K, Sirohi B, Bhagwati N, Mehta J, Singhal S, Williams T. Phase II randomized trial of nyotran (liposomal nystatin) or amphotericin for the empiric antifungal therapy in febrile neutropenic patients. *Bone Marrow Transplant* 2000; 25 (Suppl 1):S197.
495. Powles, R, Kulkarni S, Treleaven J, Mehta J, Singhal S, Sirohi B, Hobbs K, Horton C. Assessment of patients who are alive in first complete remission (CR) for more than 10 years following autograft for hematological malignancies. *Bone Marrow Transplant* 2000; 25 (Suppl 1):S211.
496. Kulkarni S, Powles R, Singhal S, Sirohi B, Horton C, Treleaven J, Barlow C, Chau I, Swanie H, Mehta J. Second autografts for relapsed multiple myeloma: Is tandem autotransplantation better? *Bone Marrow Transplant* 2000; 25 (Suppl 1):S218.
497. Sirohi B, Powles R, Sumpter K, Kulkarni S, Singhal S, Bhagwati N, Saso R, Horton C, Mehta J, Treleaven J. A comparison of kinetics of paraprotein clearance: Rapid decline of paraprotein after high-dose melphalan (HDM) versus infusional chemotherapy (IC) in previously untreated patients with IgG multiple myeloma. *Bone Marrow Transplant* 2000; 25 (Suppl 1):S218.

498. Sirohi B, Powles R, Treleaven J, Mainwaring P, Kulkarni S, Bhagwati N, Horton C, Singhal S, Saso R, Mehta J. High-dose chemotherapy (HDT) and autologous transplantation in myeloma patients aged 65 years and over: A case control comparison with younger patients. *Bone Marrow Transplant* 2000; 25 (Suppl 1):S218.
499. Sirohi B, Powles R, Kulkarni S, Bhagwati N, Saso R, Horton C, Singhal S, Raje N, Mehta J, Treleaven J. Glomerular filtration rate (GFR) as a surrogate marker for transplant-related toxicity and overall outcome in patients of multiple myeloma (MM) homogenously treated with high-dose melphalan (HDM) 200 mg/m². *Bone Marrow Transplant* 2000; 25 (Suppl 1):S218.
500. Powles R, Sirohi B, Kulkarni S, Bhagwati N, Saso R, Horton C, Singhal S, Raje N, Mehta J, Treleaven J. Acute lymphoblastic leukemia-type intensive chemotherapy (ALL-IC) to eliminate minimal residual disease post autografting in multiple myeloma: A phase I/II feasibility and tolerance study of 17 patients. *Bone Marrow Transplant* 2000; 25 (Suppl 1):S219.
501. Sirohi B, Powles R, Singhal S, Bhagwati N, Saso R, Horton C, Raje N, Mehta J, Treleaven J. Bence-Jones (BJ) Myeloma: A different form of myeloma compared to IgG and IgA myeloma. *Bone Marrow Transplant* 2000; 25 (Suppl 1):S219.
502. Kulkarni S, Powles R, Treleaven J, Singhal S, Mehta J, Horton C, Sirohi B, Swannie H. Previous autograft adversely affects the outcome of allograft for myeloma. *Bone Marrow Transplant* 2000; 25 (Suppl 1):S220.
503. Sirohi B, Powles R, Treleaven J, Kulkarni S, Horton C, Parikh P, Bhagwati N, Saso R, Singhal S, Raje N, Mehta J. The implication of compromised and normal renal function at presentation in myeloma. *Bone Marrow Transplant* 2000; 25 (Suppl 1):S226.
504. Sirohi B, Powles R, Treleaven J, Kulkarni S, Horton C, Parikh P, Bhagwati N, Saso R, Raje N, Mehta J, Singhal S. High-dose chemotherapy and autologous stem cell transplant for metastatic neuroblastoma: A single-center experience. *Bone Marrow Transplant* 2000; 25 (Suppl 1):S247.
505. Powles R, Cunningham D, Kulkarni S, Gregory K, Sirohi B, Mehta J, Singhal S, Bhagwati N, Treleaven J, O'Dea S, Miller B, Sampson M, Watson D, Penny J. Combination of ancestim (r-metHu stem cell factor, SCF) and filgrastim (r-metHu G-CSF, G-CSF) for peripheral blood stem cell (PBSC) collection in patients who have previously failed to mobilize with G-CSF alone. *Bone Marrow Transplant* 2000; 25 (Suppl 1):S255.
506. Kulkarni S, Powles R, Treleaven J, Singhal S, Sirohi B, Millar B, Shepherd V, Neville F, Swannie H, Mehta J, Horton C. Randomized trial comparing equal doses of lenograstim and filgrastim for mobilization of peripheral blood stem cells in patients with hematologic malignancies. *Bone Marrow Transplant* 2000; 25 (Suppl 1):S260.
507. Sirohi B, Powles R, Kulkarni S, Saso R, Horton C, Mehta J, Singhal S, Treleaven J. CNS relapse after auto- and allo- stem cell transplant (SCT) for acute leukemia beyond first CR. *Hematol J* 2000; 1 (Suppl 1): 213.
508. Sirohi B, Powles R, Treleaven J, Mainwaring P, Kulkarni S, Horton C, Singhal S, Saso R, Mehta J. High-dose therapy and autotransplantation in myeloma patients aged 65 years and over: a case control comparison with younger patients. *Hematol J* 2000; 1 (Suppl 1): 209.
509. Powles R, Sirohi B, Treleaven J, Kulkarni S, Horton C, Parikh P, Bhagwati N, Saso R, Singhal S, Raje N, Mehta J. Influence of renal dysfunction at presentation in myeloma – similar outcome in patients who receive high-dose therapy (HDT): a single centre study of 251 previously untreated patients. *Hematol J* 2000; 1 (Suppl 1): 209.

510. Kulkarni S, Powles R, Mehta J, Singhal S, Treleaven J, Saso R, Matutes E, Tait D, Cunningham D, Catovsky D. Allogeneic and autologous haematopoietic stem cell transplantation for chronic lymphocytic leukaemia. *Hematol J* 2000; 1 (Suppl 1): 202.
511. Sirohi B, Powles R, Kulkarni S, Bhagwati N, Saso R, Horton C, Singhal S, Raje N, Mehta J, Treleaven J. Glomerular filtration rate as a surrogate marker for transplant-related toxicity and overall outcome in patients with multiple myeloma homogeneously treated with high-dose melphalan. *Hematol J* 2000; 1 (Suppl 1): 196.
512. Powles R, Kulkarni S, Bhagwati N, Mehta J, Singhal S, Sirohi B, Treleaven J, Neville F, Indri Annesley N, Gourlay ML, Barouki F. Phase I/II evaluation of intravenous tresperimus (LF08-0299) and methylprednisolone as first line therapy for acute graft-versus-host disease. *Hematol J* 2000; 1 (Suppl 1): 194.
513. Kulkarni S, Powles R, Treleaven J, Singhal S, Sirohi B, Millar B, Shepherd V, Neville F, Horton C, Mehta J, Cunningham D. Comparison of equal doses of lenograstim and filgrastim for mobilization of peripheral blood stem cells in patients with haematologic malignancies. *Hematol J* 2000; 1 (Suppl 1): 191.
514. Sirohi B, Sumpter K, Powles R, Kulkarni S, Singhal S, Bhagwati N, Saso R, Horton C, Mehta J, Treleaven J. Kinetics of paraprotein clearance: rapid decline of paraprotein after high-dose melphalan (HDM) compared to infusional chemotherapy in previously untreated patients with IgG myeloma. *Hematol J* 2000; 1 (Suppl 1): 169.
515. Powles R, Kulkarni S, Treleaven J, Singhal S, Sirohi B, Bhagwati N, Horton C, Tait D, Mehta J. Delivery of acute myeloid leukaemia curative care in real world environments: a single center experience of 92 population based patients with potential implications to future multi-center trials. *Hematol J* 2000; 1 (Suppl 1): 104.
516. Powles R, Sirohi B, Kulkarni S, Bhagwati N, Saso R, Horton C, Mehta J, Singhal S, Treleaven J. Autotransplants for adult ALL in CR1. A single centre study of 75 patients. *Hematol J* 2000; 1 (Suppl 1): 204.
517. Sirohi B, Powles R, Treleaven J, Kulkarni S, Horton C, Parikh P, Bhagwati N, Saso R, Singhal S, Raje N, Mehta J. The implication of compromised renal function at presentation in myeloma – similar outcome in patients who receive high-dose therapy (HDT): a single centre study of 251 previously untreated patients. *Br J Haematol* 2000; 108 (Suppl 1): 21.
518. Sirohi B, Powles R, Kulkarni S, Bhagwati N, Saso R, Horton C, Singhal S, Raje N, Mehta J, Treleaven J. Bence-Jones (BJ) myeloma: a distinct entity compared to IgG and IgA myeloma. *Br J Haematol* 2000; 108 (Suppl 1): 32.
519. Sirohi B, Powles R, Kulkarni S, Bhagwati N, Saso R, Horton C, Mehta J, Singhal S, Treleaven J. Central nervous system relapse after stem cell transplantation (SCT) for acute leukemia beyond first remission. *Br J Haematol* 2000; 108 (Suppl 1): 71.
520. Chiang KY, Godder K, van Rhee F, Mehta J, Singhal S, DeRienzo S, O'Neil W, Henslee-Downey PJ. Linezolid in allogeneic bone marrow transplantation: case report. *Blood* 2000; 96 (Suppl 1):336b.
521. Chiang KY, Marshall C, Abhyankar S, Godder K, van Rhee F, Mehta J, Singhal S, Bridges K, Henslee-Downey PJ. Recombinant human soluble tissue necrosis factor-alpha receptor fusion protein as an alternative treatment for chronic graft-versus-host disease (CGvHD) following allogeneic bone marrow transplantation. *Blood* 2000; 96 (Suppl 1):401a.
522. Van Rhee F, Adams S, Godder K, Mehta J, Chiang KY, Singhal S, Geier S, Lamb L, Goon-Johnson K, Carpenter S, Higgins-Smith K, O'Neil W, Bridges K, DeRienzo S, Neglia W, Szydlo R, Henslee-

- Downey PJ. Allogeneic transplantation from partially mismatched related donors: use of younger donors improves outcome. *Blood* 2000; 96 (Suppl 1):208a.
523. Mehta J, Singhal S, Chiang KY, Godder K, van Rhee F, Geier S, Lamb L, Foster B, Goon-Johnson K, Higgins-Smith K, Carpenter S, Bridges K, Adams S, DeRienzo S, O'Neal W, Marshall C, Neglia W, Henslee-Downey PJ. Haploidentical BMT for acute leukemia: single-center experience of 220 patients. *Blood* 2000; 96 (Suppl 1):840a.
524. Singhal S, Powles R, Henslee-Downey PJ, Treleaven J, Chiang KY, Godder K, Kulkarni S, van Rhee F, Meller S, Pinkerton CR, Sirohi B, Horton C, Mehta J. Haploidentical or autologous transplantation for advanced acute leukemia? *Blood* 2000; 96 (Suppl 1):209a.
525. Singhal S, Chiang KY, Powles R, Henslee-Downey PJ, Treleaven J, Godder K, Kulkarni S, van Rhee F, Sirohi B, Pinkerton CR, Meller S, Mehta J. Allogeneic transplantation from matched sibling or partially matched related donors for primary refractory acute leukemia. *Blood* 2000; 96 (Suppl 1):210a.
526. Mehta J, Powles R, Sirohi B, Treleaven J, Kulkarni S, Murphy K, Conway A, Cole C, Saso R, Singhal S. Low-dose amphotericin B lipid complex (ABLC) is safe and effective as empiric anti-fungal therapy in immunocompromised patients with hematologic malignancies. *Blood* 2000; 96 (Suppl 1):24a.
527. Powles R, Mehta J, Treleaven J, Kulkarni S, Sirohi B, Horton C, Tait D, Long S, Singhal S. Blood or BM for allogeneic transplantation from HLA-identical siblings? Extended follow-up of a randomized study confirms significantly higher relapse with BM. *Blood* 2000; 96 (Suppl 1):196a.
528. Treleaven J, Powles R, Sirohi B, Singhal S, Kulkarni S, Saso R, Horton C, Mehta J. Autografting and post-transplant maintenance chemotherapy in CR1 acute lymphoblastic leukemia. *Blood* 2000; 96 (Suppl 1):427a.
529. Sirohi B, Powles R, Treleaven J, Singhal S, Kulkarni S, Saso R, Riggs A, Mehta J. High-dose melphalan and autotransplantation in myeloma patients with severe renal dysfunction (creatinine clearance <20 ml/min/m²): high incidence of atrial fibrillation and treatment-related mortality. *Blood* 2000; 96 (Suppl 1):388a.
530. Powles R, Sirohi B, Treleaven J, Singhal S, Cunningham D, Gore M, Kulkarni S, Saso R, Mehta J. 15-year follow-up of myeloma patients receiving 140 mg/m² melphalan without hematopoietic stem cell or growth factor support as initial therapy. *Blood* 2000; 96 (Suppl 1):292b.
531. Sirohi B, Powles R, Mehta J, Treleaven J, Pinkerton CR, Meller S, Kulkarni S, Saso R, Singhal S. Central nervous system relapse in acute leukemia patients transplanted beyond the first remission. *Blood* 2000; 96 (Suppl 1):404a.
532. Sirohi B, Powles R, Treleaven J, Singhal S, Kulkarni S, Saso R, Pinkerton CR, Meller S, Vaidya S, Murphy K, Conway A, Seybel C, Cunningham D, Mehta J. Amphotericin B colloid dispersion (ABCD) for the treatment of proven or presumed fungal infections in immunocompromised patients with hematologic malignancies. *Blood* 2000; 96 (Suppl 1):37b.
533. Powles R, Sirohi B, Treleaven J, Millar B, Singhal S, Kulkarni S, Saso R, Horton C, Hobbs K, Murphy K, Mehta J. Collection of peripheral blood stem cells in newly-diagnosed myeloma patients without any prior cytoreductive chemotherapy. *Blood* 2000; 96 (Suppl 1):182a.
534. Powles R, Sirohi B, Treleaven J, Singhal S, Kulkarni S, Saso R, Horton C, Mehta J. Early response to infusional chemotherapy is an independent prognostic factor in newly-diagnosed IgG and IgA multiple myeloma. *Blood* 2000; 96 (Suppl 1):758a.

535. Powles R, Sirohi B, Treleaven J, Singhal S, Kulkarni S, Lal R, Riggs A, Horton C, Saso R, Mehta J. Continued first complete remission in multiple myeloma for over 10 years: a series of "operationally cured" patients. *Blood* 2000; 96 (Suppl 1):515a.
536. Powles R, Sirohi B, Treleaven J, Singhal S, Kulkarni S, Chau I, Saso R, Horton C, Lal R, Mehta J. Maximal response to infusional chemotherapy prior to autotransplantation influences outcome of patients with newly-diagnosed multiple myeloma. *Blood* 2000; 96 (Suppl 1):292b.
537. El-nenaei M, Sirohi B, Powles R, Treleaven J, Brito-Babapulle V, Kulkarni S, Singhal S, Mehta J, Matutes E, Catovsky D. Deletions of 13q14 are associated with a high frequency of p53 deletions in newly-diagnosed patients with myeloma. *Blood* 2000; 96 (Suppl 1):274b.
538. Godder KT, Chiang KY, Van Rhee F, Mehta J, Singhal S, Bridges K, Goon-Johnson K, Henslee-Downey PJ. Partially mismatched related donor bone marrow transplant for patients with second remission ALL provides long term survival. *J Ped Hematol Oncol* 2000; 22:388-389.
539. Powles R, Mehta J, Kulkarni S, Treleaven J, Sirohi B, Horton C, Tait D, Marsden J, Long S, Singhal S. Blood or BM for allogeneic transplantation from HLA-identical siblings? Extended follow-up of a randomized study confirms significantly higher relapse with BM. *Bone Marrow Transplant* 2001; 27 (Suppl 1):S8-S9.
540. Powles R, Sirohi B, Kulkarni S, Mehta J, Singhal S, Bhagwati N, Saso R, Horton C, Treleaven J. Place of vincristine in maintenance of remission after autologous stem cell transplantation for first remission adult acute lymphoblastic leukaemia. *Bone Marrow Transplant* 2001; 27 (Suppl 1):S88.
541. Kulkarni S, Powles R, Sirohi B, Saso R, Rudin C, Treleaven J, Horton C, Singhal S, Mehta J. Allogeneic (allo) or autologous (auto) hematopoietic stem cell transplant (HSCT) for advanced acute myeloid leukaemia (AML). *Bone Marrow Transplant* 2001; 27 (Suppl 1):S86.
542. Powles R, Kulkarni S, Treleaven J, Mehta J, Singhal S, Saso R, Sirohi B, Horton C. Allogeneic bone marrow (BMT) or peripheral blood stem cell (PBSCT) transplant: early helper T-cell recovery results in better survival. *Bone Marrow Transplant* 2001; 27 (Suppl 1):S98.
543. Powles R, Sirohi B, Kulkarni S, Gore M, Saso R, Mehta J, Singhal S, Horton C, Treleaven J, Cunningham D. 15-year follow-up of myeloma patients receiving 140 mg/m² melphalan without hematopoietic stem cell or growth factor support as initial therapy. *Bone Marrow Transplant* 2001; 27 (Suppl 1):S246.
544. Powles R, Sirohi B, Kulkarni S, Millar B, Mehta J, Singhal S, Horton C, Murphy K, Fletcher L, Saso R, Treleaven J. Feasibility of collecting peripheral blood stem cells in previously untreated myeloma patients without any prior cytoreductive therapy. *Bone Marrow Transplant* 2001; 27 (Suppl 1):S251.
545. Kulkarni S, Powles R, Sirohi B, Horton C, Saso R, Mehta J, Singhal S, Treleaven J. Predictive model to assess the risk of treatment related mortality (TRM) in patients undergoing allogeneic hematopoietic stem cell transplant (AHSCT). *Bone Marrow Transplant* 2001; 27 (Suppl 1):S280.
546. Kulkarni S, Powles R, Saso R, Sirohi B, Horton C, Mehta J, Singhal S, Tait D, Hyianakis D, Rudin C, Treleaven J. Single centre analysis of allogeneic hematopoietic stem cell transplant for acute leukemia in first complete remission: comparison of two single fraction dose schedules (9.5Gy or 10.5Gy). *Bone Marrow Transplant* 2001; 27 (Suppl 1):S309.
547. Sirohi B, Powles R, Kulkarni S, Treleaven J, Saso R, Singhal S, Mehta J. Role of defibrotide (Dt) and therapeutic plasma exchange (TPE) in the management of transplant associated thrombotic thrombocytopenic purpura/hemolytic uremic syndrome (TTP/HUS): a single centre experience. *Bone Marrow Transplant* 2001; 27 (Suppl 1):S314.

548. Powles R, Kulkarni S, Sirohi B, Saso R, Treleaven J, Horton C, Singhal S, Mehta J. Results of allogeneic transplant in patients with chronic myeloid leukemia (CML): single centre evaluation of 141 patients. *Bone Marrow Transplant* 2001; 27 (Suppl 1):S37.
549. Powles R, Sirohi B, Kulkarni S, Singhal S, Mehta J, Saso R, Horton C, Lal R, Treleaven J. Continued complete remission of patients with multiple myeloma beyond 10 years: are they "operationally cured"? *Bone Marrow Transplant* 2001; 27 (Suppl 1):S245.
550. Sirohi B, Powles R, Kulkarni S, Parikh P, Mehta J, Singhal S, Saso R, Treleaven J. High-dose melphalan and autotransplantation in myeloma patients with severe renal dysfunction: high incidence of atrial fibrillation and treatment-related mortality. *Bone Marrow Transplant* 2001; 27 (Suppl 1):S246-S247.
551. Powles R, Sirohi B, El-Nenaei M, Swansbury J, Singhal S, Treleaven J, Saso R, Kulkarni S, Mehta J, Goyal S, Catovsky D. Influence of chromosome 13 abnormalities on the likelihood of achieving complete remission (CR) in new patients treated with C-VAMP to maximum response. *Blood* 2001; 98 (Suppl 1):164a-165a.
552. Powles R, Sirohi B, Singhal S, Treleaven J, Kulkarni S, Goyal S, Horton C, Mehta J. Using the original infusional induction chemotherapy again as salvage therapy in myeloma patients relapsing after one autograft. *Blood* 2001; 98 (11):165a.
553. Powles R, Sirohi B, Kulkarni S, Singhal S, Mehta J, Horton C, Saso R, Goyal S, Lloyd C, Treleaven J. Relapse following complete remission: outcome predictors in patients with secretory myeloma. *Blood* 2001; 98 (11):165a-166a.
554. Powles R, Singhal S, Sirohi B, Horton C, Treleaven J, Mehta J. "Discontinuous complete remission": a new endpoint to evaluate the success of therapy in keeping myeloma patients disease-free for extended periods of time. *Blood* 2001; 98 (11):166a.
555. Sirohi B, Powles R, Singhal S, Treleaven J, Kulkarni S, Saso R, Goyal S, Horton C, Mehta J. The addition of weekly cyclophosphamide to infusional induction chemotherapy (vincristine, doxorubicin, methylprednisolone) does not affect subsequent stem cell collection in patients with myeloma. *Blood* 2001; 98 (11):173a.
556. Mehta J, Oyama Y, Winter J, Williams S, Tallman M, Singhal S, Gordon L. Lack of correlation between the pre-leukapheresis hematocrit and the CD34+ cell collection efficiency of the cell separator. *Blood* 2001; 98 (11):174a.
557. Mehta J, Singhal S, Gordon L, Tallman M, Williams S, Ali Y, Oyama Y, Villa M, Shook T, Winter J. Cobe Spectra or Fenwal CS 3000 Plus for collection of hematopoietic stem cells? *Blood* 2001; 98 (11):175a.
558. Kulkarni S, Powles R, Sirohi B, Treleaven J, Horton C, Saso R, Tait D, Hijiyanakis P, Singhal S, Mehta J. Single centre analysis of allogeneic hematopoietic stem cell transplant for acute leukaemia in first complete remission: comparison of two single fraction dose schedules (9.5Gy or 10.5Gy). *Blood* 2001; 98 (11):195a-196a.
559. Ali Y, Oyama Y, Monreal J, Winter J, Tallman M, Gordon L, Williams S, Singhal S, Mehta J. Engraftment after transplantation revisited: is it necessary to see $0.5 \times 10^9/l$ neutrophils on 3 consecutive days to define myeloid recovery? *Blood* 2001; 98 (11):198a.
560. Ali Y, Oyama Y, Monreal J, Winter J, Tallman M, Williams S, Singhal S, Gordon L, Mehta J. Ideal or actual body weight to calculate CD34+ cell doses for autologous hematopoietic stem cell transplantation? *Blood* 2001; 98 (11):201a-202a.

561. Tomblyn M, Gordon L, Singhal S, Tallman M, Williams S, Winter J, Mehta J. Rarity of toxigenic *Clostridium difficile* infections after hematopoietic stem cell transplantation despite broad-spectrum antimicrobial therapy: implications for symptomatic management of diarrhea. *Blood* 2001; 98 (11):206a.
562. Kulkarni S, Powles R, Sirohi B, Treleaven J, Singhal S, Saso R, Rudin C, Horton C, Mehta J. Use of peripheral blood stem cells (PBSC) is likely to be associated with higher incidence of lung involvement in chronic graft vs. host disease (GVHD) following allogeneic hematopoietic stem cell transplant (AHSCT). *Blood* 2001; 98 (11):397a.
563. Sirohi B, Powles R, Singhal S, Treleaven J, Kulkarni S, Saso R, Tait D, Mehta J. 20-Year follow-up of allogeneic bone marrow transplantation with cyclophosphamide-TBI and cyclosporine for acute myeloid leukemia in first complete remission. *Blood* 2001; 98 (11):402a.
564. Sirohi B, Powles R, Singhal S, Treleaven J, Kulkarni S, Horton C, Mehta J. High-dose melphalan and second autografts for myeloma relapsing after one autograft: results equivalent to tandem autotransplantation. *Blood* 2001; 98 (11):402a.
565. Mehta J, Powles R, Sirohi B, Treleaven J, Kulkarni S, Horton C, Saso R, Tait D, Singhal S. Does donor-recipient ABO-incompatibility protect against relapse after allogeneic bone marrow transplantation in first remission acute myeloid leukemia? *Blood* 2001; 98 (11):407a.
566. Singhal S, Powles R, Sirohi B, Treleaven J, Kulkarni S, Saso R, Tait D, Mehta J. Enhancement of the anti-tumor efficacy of allogeneic transplantation with the use of blood-derived stem cells: 5-year follow-up of a prospective study comparing marrow and blood allografts. *Blood* 2001; 98 (11):419a.
567. Singhal S, Powles R, Sirohi B, Treleaven J, Kulkarni S, Saso R, Mehta J. The effect of CD34+ cell doses on long-term overall and disease-free survival after allogeneic blood or marrow stem cell transplantation for hematologic malignancies: more is better. *Blood* 2001; 98 (11):420a.
568. Powles R, Milan S, Horton C, Sirohi B, Treleaven J, Singhal S, Mehta J. The Royal Marsden Hospital leukemia-myeloma database: an "operations research" resource for assessing clinical outcomes and planning new drug trials. *Blood* 2001; 98 (11):426a.
569. Kulkarni S, Powles R, Sirohi B, Treleaven J, Saso R, Riley U, Rudin C, Horton C, Mehta J, Singhal S. Predictors of CMV reactivation following allogeneic hematopoietic stem cell transplant (AHSCT) for haematological malignancies. *Blood* 2001; 98 (11):552a-553a.
570. Sirohi B, Powles R, Singhal S, Kulkarni S, Treleaven J, Rudin C, Horton C, Saso R, Heming D, Mehta J. Hyperleukocytosis in patients with newly-diagnosed acute myeloid leukemia: clinical implications and consequences of leukapheresis to reduce the tumor burden. *Blood* 2001; 98 (11):588a.
571. Winter JN, Inwards D, Erwin W, Wiseman G, Rademaker A, Patton D, Williams S, Tallman M, Mehta J, Singhal S, Micallef I, Spies S, Multani P, Zimmer M, White C, Gordon LI. Phase I trial combining ⁹⁰y Zevalin and high-dose BEAM chemotherapy with hematopoietic progenitor cell transplant in relapsed or refractory B-cell NHL. *Blood* 2001; 98 (11):677a-678a.
572. Gordon LI, Mittal BB, Rademaker A, Tallman MS, Williams SF, Kaminer L, Mehta J, Singhal S, Patton D, Welles C, Falco A, Fishman M, Winter JN. Phase I dose-escalation trial of total lymphoid irradiation (TLI) and high-dose chemotherapy with cyclophosphamide, carboplatin and etoposide (CyCE) and autologous peripheral blood stem cell transplantation (AuPBSCT) in patients with relapsed/refractory Hodgkins disease: the Northwestern University/Robert H. Lurie Comprehensive Cancer Center experience. *Blood* 2001; 98 (11):680a-681a.
573. Powles R, Sirohi B, Mehta J, Treleaven J, Horton C, Kulkarni S, Saso R, Bowen A, Norman A, Singhal S. Reduced relapse rates in newly-treated myeloma patients by using peripheral blood stem

- cells over bone marrow as the source of stem cells for autologous transplantation: single-center experience of 435 patients treated with 200 mg/m² melphalan. *Blood* 2001; 98 (11):684a.
574. Powles R, Sirohi B, Mehta J, Treleaven J, Kulkarni S, Horton C, Saso R, Menon A, Macey D, Singhal S. Does the number of infused CD34+ cells affect the long-term outcome of myeloma patients treated with high-dose melphalan and autotransplantation? *Blood* 2001; 98 (11):685a.
575. Sirohi B, Powles R, Singhal S, Treleaven J, Kulkarni S, Saso R, Horton C, Heming D, Mehta J. Implication of impaired renal function at the time of initiation of infusional chemotherapy (C-VAMP) in patients with newly-diagnosed myeloma. *Blood* 2001; 98 (11):686a.
576. Powles R, Sirohi B, Singhal S, Treleaven J, Kulkarni S, Horton C, Mehta J. The role of maintenance therapy after autotransplantation in adult acute lymphoblastic leukemia. *Blood* 2001; 98 (11):689a-690a.
577. Sirohi B, Powles R, Singhal S, Treleaven J, Saso R, Kulkarni S, Horton C, Tait D, Mehta J. The impact of consolidation chemotherapy on the outcome of autotransplantation for acute myeloid leukemia in first remission: single-center experience of 118 adult patients. *Blood* 2001; 98 (11):690a.
578. Mehta J, Powles R, Sirohi B, Treleaven J, Swansbury GJ, Min T, Kulkarni S, Saso R, Tait D, Singhal S. Impact of cytogenetics on the outcome of autotransplantation for acute myeloid leukemia in first remission: is the benefit of intensive pre-transplant therapy limited to patients with good karyotypes? *Blood* 2001; 98 (11):716-717a.
579. Singhal S, Powles R, Sirohi B, Treleaven J, Mehta J. Response to induction chemotherapy is not essential to obtain survival benefit from high-dose melphalan and autotransplantation in myeloma. *Blood* 2001; 98 (11):816a.
580. Kulkarni S, Powles R, Sirohi B, Treleaven J, Saso R, Singhal S, Rudin C, Goyal S, Horton C, Earl J, Mehta J. Combination of tissue plasminogen activator (rT-PA) and low dose heparin with or without defibrotide for the treatment of clinically suspected hepatic veno-occlusive disease (HVD) following allogeneic hematopoietic stem cell transplant (AHSCT) for hematological malignancies. *Blood* 2001; 98 (11):853-854a.
581. Powles R, Sirohi B, Kulkarni S, Singhal S, Treleaven J, Saso R, Rudin C, Horton C, Mehta J. High dose ara-c (HDARA) as a part of the first course of treatment for de novo AML patients above the age of 50 yr. *Blood* 2001; 98 (11):219b.
582. Oyama Y, Ali Y, Tallman M, Winter J, Falco A, O'Connor N, Fishman M, Welles C, Williams S, Singhal S, Gordon L, Mehta J. TNF- α blockade with etanercept for successful therapy of refractory acute and chronic graft-versus-host disease. *Blood* 2001; 98 (11):360b.
583. Oyama Y, Ali Y, Fishman M, Welles C, O'Connor N, Falco A, Winter J, Tallman M, Williams S, Singhal S, Gordon L, Mehta J. Routine sinus CT scanning is unnecessary prior to hematopoietic stem cell transplantation. *Blood* 2001; 98 (11):360b.
584. Mehta J, Oyama Y, Ali Y, Tallman M, Winter J, Williams S, Gordon L, Singhal S. 100 mg/m² melphalan and repeated infusions of g-csf-mobilized allogeneic blood stem cells ("microallograft") as therapy of high-risk myeloma relapsing after 1-2 previous autografts: high complete response rates in association with chronic graft-versus-host disease. *Blood* 2001; 98 (11):378b-379b.
585. Sirohi B, Powles R, Singhal S, Treleaven J, Horton C, Tait D, Kulkarni S, Saso R, Mehta J. Melphalan-total body irradiation and allogeneic transplantation from HLA-identical siblings for acute myeloid leukemia in first remission: higher relapse after marrow-derived stem cell grafts compared to blood despite similar chronic graft-versus-host disease. *Blood* 2001; 98 (11):381b.

586. Kulkarni S, Powles R, Cunningham D, Sirohi B, Treleaven J, Rudin C, Saso R, Singhal S, Mehta J, Matutes E, Catovsky D. Allogeneic and autologous haematopoietic stem cell transplantation for chronic lymphocytic leukaemia. *Blood* 2001; 98 (11):393b.
587. Powles R, Sirohi B, Singhal S, Goyal S, Treleaven J, Lloyd C, Kulkarni S, Mehta J. 200 mg/m² melphalan as initial therapy in multiple myeloma: a key to rapid achievement of complete remission. *Blood* 2001; 98 (11):397b.
588. Powles R, Sirohi B, Frassoni F, Singhal S, Labopin M, Michallet M, Blaise D, Reiffers J, Meloni G, Rio B, Horton C, Kulkarni S, Mehta J. Bone marrow or peripheral blood stem cell autotransplantation for acute myeloid leukemia in first remission? a matched-pair analysis from the Royal Marsden Hospital and the European Blood and Marrow Transplant Group (EBMT). *Blood* 2001; 98 (11):397b-398b.
589. Sirohi B, Powles R, Singhal S, Treleaven J, Kulkarni S, Sankpal S, Goyal S, Horton C, Mehta J. Second high-dose melphalan autografts for myeloma patients relapsing after one autograft: results equivalent to tandem transplantation. *Bone Marrow Transplant* 2002; 29 (Suppl 2):S12.
590. Richardson P, Barlogie B, Berenson J, Traynor A, Singhal S, Jagannath S, Irwin D, Rajkumar V, Srkalovic G, Alsina M, Alexanian R, Siegel D, Orlowski RZ, Kuter D, Limentani SA, Lee S, Esseltine DL, Kauffman M, Adams J, Schenkein DP, Anderson KC. A phase II multicenter study of the proteasome inhibitor bortezomib (Velcade™, formerly PS-341) in multiple myeloma patients (pts) with relapsed/refractory disease. *Blood* 2002; 100 (11): Abstract #385.
591. Cilley J, Rihn C, Monreal J, Gordon L, Singhal S, Tallman M, Williams S, Winter J, Mehta J. CD34+ cell dose based on ideal body weight is a better predictor of myeloid engraftment after allogeneic transplantation than actual body weight. *Blood* 2002; 100 (11):417a.
592. Rihn C, Cilley J, Monreal J, Gordon L, Singhal S, Tallman M, Williams S, Winter J, Mehta J. Definition of myeloid engraftment after allogeneic hematopoietic stem cell transplantation. *Blood* 2002; 100 (11):417a-418a.
593. Powles R, Sirohi B, Singhal S, Kulkarni S, Horton C, Treleaven J, Mehta J. 10-year survival in myeloma: a new endpoint for testing potentially curative strategies? *Blood* 2002; 100: Abstract #1555.
594. Powles R, Sirohi B, Lawrence D, Kulkarni S, Hollis H, Heming, D Sankpal S, Patel G, Singhal S, Treleaven J, Mehta J. An open, randomized, controlled, phase II, single centre, two-period cross over study to compare the quality of life (QoL) and toxicity experienced on PEG interferon (P-IFN) with interferon- α 2b (IFN) in patients with multiple myeloma (MM) maintained on a steady dose of IFN. *Blood* 2002; 100: Abstract #1561.
595. Winter JN, Inwards D, Erwin W, Wiseman G, Rademaker A, Patton DR, Williams S, Tallman MS, Mehta J, Singhal S, Micalllef I, Multani, P, Zimmer M, Smith L, Spies S, White C, Gordon LI. Zevalin dose-escalation followed by high-dose BEAM and autologous peripheral blood progenitor cell (PBPC) transplant in non-hodgkin's lymphoma: early outcome results. *Blood* 2002; 100: Abstract #1597
596. Singhal S, Powles R, Sirohi B, Kulkarni S, Treleaven J, Mehta J. CD34+ cell dose based upon ideal body weight (IBW) is a better predictor of transplant-related mortality (TRM) and disease-free survival (DFS) than that based upon actual body weight (ABW). *Blood* 2002; 100: Abstract # 1667.
597. Powles R, Mehta J, Sirohi B, Kulkarni S, Treleaven J, Singhal S. 7-year follow-up of a randomized study of allogeneic marrow versus blood stem cell transplantation: lower relapse and higher disease-free survival with blood. *Blood* 2002; 100: Abstract # 1668
598. Sirohi B, Powles R, Singhal S, Kulkarni S, Sankpal S, Treleaven J, Saso R, Horton C, M. Stephens, Mehta J. 200 mg/m² melphalan (HDM200) and salvage autotransplantation in myeloma patients relapsing after a preceding autograft. *Blood* 2002; 100: Abstract # 1680.

599. Evens AM, Winter JN, Tallman MS, Nelson B, Fung BB, Fitzpatrick J, Gartenhaus R, Singhal S, O'Regan R, Williams SF, Mehta J, Gordon LI. Multi-modality therapy with a new chemotherapy regimen (T-CAP/V-MAC) followed by hematopoietic stem cell transplant (HSCT) and immunotherapy (α IFN/IL-2) for mantle cell lymphoma (MCL): prospective analysis of response and toxicity. *Blood* 2002; 100: Abstract #2243.
600. Powles R, Sirohi B, Singhal S, Kulkarni S, Treleaven J, Mehta J. Predictors of length of first complete remission in new patients with secretory myeloma. *Blood* 2002; 100: Abstract #2381
601. Parmar S, Stosor V, Gordon LI, Singhal S, Tallman M, Williams S, Winter JN, Mehta J. Fever and empiric antibiotic use in hematopoietic stem cell transplant patients receiving quinolone prophylaxis. *Blood* 2002; 100: Abstract #2469
602. Evens AM, Stosor V, Gordon LI, Singhal S, Tallman MS, Tomblyn M, Winter JN, Williams S, Mehta J. Increasing enterococcus species (ENT spp) colonization and bacteremia after hematopoietic stem cell transplantation (HSCT). *Blood* 2002; 100: Abstract # 2474.
603. Powles R, Kulkarni S, Sirohi B, Treleaven J, Saso R, Sankpal S, Mehta J, Singhal S, Horton C. Predictive model based on day 7 parameters to predict the risk of treatment related mortality (TRM) in patients undergoing allogeneic hematopoietic-stem cell transplant (AHSCT). *Blood* 2002; 100: Abstract #412.
604. Sirohi B, Powles R, Singhal S, Kulkarni S, Sankpal S, Treleaven J, Horton C, Saso R, Mehta J. Long-term outcome of myeloma patients treated with an elective single autograft with follow-up ≥ 5 years: results comparable to tandem autotransplantation. *Blood* 2002; 100: Abstract 671.
605. Sirohi B, Powles R, Mehta J, Kulkarni S, Sankpal S, Treleaven J, Rudin C, Horton C, Singhal S. Prognostic factors at the time of single autotransplantation in 451 myeloma patients treated with 200 mg/m² melphalan: results equivalent to tandem autotransplantation. *Blood* 2002; 100: Abstract #673.
606. Powles R, Cavenagh JD, Sirohi B, Oakervee H, Singhal S, Bishop L, Horton C, Kulkarni S, Barnett M, Dyer P, Rintala T, Mehta J. Upfront collection of peripheral blood stem cells (PBSC) in new patients with myeloma receiving minimal or no prior cytoreductive therapy: comparison of two regimes from Royal Marsden Hospital and St. Bartholomew's Hospital. *Blood* 2002; 100 Abstract # 3270.
607. Tomblyn M, Villa M, Shook T, Gordon LI, Singhal S, Tallman MS, Williams S, Winter JN, Mehta J. Use of total leukocyte and platelet counts to guide stem cell apheresis in healthy allogeneic donors receiving G-CSF. *Blood* 2002; 100: Abstract # 3275.
608. Kulkarni S, Powles R, Sirohi B, Brennan J, Treleaven J, Saso R, Sankpal S, Ortin M, Mehta J, Singhal S, Horton C. Single centre evaluation of thyroid function abnormalities following haematopoietic stem cell transplant (HSCT). *Blood* 2002; 100: Abstract # 3351.
609. Powles R, Kulkarni S, Sirohi B, Treleaven J, Saso R, Sankpal S, Horton C, Singhal S, Mehta J. HLA-matched sibling allograft for acute myeloid leukemia (AML) in second complete remission (CR2): potential for reversal of remission. *Blood* 2002; 100: Abstract #3368.
610. Mehta J, Powles R, Sirohi B, Treleaven J, Kulkarni S, Singhal S. Excellent results of unpurged autotransplantation in first-remission acute myeloid leukemia with t(8;21), inv(16), and t(15;17). *Blood* 2002; 100: Abstract # 3391.
611. Mehta J, Powles R, Sirohi B, Kulkarni S, Treleaven J, A. Zomas, Singhal S. Poor outcome of autotransplantation in acute myeloid leukemia patients not attaining complete remission with 1 cycle of induction chemotherapy: Identifying candidates for an alternative-donor allograft in first remission. *Blood* 2002; 100: Abstract #3392.

612. Powles R, Kulkarni S, Sirohi B, Treleaven J, Saso R, Horton C, Singhal S, Mehta J. results of allogeneic transplant in patients with chronic myeloid leukaemia (CML): single centre evaluation of 141 patients - Royal Marsden Hospital experience over 20 years. *Blood* 2002; 100: Abstract #4878.
613. Powles R, Sirohi B, Singhal S, Kulkarni S, Horton C, Treleaven J, Sankpal S, Mehta J. Leukocyte count on day 14 of infusional chemotherapy with C-VAMP in new patients with multiple myeloma: predictor of early mortality. *Blood* 2002; 100: Abstract #5087.
614. Sirohi B, Powles R, Kulkarni S, Carr-Smith HD, Sankpal S, Patel G, Singhal S, Igbal J, Bradwell AR, Mehta J. Serum free light chain assessment in myeloma patients who are in complete remission by immunofixation. *Blood* 2002; 100: Abstract #5095.
615. Sirohi B, Powles R, Singhal S, Kulkarni S, Stephens M, Mehta J. Feasibility of administering infusional induction chemotherapy (C-VAMP) in myeloma patients over the age of 70 years. *Blood* 2002; 100: Abstract #5131.
616. Sirohi B, Powles R, Singhal S, Kulkarni S, Saso R, Horton C, Sankpal S, Treleaven J, Patel G, Mehta J. Total cumulative dose of cyclophosphamide administered during induction infusional chemotherapy (C-VAMP) is an independent prognostic marker in new patients with myeloma. *Blood* 2002; 100: Abstract #5134.
617. Mehta J, Evens A, Gordon LI, Tallman MS, Williams S, Winter JN, Singhal S. Multiple infusions of donor stem cells after melphalan-based submyeloablative conditioning ("microallograft") in patients with hematologic malignancies: strong relationship between GVHD and tumor control. *Blood* 2002; 100: Abstract #5294.
618. Powles R, Kulkarni S, Sirohi B, Treleaven J, Saso R, Sankpal S, Singhal S, Horton C, Mehta J. Is Clinical graft-vs. host disease (GVHD) essential for the benefit of allogeneic bone marrow transplant (BMT)? *Blood* 2002; 100: Abstract #5361.
619. Powles R, Sirohi B, Singhal S, Kulkarni S, Patel G, Sankpal S, Brennan J, Stephens M, Treleaven J, Mehta J. Tolerability of high-dose melphalan 200 mg/m² in patients with myeloma and leukemia over the age of 65 Years: a single-centre study of 42 patients. *Blood* 2002; 100: Abstract #5501.
620. Sirohi B, Powles R, Mehta J, Kulkarni S, Horton C, Saso R, Singhal S. Prognostic factors at the time of single autotransplantation with 200 mg/m² melphalan: a single-center study of 451 myeloma (MM) patients. *Hematology J* 2003; 4 (Suppl 1): S204.
621. Sirohi B, Powles R, Singhal S, Sankpal S, Kulkarni S, Saso R, Patel G, Horton C, Mehta J. Long-term event free survival (≥5 years) with myeloma planned to receive a single autotransplant: better or comparable results compared to tandem autotransplantation. *Hematology J* 2003; 4 (Suppl 1): S217.
622. Richardson PG, Briemberg H, Jagannath S, Barlogie B, Berenson J, Singhal S, Traynor A, Siegel D, Irwin D, Schuster M, Srkalovic G, Alexanian R, Rajkumar SV, Limentani S, Alsina M, Orlowski R, Kuter D, Esseltine D, Adams J, Schenkein DP, Wen P, Amato A, Anderson KC. Peripheral neuropathy following bortezomib (VELCADE™, formerly PS-341) therapy in patients with advanced multiple myeloma (MM): characterization and reversibility. *Blood* 2003; 102: Abstract #512.
623. Jagannath S, Barlogie B, Berenson J, Singhal S, Alexanian R, Srkalovic G, Orlowski R, Richardson PG, Nix D, Guerciolini R, Esseltine D, Anderson KC. Limited experience from 2 phase 2 trials suggests bortezomib can be given safely in multiple myeloma (MM) patients (pts) with severe renal impairment with comparable responses and toxicities. *Blood* 2003; 102: Abstract #828.
624. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, Rajkumar SV, Hideshima T, Bryant B, Mulligan G, Xiao H, Esseltine D, Schenkein DP, Anderson KC. Prognostic factors for

response parameters and overall survival in patients with multiple myeloma (MM) following treatment with bortezomib. Blood 2003; 102: Abstract #1629.

625. Lonial S, Waller EK, Richardson PG, Jagannath S, Francis D, Lehman M, Torre C, Barlogie B, Berenson JR, Singhal S, Schenkein DP, Esseltine D, Anderson J, Heffner LT, Anderson KC. Evaluation of the degree of thrombocytopenia and associated risk factors following bortezomib therapy for relapsed multiple myeloma. Blood 2003; 102: Abstract #1632.
626. Sirohi B, Powles R, Singhal S, Kulkarni S, Dearden C, Horton C, Saso R, Treleaven J, Mehta J. Significance of length of first complete remission (CR) in newly-diagnosed dectory patients with myeloma: a study of 131 with a minimum follow-up of 5 years. Blood 2003; 102: Abstract #1633.
627. Verma A, Tomblyn M, Evens A, Gordon LI, Grinblatt D, Kaminer L, Singhal S, Tallman MS, Williams S, Winter JN, Mehta J. 100 mg/m² melphalan results in significant cytoreduction when used as conditioning prior to non-myeloablative allogeneic hematopoietic stem cell transplantation. Blood 2003; 102: Abstract #1759.
628. Sirohi B, Powles R, Singhal S, Treleaven J, Kulkarni S, Horton C, Dearden C, Mehta J. Adult patients with de novo acute myeloid leukemia receiving high-dose cytarabine-based induction chemotherapy: A single center study of 136 patients. Blood 2003; 102: Abstract #2273.
629. Powles R, Sirohi B, Singhal S, Kulkarni S, Rudin C, Dearden C, Saso R, Mehta J. Primary refractory (PRef) myeloma: recommendations for treatment. Blood 2003; 102: Abstract #2542.
630. Powles R, Sirohi B, Singhal S, Treleaven J, Kulkarni S, Horton C, Dearden C, Mehta J. 10-year survival in myeloma: have the results improved in the last decade? Blood 2003; 102: Abstract #2553.
631. Mehta J, Verma A, Tallman MS, Winter JN, Williams S, Gordon LI, Singhal S. Depicting treatment failure after non-myeloablative allogeneic transplantation (NMAT): the concept of "sustained relapse". Blood 2003; 102: Abstract #2685.
632. Mehta J, Powles R, Sirohi B, Treleaven J, Kulkarni S, Singhal S. 200 mg/m² melphalan and autograft followed by maintenance chemotherapy with 6-mercaptopurine (6MP), methotrexate (MTX), and vincristine-prednisone (VP) in 65 first remission cute lymphoblastic leukemia patients. Blood 2003; 102: Abstract # 2729.
633. Sirohi B, Powles R, Singhal S, Treleaven J, Kulkarni S, Horton C, Dearden C, Das M, Mehta J. Prognostic significance of immunoparesis (IP) at diagnosis and continued complete remission (CR) in newly diagnosed secretory myeloma patients. Blood 2003; 102: Abstract #3490.
634. Tomblyn M, Villa M, Shook T, Clifton R, Gordon LI, Singhal S, Tallman MS, Williams S, Winter JN, Mehta J. Total leukocyte and platelet counts are highly predictive of good CD34+ cell collections in healthy allogeneic hematopoietic stem cell donors undergoing leukapheresis. Blood 2003; 102: Abstract #3559.
635. Mehta J, Beohar N, Singhal S, Davidson CJ. Early administration of filgrastim following experimental myocardial infarction in a porcine ischemia reperfusion model may help myocardial repair. Blood 2003; 102: Abstract #4328.
636. Singhal S, Goolsby C, Taylor R, Tariman J, Karpus W, Mehta J. Identifying novel therapeutic targets in myeloma: CD20, CD25 and CD52 expression on malignant plasma cells. Blood 2003; 102: Abstract # 5221.
637. Sirohi B, Powles R, Singhal S, Kulkarni S, Treleaven J, Das M, Horton C, Patel G, Dearden C, Mehta, J. Results of toxicity assessment of an open, randomized, phase II, single-centre study comparing

- PEG interferon (P-IFN) with interferon- α 2b (IFN) maintenance in patients with myeloma may allow for dose escalation studies. Blood 2003; 102: Abstract #5265.
638. Mehta J, Jakob C, Singhal S, Stadtmauer E, Richardson P, Vesole D, Boral AL, Esseltine DL, Sezer, O. USA. Bortezomib causes tumor lysis syndrome in approximately 1% of patients with myeloma. Blood 2003; 102: Abstract #5273.
639. Singhal S, Tariman J, Smith K, Riley MB, Mistina J, Mehta J. Bortezomib Is effective therapy for relapsed multiple myeloma. Blood 2003; 102: Abstract #5289.
640. Gidron A, Verma A, Villa M, Shook T, Gordon LI, Singhal S, Tallman MS, Williams S, Winter JN, Mehta J. Can the stem cell mobilization technique influence CD34+ cell collection efficiency of leukapheresis procedures in patients with hematologic malignancies? Blood 2003; 102: Abstract #5380.
641. Gidron A, Gordon LI, Singhal S, Tallman MS, Williams S, Winter JN, Tomblyn M Verma A, Mehta J. Significance of low peripheral blood CD34+ cell numbers prior to leukapheresis: the 5/mm³ threshold required for apheresis is arbitrary and should be changed. Blood 2003; 102: Abstract #5390.
642. Verma A, Pedicano J, Trifilio S, Gordon LI, Singhal S, Tallman MS, Williams S, Winter JN, Mehta J. Early or late administration of myeloid growth factors after autotransplantation to hasten neutrophil recovery? Blood 2003; 102: Abstract #5433.
643. Verma A, Gordon LI, Singhal S, Tallman MS, Williams S, Winter JN, Mehta J. Optimizing results of non-myeloablative allogeneic transplantation (NMAT): identification of patients at high risk of treatment failure based upon pre-transplant variables. Blood 2003; 102: Abstract #5438.
644. Pedicano J, Verma A, Tomblyn M, Gordon LI, Singhal S, Tallman MS, Williams S, Winter JN, Mehta J. Lower post-transplant serum albumin levels predict significantly poorer survival after allogeneic hematopoietic stem cell transplantation. Blood 2003; 102: Abstract #5439.
645. Naik P, Verma A, Pedicano J, Gordon LI, Singhal S, Tallman MS, Williams S, Winter JN, Mehta J. Tempo of neutrophil recovery and the definition of myeloid engraftment after allogeneic hematopoietic stem cell transplantation (HSCT) in patients not receiving growth factors post-transplant. Blood 2003; 102: Abstract #5440.
646. Verma A, Pedicano J, Tomblyn M, Gordon LI, Singhal S, Tallman MS, Williams S, Winter JN, Mehta, J. Platelet counts 2 and 3 months after non-myeloablative allogeneic transplantation (NMAT) predict survival. Blood 2003; 102: Abstract #5443.
647. Powles R, Mehta J, Sirohi B, Treleaven J, Kulkarni S, Singhal S. Bone marrow versus blood for allogeneic stem cell transplantation in patients with hematologic malignancies: final follow-up of a double-blind, randomized prospective study. Blood 2003; 102: Abstract #5584.
648. Verma A, Trifilio S, Singhal S, Tallman MS, Winter JN, Williams S, Gordon LI, Monreal J, Mehta J. How long after neutrophil recovery should myeloid growth factors be continued in autologous hematopoietic stem cell transplant recipients? Blood 2003; 102: Abstract #5652.
649. Sirohi B, Powles R, Kulkarni S, Carr-Smith HD, Patel G, Das M, Iqbal J, Bradwell AR, Dearden C, Mehta J. Serum free light chain assessment in myeloma patients who are in complete remission (CR) by immunofixation predicts early relapse. Blood 2003; 102: Abstract #5195.
650. Kut V, Mehta J, Tariman J, Olsson A, Singhal S. Osteonecrosis of the jaw in myeloma patients receiving pamidronate or zoledronate. Blood 2004; 104: Abstract #4933.

651. Mehta J, Kwaan H, Gordon L, Evens A, Singhal S, Winter J, Williams S, Rowe J, Goldstone A, Tallman M. Does concomitant methotrexate (MTX) and GM-CSF administration after allogeneic hematopoietic stem cell transplantation (HSCT) predispose to thrombotic microangiopathy (TMA)? Blood 2004; 104: Abstract #1835.
652. Trifilio S, Tallman M, Singhal S, Gordon L, Evens A, Mehta J. Low-dose recombinant urate oxidase (Rasburicase) is effective in hyperuricemia. Blood 2004; 104: Abstract #3312.
653. Singhal S, Gordon L, Meagher R, Evens A, Tallman M, Williams S, Winter J, Grinblatt D, Kaminer L, Mehta J. The CD34+ cell dose, even in an "acceptable" range, affects outcome of allogeneic blood stem cell transplantation. Blood 2004; 104: Abstract #1153.
654. Mehta J, Singhal S, Tallman M, Williams S, Winter J, Evens A, Grinblatt D, Kaminer, Gordon L. Pre-transplant variables affecting the outcome of submyeloablative allogeneic hsct in uniformly treated patients with hematologic malignancies. Blood 2004; 104: Abstract #2324.
655. Kut V, Mehta J, Singhal S, Bennett C. Post-marketing assessments of serious adverse drug reactions reported by the manufacturer to the FDA differ markedly with those from an independent pharmacovigilance program: empirical findings based on bisphosphonate-associated osteonecrosis descriptions by the Research on Adverse Events and Reports Project and the product manufacturer. Blood 2004; 104: Abstract #3151.
656. Mehta J, Gordon L, Tallman M, Winter J, Williams S, Evens A, Grinblatt D, Kaminer L, Singhal S. Is a younger 10-allele-matched unrelated donor (MUD) better than an older 6-antigen-matched sibling donor (MSD) for allogeneic HSCT? Blood 2004; 104: Abstract #2757.
657. Winter JN, Inwards DJ, Spies S, Wiseman G, Patton D, Erwin W, Rademaker A, Williams SF, Tallman MS, Micallef I, Mehta J, Singhal S, Zimmer M, Molina A, White C, Gordon LI. ⁹⁰Y Ibritumomab tiuxetan (Zevalin®; ⁹⁰YZ) doses higher than .4 mCi/kg may be safely combined with high-dose beam and autotransplant: the role for dosimetry. Blood 2004; 104: Abstract #1162.
658. Evens AO, Tallman MS, Singhal S, McKoy JM, Lyons EA, Raisch DW, Yarnold PR, Kwaan H, Kuzel TM, Mehta J, Bennett CL. FDA policies should be amended to allow pharmaceutical manufacturers to disseminate information regarding potentially fatal toxicities that occur with off-label use of oncology agents: a policy recommendation based on review of thalidomide-associated thromboembolism cases by the RADAR project. Blood 2004; 104: Abstract #265.
659. Mehta J, Gordon L, Tallman M, Winter J, Williams S, Evens A, Frankfurt O, Grinblatt D, Kaminer L, Meagher R, Singhal S. Identifying patients at risk of early relapse after submyeloablative allogeneic HSCT. Blood 2005; 106: Abstract #5390.
660. Gidron A, Tariman J, Shabbir M, Mehta J, Singhal S. High plasma cell labeling index (PCLI) is an adverse prognostic factor in bortezomib-treated patients with relapsed myeloma. Blood 2005; 106: Abstract #3471.
661. Trifilio S, Evens A, Gordon L, Singhal S, Tallman M, Mehta J. Low-dose recombinant urate oxidase (Rasburicase) is effective in treating hyperuricemia in patients with hematologic malignancies. Blood 2005; 106: Abstract #3123.
662. Singhal S, Evens A, Frankfurt O, Gordon L, Meagher R, Tallman M, Williams S, Winter J, Kaminer L, Grinblatt D, Mehta J. Graft CD3+ cell content affects acute GVHD after submyeloablative allogeneic HSCT. Blood 2005; 106: Abstract #3663.
663. Mehta J, Meagher R, Evens A, Frankfurt O, Singhal S, Tallman M, Williams S, Winter J, Grinblatt D, Kaminer L, Gordon L. The effect of the platelet content of blood stem cell grafts on GVHD. Blood 2005; 106: Abstract #1077.

664. Mehta J, Evens A, Frankfurt O, Gordon L, Grinblatt D, Kaminer L, Meagher R, Tallman M, Williams S, Winter J, Singhal S. Outcome of submyeloablative allogeneic HSCT for hematologic malignancies: development of a prognostic model based on pre-transplant characteristics. *Blood* 2005; 106: Abstract #1145.
665. Chanan-Khan AA, Richardson P, Lonial S, Siegel D, Jagannath S, Mehta J, Doran J, Singhal S. Safety and efficacy of bortezomib in multiple myeloma patients with renal failure requiring dialysis. *Blood* 2005; 106: Abstract #2550.
666. Altman JK, Gordon LI, Monreal J, Evens AM, Williams SF, Tallman MS, Singhal S, Mehta J, Winter JN. Allogeneic stem cell transplantation (AlloSCT) for relapsed hodgkin's lymphoma (HL) following autologous stem cell transplantation (AuSCT): improved progression-free survival (PFS) in patients with graft vs host-disease (GvHD) suggests a graft vs lymphoma (GVL) effect. *Blood* 2005; 106: Abstract #5455.
667. Singhal S, Evens A, Frankfurt O, Gordon L, Meagher R, Tallman M, Williams S, Winter J, Grinblatt D, Kaminer L, Mehta J. Ideal (IBW) rather than actual (ABW) body weight should be used to calculate cell dose in allogeneic HSCT. *Blood* 2005; 106: Abstract #1765.
668. Evens AM, Rademaker A, Mittal BB, Altman JK, Patton D, Kaminer L, Singhal S, Variakojis D, Williams S, Tallman MS, Mehta J, Winter JN, Gordon LI. Autologous stem cell transplantation (ausct) with total lymphoid irradiation (TLI) and high-dose chemotherapy (CT) results in high survival rates for "poor-prognosis" relapsed/refractory (R/R) Hodgkin's disease (HD): multivariate analysis of outcome shows marked benefit for TLI in a prospective phase I/II trial. *Blood* 2005; 106: Abstract #2080.
669. Richardson P, Jagannath S, Hussein M, Berenson J, Singhal S, Irwin D, Williams SF, Bensinger W, Badros AZ, Vescio R, Kenvin L, Yu Z, Olesnyckyj M, Faleck H, Zeldis J, Knight R, Anderson KC. A multicenter, single-arm, open-label study to evaluate the efficacy and safety of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma; preliminary results. *Blood* 2005; 106: Abstract #1565.
670. Zhao LR, Singhal S, Duan WM, Mehta J, Kessler JA. The beneficial effects of hematopoietic cytokines on experimental stroke in rats. *Proceedings of the Thirteenth Annual Conference of the American Society for Neural Therapy and Repair. Exp Neurol* 2006; 198:597.
671. Winter JN, Inwards S, Spies S, Wiseman G, Patton D, Erwin W, Rademaker A, Williams S, Tallman MS, Micallef I, Mehta J, Singhal S, Evens A, Zimmer M, Molina A, White C, Gordon LI. ⁹⁰Y ibritumomab tiuxetan (Zevalin; 90YZ) doses calculated to deliver up to 1500 cGy to critical organs may be safely combined with high-dose BEAM and autotransplant in NHL. *Blood* 2006; 108: Abstract #330.
672. Mehta J, Stein R, Vickrey E, Resseguie W, Singhal S. Significance of serum free light chain estimation with detectable serum monoclonal protein on immunofixation electrophoresis. *Blood* 2006; 108: Abstract #5048.
673. Stein R, Mehta J, Vickrey E, Resseguie W, Singhal S. Serum free light chain measurement in myeloma patient samples with oligoclonal protein bands. *Blood* 2006; 108: Abstract #5044.
674. Stein R, Mehta J, Vickrey E, Resseguie W, Singhal S. Correlation of serum free light chain levels with other parameters in myeloma. *Blood* 2006; 108: Abstract #5019.
675. Evens AM, Winter JN, Hou N, Rademaker F, Kelemen K, Nelson B, Patton D, Frankfurt O, Williams S, Singhal S, Tallman MS, Rosen ST, Mehta J, Gordon LI. Durable event-free and overall survival (EFS/OS) in mantle cell lymphoma (MCL) without rituximab: long-term follow-up of a phase II trial with

- intensive chemotherapy (CTAP/VMAC) followed by autologous hematopoietic stem cell transplant (aHSCT). Blood 2006; 108: Abstract #2448.
676. Mehta J, Winter J, Tallman M, Gordon L, Williams S, Frankfurt O, Evens A, Grinblatt D, Kaminer L, Meagher R, Singhal S. Submyeloablative allografts for hematologic malignancies: validation of a prognostic model based on pre-transplant variables. Blood 2006; 108: Abstract #3036.
677. Singhal S, Gordon L, Tallman M, Winter J, Williams S, Frankfurt O, Evens A, Meagher R, Kaminer L, Grinblatt D, Mehta J. Submyeloablative allogeneic HSCT for hematologic malignancies: effect of body weight. Blood 2006; 108: Abstract #2949.
678. Trifilio S, Singhal S, Williams S, Winter J, Tallman M, Gordon L, Frankfurt O, Evens A, Mehta J. Breakthrough fungal infections after allogeneic hematopoietic stem cell transplantation in patients on prophylactic voriconazole. Blood 2006; 108: Abstract #2849.
679. Mehta J, Gordon L, Tallman M, Winter J, Williams S, Frankfurt O, Evens A, Grinblatt D, Kaminer L, Meagher R, Rashid K, Grabowski D, Singhal S. Reduced-intensity allogeneic HSCT in hematologic malignancies: influence of underlying diagnosis and prior autograft on outcome. Blood 2006; 108: Abstract #3040.
680. Altman J, Venepalli N, Monreal J, Rashid K, Gordon L, Winter J, Williams S, Tallman M, Frankfurt O, Evens A, Singhal S, Mehta J. Oral busulfan and cyclophosphamide or IV busulfan and fludarabine for allogeneic HSCT in hematologic malignancies? Blood 2006; 108: Abstract #2940.
681. Singhal S, Stein R, Vickrey E, Resseguie W, Mehta J. The serum free light chain assay cannot replace 24-hour urine protein estimation in plasma cell dyscrasias. Blood 2006; 108: Abstract #3519.
682. Mehta J, Chunduri S, Dobogai L, Singhal S, Rondelli D. Allogeneic hematopoietic stem cell transplantation for myeloma: does the melphalan dose matter? Blood 2007; 110: Abstract #3035.
683. Vickrey E, Fellingham S, Mehta J, Singhal S. Acyclovir to prevent herpes zoster in myeloma patients treated with bortezomib. Blood 2007; 110: Abstract #4807.
684. Trifilio S, Pi J, Singhal S, Frankfurt O, Evens A, Gordon L, Tallman M, Winter J, Williams S, Mehta J. Tacrolimus dosing in allogeneic hematopoietic stem cell transplant (HSCT) recipients receiving concomitant voriconazole. Blood 2007; 110: Abstract #4956.
685. Singhal S, Frankfurt O, Evens A, Gordon L, Tallman M, Williams S, Winter J, Grinblatt D, Kaminer L, Mehta J. outcome of relapse after reduced-intensity allogeneic hematopoietic stem cell transplantation (HSCT) - the effect of the underlying disease on survival following relapse. Blood 2007; 110: Abstract #5020.
686. Sirohi B, Powles R, Treleaven J, Kulkarni S, Saso R, Potter M, Ethell M, Morgan G, Singhal S, Mehta J. Maintenance chemotherapy (MC) after autotransplantation in first-remission acute lymphoblastic leukemia (ALL): single-center experience of 100 patients. Blood 2007; 110: Abstract #2874.
687. Richardson P, Lonial S, Jakubowiak A, Krishnan A, Wolf J, Densmore J, Singhal S, Ghobrial I, Stephenson J, Mehta J, Colson K, Francis D, Kendall T, Obadike N, Sullivan K, Martin J, Hideshima T, Lai L, Sportelli P, Gardner L, Birch R, Henderson IC, Anderson K. Multi-center phase II study of perifosine (KRX-0401) alone and in combination with dexamethasone (dex) for patients with relapsed or relapsed/refractory multiple myeloma (MM): promising activity as combination therapy with manageable toxicity. Blood 2007; 110: Abstract # 1164.
688. Bensinger W, Zonder J, Singhal S, Mohrbacher A, Dean RM, van Rhee F, Al-Homsi AS, Munshi NC, Conner ER, Hussein MA. Phase I trial of HuLuc63 in multiple myeloma. Blood 2007; 110: Abstract # 1180.

Conference Abstracts (Proceedings)

689. Mehta J, Powles R, Singhal S, Chang J, Smith J, Horton C, Milan S, Treleaven J. Durability of autologous bone marrow or peripheral blood stem cells to post-transplant maintenance chemotherapy in acute lymphoblastic leukemia. Abstract Book of the Seventh International Symposium on Autologous Bone Marrow Transplantation, Arlington, 17-20 August 1994, p. 84.
690. Mehta J, Powles R, Singhal S, Chang J, Smith J, Horton C, Milan S, Treleaven J. Autologous bone marrow transplantation for acute promyelocytic leukemia. Abstract Book of the Seventh International Symposium on Autologous Bone Marrow Transplantation, Arlington, 17-20 August 1994, p. 87.
691. Powles R, Mehta J, Cunningham D, Singhal S, Norman A, Iveson T, Viner C, Gore M, Malpas J. High-dose melphalan with bone marrow or peripheral blood stem cell transplantation followed by interferon- α for multiple myeloma. Abstract Book of the Seventh International Symposium on Autologous Bone Marrow Transplantation, Arlington, 17-20 August 1994, p. 77.
692. Powles R, Cunningham D, Malpas JS, Raje N, Milan S, Singhal S, Mehta J, Viner C, Treleaven J. Maintenance therapy for remission in myeloma with Intron-A following high-dose melphalan and either an autologous bone marrow transplant or peripheral stem cell rescue. Proceedings of an International Symposium on Multiple Myeloma: From Biology to Therapy - Current Concepts, Mulhouse, 24-26 October 1994, p. 76.
693. Powles R, Singhal S, Mehta J, Milan S, Horton C, Raje N, Viner C, Treleaven J, Cunningham D. Clearance of paraprotein after autografting for multiple myeloma. Proceedings of an International Symposium on Multiple Myeloma: From Biology to Therapy - Current Concepts, Mulhouse, 24-26 October 1994, p. 44.
694. Powles RL, Raje NS, Milan S, Horton C, Singhal S, Mehta J, Viner C, Treleaven J, Raymond J. Robustness of autologous peripheral stem cell transplantation for post-transplantation maintenance interferon in multiple myeloma. Proceedings of an International Symposium on Multiple Myeloma: From Biology to Therapy - Current Concepts, Mulhouse, 24-26 October 1994, p. 43.
695. Mehta J, Powles R, Singhal S, Horton C, Tait D, Milan S, Treleaven J. Autologous bone marrow transplantation (ABMT) for acute myeloid leukemia (AML) after melphalan and total body irradiation (TBI): evaluation of prognostic factors. Proceedings of the 1st Annual Meeting of the American Society for Blood and Marrow Transplantation, Keystone, 26-28 January 1995, p. 66.
696. Mehta J, Powles R, Singhal S, Tait D, Milan S, Horton C, Treleaven J. Post-autograft maintenance chemotherapy for adult acute lymphoblastic leukemia. Proceedings of the 1st Annual Meeting of the American Society for Blood and Marrow Transplantation, Keystone, 26-28 January 1995, p. 96.
697. Singhal S, Powles R, Mehta J, Treleaven J, Horton C, Tait D, Milan S, Catovsky D. Allogeneic bone marrow transplantation for first remission acute myeloid leukemia: melphalan versus cyclophosphamide with total body irradiation. Proceedings of the 1st Annual Meeting of the American Society for Blood and Marrow Transplantation, Keystone, 26-28 January 1995, p. 78.
698. Singhal S, Powles R, Treleaven J, Jameson B, Mehta J. Amphotericin B lipid complex (ABLC) for fungal sepsis in immunocompromised patients with hematologic malignancies. Proceedings of Trends in Invasive Fungal Infections 3, Brussels, 7-9 September 1995, p. 89.
699. Raje NS, Powles RL, Milan S, Hickish T, Gore M, Mehta J, Singhal S, Viner C, Treleaven J, Cunningham D. VAMP/C-VAMP infusional chemotherapy as induction treatment for previously untreated multiple myeloma. Abstract Book of the Vth International Workshop on Multiple Myeloma, La Baule, 10-13 September 1995, p. 3.172.

700. Raje NS, Powles RL, Milan S, Hickish T, Mehta J, Singhal S, Viner C, Treleaven J, Cunningham D. Prognostic factors in multiple myeloma. Abstract Book of the Vth International Workshop on Multiple Myeloma, La Baule, 10-13 September 1995, p. 3.124.
701. Powles RL, Raje NS, Hickish T, Milan S, Mehta J, Singhal S, Viner C, Treleaven J, Cunningham D. Autologous stem cell transplantation - the merits of complete remission. Abstract Book of the Vth International Workshop on Multiple Myeloma, La Baule, 10-13 September 1995, p. 3.33.
702. Raje NS, Powles RL, Horton CAP, Hickish T, Mehta J, Singhal S, Viner C, Treleaven J. Peripheral blood stem cell transplantation in multiple myeloma. Abstract Book of the Vth International Workshop on Multiple Myeloma, La Baule, 10-13 September 1995, p. 3.172.
703. Singhal S, Powles R, Treleaven J, Jameson B, Mehta J. Amphotericin b lipid complex (ABLC) for fungal sepsis in immunocompromised patients with hematologic malignancies. Abstract Book of the XIIIth Meeting of the International Society of Haematology (European & African Division), Istanbul, September 1995, Abstract No. 936.
704. Singhal S, Powles R, Horton C, Treleaven J, Mehta J. Idarubicin, high-dose cytarabine and etoposide for induction of remission in acute myeloid leukemia. Abstract Book of the XIIIth Meeting of the International Society of Haematology (European & African Division), Istanbul, September 1995, Abstract No. 537.
705. Singhal S, Powles R, Treleaven J, Mehta J. Immunotherapy for acute leukemia relapsing after allogeneic bone marrow transplantation. Abstract Book of the XIIIth Meeting of the International Society of Haematology (European & African Division), Istanbul, September 1995, Abstract No. 564.
706. Singhal S, Powles R, Treleaven J, Long S, Shepherd V, Millar B, Bell J, Mehta J. Comparison of marrow and blood stem cell yields in a double-blind, randomized study of allogeneic marrow versus blood stem cell transplantation. Proceedings of the Sixth Biennial Sandoz-Keystone Symposium on Bone Marrow Transplantation, Keystone, 15-21 January 1996, abstract no. 409.
707. Mehta J, Powles R, Singhal S, Horton C, Treleaven J. Role of sequential auto and allografting in adult acute lymphoblastic leukemia. Proceedings of the Sixth Biennial Sandoz-Keystone Symposium on Bone Marrow Transplantation, Keystone, 15-21 January 1996, abstract no. 306.
708. Jagannath S, Tricot G, Desikan KR, Siegel D, Mehta J, Singhal S, Barlogie B. Double autotransplants (DAT) for 542 patients with multiple myeloma (MM). Proc ASCO, Denver, 17-20 May 1997, 14a (abstract no.49).
709. Jagannath S, Tricot G, Desikan KR, Vesole D, Siegel D, Mehta J, Singhal S, Barlogie B. Double autotransplants (DAT) for patients with multiple myeloma (MM). Abstract book of the VI International Workshop on Multiple Myeloma, Boston, 14-18 June 1997.
710. Siegel D, Jagannath S, Desikan KR, Fassas A, Singhal S, Mehta J, Tricot G, Anaissie E, Vesole D, Barlogie B. Single institution experience with 900 tandem auto-transplants (TAT) for multiple myeloma (MM). Proc ASCO, Los Angeles, 16-19 May 1998, 8a (abstract no. 29).
711. Chodimella U, Dhodapkar M, Weinstein R, Angtuaco E, Desikan K, Jaganath S, Siegel D, Fassas A, Mehta J, Singhal S, Barlogie B. Differential effects of pamidronate (Pam) on cortical and cancellous bone in patients with myeloma (MM) undergoing autotransplants (AT). Proc ASCO, Los Angeles, 16-19 May 1998, 18a (abstract no. 68).
712. Munshi N, Spoon D, Anaissie E, Desikan R, Mehta J, Singhal S, Barlogie B. The age factor in autologous transplant (AT) tials for multiple myeloma (MM). Proc ASCO, Atlanta, 15-18 May 1999, 19a (abstract no. 66).

713. Mehta J, Desikan R, Spoon D, Sawyer J, Shaughnessy J, Singhal S, Munshi N, Anaissie E, Barlogie B. Autotransplants for multiple myeloma - implications of renal failure. Proc ASCO, Atlanta, 15-18 May 1999, 18a (abstract no. 64).
714. Munshi NC, Wilson CS, Penn J, Epstein J, Singhal S, Hough A, Sanderson R, Desikan RK, Siegel D, Mehta J, Anaissie E, Barlogie B. Bone marrow neo-angiogenesis in multiple myeloma predicts poor prognosis. Proc ASCO, Atlanta, 15-18 May 1999, 18a (abstract no. 63).
715. Barlogie B, Desikan R, Spoon D, Sawyer J, Shaughnessy J, Mehta J, Singhal S, Munshi N, Anaissie E. Tandem transplants (TAT) in over 1,000 patients with multiple myeloma (MM) - inferior prognosis with chromosome 13 deletion. Proc ASCO, Atlanta, 15-18 May 1999, 5a (abstract no. 16).
716. Shah RV, Singhal S, Govindarajan R, Parham GP, Hutchins L, Jazieh AR. Thalidomide in treatment of solid tumors. Abstract book of the 91st Annual Meeting of the American Association for Cancer Research, San Francisco, 1-5 April 2000.
717. Godder K, Chiang KY, van Rhee F, Mehta J, Singhal S, Adams S, O'Neal W, DeRienzo S, Goon-Johnson K, Henslee-Downey PJ. Long-term follow-up of pediatric patients who received haplo-identical mismatched allogeneic bone marrow transplant (BMT) for acute leukemia. Abstract book of the 6th International Conference on the Long-Term Complications of Treatment of Children and Adolescents for Cancer, Niagra-on-the-Lake, Ontario, Canada, 23-24 June 2000.
718. Godder K, Chiang KY, van Rhee F, Mehta J, Singhal S, Bridges K, Goon-Johnson K, Henslee-Downey PJ. Partially mismatched related donor bone marrow transplant for patients with second remission ALL provides long term survival. Abstract book of the 13th Annual Meeting of the American Society of Pediatric Hematology/Oncology, Minneapolis, 14-16 September 2000.
719. Van Rhee F, Paoli M, Godder K, Chiang KY, Mehta J, Singhal S, Abhyankar S, Bridges K, Adams S, Henslee-Downey PJ. Large numbers of stem cells are not required for successful engraftment in partially mismatched related donor transplantation. Abstract book of the Annual ISHAGE Meeting, San Diego, 2000.
720. Sirohi B, Powles R, Mehta J, Kulkarni S, Treleaven J, Horton C, Saso R, Goyal S, Singhal S. Single-center results of 200 mg/m² melphalan (HDM200) and autograft (tx) in 451 myeloma (MM) patients: identifying patients with prolonged survival based upon albumin (ALB) and β_2 -microglobulin (β_2M) at transplant. Proc ASCO, Orlando, 18-21 May 2002, 269a (abstract no. 1072).
721. Richardson PG, Barlogie B, Berenson J, Traynor A, Singhal S, Jagannath S, Irwin D, Rajkumar V, Srkalovic G, Alsina M, Alexanian R, Siegel D, Orlowski RZ, Kuter D, Limentani S, Esseltine D, Kauffman M, Adams J, Schenkein D, Anderson KC. Phase II study of the proteasome inhibitor PS-341 in multiple myeloma (MM) patients (pts) with relapsed/refractory disease. Proc ASCO, Orlando, 18-21 May 2002, 11a (abstract no. 40).
722. Lee S, Richardson PG, Barlogie B, Berenson JR, Singhal S, Jagannath S, Irwin D, Schenkein D, Esseltine D, Anderson KC. Quality-of-life (QOL) and clinical benefit assessment in patients with relapsed and refractory multiple myeloma (MM) treated with bortezomib. Proc ASCO, Chicago, 31 May - 3 June 2003, Abstract no. 2339.
723. Jagannath S, Richardson P, Barlogie B, Berenson JR, Singhal S, Irwin D, Srkalovic G, Schenkein D, Esseltine D, Anderson KC. Phase II trials of bortezomib in combination with dexamethasone in multiple myeloma (MM): Assessment of additional benefits to combination in patients with sub-optimal responses to bortezomib alone. Proc ASCO, Chicago, 31 May - 3 June 2003, Abstract no. 2341.
724. Richardson PGG, Barlogie B, Berenson JR, Singhal S, Jagannath S, Irwin D, Rajkumar V, Esseltine D, Schenkein D, Anderson KC. Prognostic factors associated with response in patients with relapsed

and refractory multiple myeloma (MM) treated with bortezomib. Proc ASCO, Chicago, 31 May - 3 June 2003, Abstract no. 2338.

725. Mehta J, Cetiner M, Gordon L, Evens A, Tallman M, Williams S, Winter J, Meagher R, Singhal S. Effect of impaired renal function on the outcome of submyeloablative allogeneic hematopoietic stem cell transplantation in patients with hematologic malignancies. Proc ASCO, Orlando, May 2005, Abstract no. 6666.
726. Singhal S, Cetiner M, Gordon L, Evens A, Tallman M, Williams S, Winter J, Meagher R, Mehta J. Factors affecting survival after submyeloablative allogeneic hematopoietic stem cell transplantation (HSCT) for hematologic malignancies. Proc ASCO, Orlando, May 2005, Abstract no. 6662.

Book Chapters

727. Mehta J, Singhal S, Powles R. Peripheral blood stem cell transplantation. In: Shankar PS, ed. *Medicine Update: Volume V*. Madras, Association of Physicians of India, 1995; 285-292 (ISBN -81-900345-5-3).
728. Mehta J, Powles R, Singhal S, Horton C, Milan S, Tait D, Treleaven J. Sequential high-dose therapy of adult acute lymphoblastic leukemia: Role of maintenance chemotherapy after peripheral blood stem cell transplantation in first remission. In: Dicke KA, Keating A, eds. *Autologous Marrow and Blood Transplantation: Proceedings of the Seventh International Symposium*, Arlington, Texas. Arlington, The Cancer Treatment Research and Educational Institute, 1995; 135-144.
729. Mehta J, Singhal S. Graft failure: diagnosis and management. In: Barrett J, Treleaven JG, eds. *The Clinical Practice of Stem Cell Transplantation*. Oxford, Isis Medical Media, 1998:645-658 (ISBN 1-8990666-70-5).
730. Mehta J, Singhal S. Pre-transplant evaluation of the patient and the donor. In: Barrett J, Treleaven JG, eds. *The Clinical Practice of Stem Cell Transplantation*. Oxford, Isis Medical Media, 1998:315-323 (ISBN 1-8990666-70-5).
731. Singhal S, Mehta J. Reimmunisation after transplantation. In: Barrett J, Treleaven JG, eds. *The Clinical Practice of Stem Cell Transplantation*. Oxford, Isis Medical Media, 1998:745-756 (ISBN 1-8990666-70-5).
732. Singhal S, Mehta J, Jagannath S, Barlogie B. Hematopoietic stem cell transplantation for myeloma. In: Foley JF, Vose JM, Armitage JO, eds. *Current Therapy in Cancer*, second edition. Philadelphia, WB Saunders, 1999:475-484.
733. Siegel DS, Lim SH, Tricot G, Desikan KR, Fassas A, Mehta J, Singhal S, Anaissie E, Jagannath S, Barlogie B. Stem cell transplantation for myeloma - 10 years later. In: Ho AD, Haas R, Champlin RE, eds. *Hematopoietic Stem Cell Transplantation*. New York, Marcel Dekker, 2000:499-516 (ISBN 0-8247-0273-5).
734. Mehta J, Singhal S, Desikan K, Munshi N, Badros A, Zangari M, Anaissie E, Lim S, Barlogie B. High-dose therapy and stem-cell support in myeloma. In: De Vita VT Jr, Hellman S, Rosenberg SA, eds. *PPO Updates*. Lippincott Williams & Wilkins, 1999; 13:1-12.
735. Henslee-Downey PJ, Godder K, Abhyankar S, Chiang KY, Lamb LS, Geier SS, Van Rhee F, Singhal S, Mehta J. Sequential immunomodulation to achieve engraftment and control graft-versus-host disease across mismatched MHC barriers. *Hematology 1999. Education Book of the 41st Annual Meeting of the American Society of Hematology* 1999:317-323.
736. Atkinson K, Singhal S. Bacterial infections. In: Atkinson K, ed. *Clinical Bone Marrow and Blood Stem Cell Transplantation*, second edition. Cambridge, Cambridge University Press, 2000:716-736 (ISBN 0-521-62288-3).
737. Singhal S. High-dose therapy and autologous transplantation. In: Mehta J, Singhal S, eds. *Myeloma*. London, Martin Dunitz, 2002:327-347.
738. Sawyer J, Singhal S. Cytogenetics in plasma cell disorders. In: Mehta J, Singhal S, eds. *Myeloma*. London, Martin Dunitz, 2002:65-80.
739. Vacca A, Singhal S, Ribatti D, Dammacco F. Angiogenesis in plasma cell disorders. In: Mehta J, Singhal S, eds. *Myeloma*. London, Martin Dunitz, 2002:119-135.